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1. Introduction	
	
1.1. Screening	Tools	in	Drug	Discovery	
	
For	a	 long	time,	new	drug	substances	were	found	by	chance	before	they	were	used	 in	the	
therapy	of	diseases.	Important	examples	of	such	coincidentally	found	drug	substances,	which	
are	still	in	use	are	salicylic	acid	(administered	as	acetylsalicylic	acid),	morphine,	and	penicillin,	
just	 to	 name	 a	 few.	 With	 the	 advance	 of	 medicinal	 sciences,	 target-oriented	 screening	
techniques	 were	 employed	 in	 modern	 drug	 discovery.	 Typically,	 the	 binding	 of	 a	 ligand	
towards	a	target	molecule	is	observed.	These	screening	techniques	are	important	tools	in	the	
early	 to	medium	 stages	of	 the	drug	discovery	process	 [1,2].	 They	 can	be	divided	 into	 two	
groups	based	on	what	component	of	the	ligand-target	complex	 is	 investigated	–	either	the	
change	at	the	target,	caused	by	the	binding	of	the	ligand,	is	measured,	or	the	bound	ligand	is	
detected.	By	measuring	the	change	at	the	target	induced	by	ligand	binding,	information	on	
the	binding	mechanism	and	the	binding	site	can	be	gained,	but	such	techniques	can	only	be	
used	with	a	single	ligand	and	they	have	a	limited	throughput.	With	techniques	that	detect	the	
bound	 compounds,	 ligands	 can	 be	 identified	 in	 mixtures	 of	 compounds	 with	 a	 high	
throughput,	but	no	information	on	the	binding	interactions	and	binding	mechanism	can	be	
obtained	[3].		
	
	
	
Figure	1:	Simplified	outline	of	the	drug	development	process.	Areas,	in	which	binding	assays	
can	be	applied	are	highlighted	(adopted	from	Cooper	[1]).	
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A	schematic	overview	of	the	different	stages	in	drug	development	is	shown	in	figure	1.	The	
first	steps	 in	contemporary	drug	discovery	are	the	 identification	and	validation	of	a	target,	
that	can	be	influenced	in	order	to	treat	a	disease.	Afterwards,	a	strategy	for	the	identification	
of	 ligands,	 which	 interact	 with	 the	 target,	 is	 established,	 since	 only	 such	 substances	 can	
influence	the	target	and	thus	affect	the	progression	of	a	disease.	In	multiple	screening	and	
optimization	steps,	mediators	for	the	target	are	identified	and	developed,	until	a	prospective	
new	 drug	 substance,	 which	 can	 then	 proceed	 to	 the	 clinical	 development,	 is	 found.	
Pharmacological	assays	are	an	essential	tool	in	all	stages	of	the	drug	development	process	up	
to	 the	 clinical	 development.	 In	 contrast	 to	 functional	 assays,	 monitoring	 a	 change	 in	 the	
biological	response,	induced	by	a	test	compound,	binding	assays	are	based	on	the	binding	of	
the	test	compound.	In	such	binding	assays,	the	bound	ligand	for	a	given	target	is	quantified	or	
identified.	 Various	 assays,	 based	 on	 the	 affinity	 of	 a	 ligand	 towards	 a	 target	 have	 been	
developed	[3–8].	The	readout	of	these	assays	can	either	be	done	by	optical	sensors	or	mass	
spectrometry	 (e.g.	 automated	 ligand	 identification	 system	 (ALIS),	 multitarget	
affinity/specificity	 screening	 (MASS))	 [9–12].	 A	 powerful	 and	 very	 versatile	 approach	 to	
quantify	the	bound	ligand	at	a	target,	are	radioligand	binding	assays	[2,5,13,14].	
	
1.1.1. Radioligand	Binding	Assays	
	
Radioligand	binding	assays	have	been	developed	in	the	1970s	to	analyse	ligand-target	binding	
[15].	 They	 are	 based	 on	 a	 radioactively	 labelled	 reporter	 ligand,	 the	 so-called	 radioligand,	
which	binds	 towards	 the	 target	of	 interest	and	can	be	quantified	by	means	of	 scintillation	
counting.	Radioisotopes	used	for	the	synthesis	of	radioligands	are	commonly	3H,	125I,	or	32P.	
Compared	to	alternative	labels,	such	as	bulky	fluorophores,	necessary	for	fluorescence-based	
assays,	the	inclusion	of	radioisotopes	only	has	negligible	effect	on	the	binding	affinity	of	the	
radioligand	 towards	 its	 target.	 With	 different	 assay	 types	 (see	 1.1.3	 Ligand	 Binding	
Experiments)	a	variety	of	information	about	the	target,	the	binding	affinity	and	kinetics	of	the	
radioligand	or	the	binding	affinities	of	test	substances	can	be	obtained.	Besides	the	above-
mentioned	benefit	of	only	minor	alteration	of	the	reporter	ligand	by	the	insertion	of	the	label,	
radioligand	binding	assays	have	further	advantages.	Commercial	availability	of	a	large	number	
of	highly	affine	and	selective	radioligands	for	various	targets,	enables	the	user	to	quickly	set-
up	 a	 radioligand	 binding	 assay.	 The	 readout	 by	 scintillation	 counting	 is	 selective	 for	 the	
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radioisotope	 and	 has	 a	 high	 sensitivity.	 Drawbacks	 are	mainly	 associated	with	 the	 use	 of	
radioactivity,	which	results	in	potential	health	hazards	for	the	operators	if	the	assays	are	not	
performed	 with	 care,	 expensive	 licences	 for	 the	 authorisation	 to	 work	 with	 radioactive	
materials,	 as	 well	 as	 high	 costs	 for	 the	 purchase	 of	 the	 radioligands	 and	 disposal	 of	 the	
radioactive	contaminated	waste.	
	
To	perform	a	radioligand	binding	assay,	the	target	protein	is	incubated	with	the	radioligand	
and	 –	 if	 needed	 for	 the	 experiment	 –	 an	 inhibitor.	 After	 the	 incubation,	 the	 unbound	
radioligand	 is	 separated	 from	 the	 radioligand-target	 complexes,	which	 can	be	achieved	by	
filtration	or	centrifugation	(see	figure	2).	 In	radioligand	binding	assays,	 the	bound	reporter	
ligand	is	then	quantified	by	scintillation	counting.	
	
	
	
Figure	2:	Experimental	procedure	of	a	radioligand	binding	assay.	The	target	(blue)	is	incubated	
with	 the	 radioligand	 (red	 spheres).	 For	 the	 separation	 of	 the	 radioligand-target	 complexes	
from	 the	unbound	 radioligand,	 the	 sample	 is	 filtrated	 (filter	 is	 represented	by	dotted	 line).	
Afterwards,	the	bound	radioligand	is	quantified	by	scintillation	counting	of	the	filter	with	the	
radioligand-target	complexes.	
	
1.1.2. MS	Binding	Assays	
	
As	an	alternative	to	radioligand	binding	assays,	MS	Binding	Assays	have	been	developed	for	a	
variety	 of	 different	 targets	 [16–22].	 In	 contrast	 to	 radioligand	 binding	 assays,	 the	
quantification	of	the	bound	reporter	ligand,	which	is	called	MS	Marker	or	simply	marker	in	MS	
Binding	 Assays,	 is	 done	 by	 liquid	 chromatography-mass	 spectrometry	 (LC-MS).	 Since	 the	
marker	 can	 be	 selectively	 detected	 by	 tandem	mass	 spectrometry	 (MS/MS)	 based	 on	 the	
mass/charge-ratio	(m/z)	of	its	ionized	species	and	specific	fragment	ions,	no	label	is	necessary.	
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Thus,	 the	 native	 compound	 can	 be	 used,	 which	 results	 in	 some	 advantages.	 Commercial	
availability	 of	 native	 compounds	 is	 much	 better,	 than	 for	 radiolabelled	 compounds.	
Additionally,	the	cost	for	the	purchase	of	such	native	compounds	is	usually	lower	than	for	its	
radiolabelled	counterparts.	Due	to	the	absence	of	a	label,	there	is	no	effect	on	the	binding	
affinity	 and	 kinetics,	 compared	 to	 (especially	 fluorophore-)	 labelled	 ligands.	 Further	
advantages	 originate	 from	 the	 avoidance	 of	 radioactivity	 in	 MS	 Binding	 Assays.	 The	
implementation	 of	 MS	 Binding	 Assays	 can	 be	 done	 in	 any	 suitably	 equipped	 chemical	
laboratory,	 without	 the	 need	 for	 special	 authorisations	 and	 risk	 of	 health	 hazards	 from	
radioligand	binding	assays.	Arising	waste	can	be	treated	like	normal	laboratory	waste,	without	
additional	 costs	 and	 ecological	 issues	 associated	 with	 the	 disposal	 of	 radioactively	
contaminated	waste.	The	principle	of	MS	Binding	Assays	is	as	simple,	robust	and	flexible,	as	
the	one	of	radioligand	binding	assays.	
	
For	the	use	in	MS	Binding	Assays,	there	are	some	requirements	concerning	the	marker.	First	
of	all,	like	in	radioligand	binding	assays,	the	reporter	ligand	should	label	the	target	of	interest	
with	a	high	affinity	and	selectivity.	A	low	affinity	is	typically	associated	with	a	fast	dissociation	
of	the	reporter	ligand-target	complexes,	which	results	in	problems	during	the	separation	of	
the	reporter	 ligand-target	complexes	from	the	unbound	reporter	 ligand	[23].	Filtration	and	
subsequent	washing	of	the	reporter	ligand-target	complexes	takes	a	few	seconds,	 in	which	
the	 reporter	 ligand-target	 complexes	 should	 not	 dissociate.	 For	 reporter	 ligands	 with	 an	
affinity	in	the	low	nanomolar	(nM)	range,	reporter	ligand-target	complexes	are	stable	enough	
during	the	time	required	for	the	filtration	and	extensive	washing.	Contrary	to	this,	too	high	
affinity	of	the	marker	results	in	issues	concerning	the	quantification	of	the	bound	marker	in	
MS	Binding	Assays.	Since	 free	marker	concentrations	of	0.1	of	 the	equilibrium	dissociation	
constant	(Kd)	should	be	analysable	and	the	target	concentration	should	be	not	higher	than	0.1	
Kd	(see	1.1.3	Ligand	Binding	Experiments),	according	to	the	Langmuir	adsorption	model	(1,	for	
further	discussion	of	this	formula,	see	1.1.3	Ligand	Binding	Experiments)	
	
	 [LT]	=	 [L]	×	(max[L]	+	-d 	 (1)	
marker	concentrations	of	at	least	0.0091	Kd	have	to	be	reliably	quantified	[19].		
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	 [LT]	=	 0.1	-d	×	0.1	-d0.1	-d	+	-d = 0.0091	-d	 	
	
So	far,	quantification	limits	in	the	low	picomolar	(pM)	range	were	achieved	in	quantification	
methods	of	MS	Binding	Assays,	allowing	the	quantification	of	markers	with	a	low	nanomolar	
affinity	for	the	target.		
	
An	additional	requirement	is	a	high	ionization	efficiency	of	the	marker.	Chemical	compounds	
can	differ	 extremely	 in	 their	 ionization	behaviour,	which	has	 a	huge	 impact	on	 the	 LC-MS	
quantification	limits.	The	ionization	efficiency	of	the	marker	can	be	influenced	by	the	chosen	
LC-MS	method	parameters,	but	a	low	ionization	efficiency	can	result	in	the	unsuitability	of	the	
marker	for	an	MS	Binding	Assay.	
	
	
	
Figure	3:	Experimental	procedure	of	MS	Binding	Assays.	The	marker	is	incubated	together	with	
the	 target.	After	 the	 incubation,	 the	unbound	marker	 is	 separated	 from	 the	marker-target	
complexes	by	filtration.	To	denature	the	target	proteins,	the	filters	are	dried	prior	to	elution	of	
the	formerly	bound	marker.	
	
MS	Binding	Assays	are	performed	very	 similar	 to	 radioligand	binding	assays	 (see	 figure	3).	
Incubation	 of	 the	marker	 with	 the	 target,	 as	 well	 as	 the	 separation	 of	 the	marker-target	
complexes	 from	 the	 unbound	marker	 is	 done	 analogous	 to	 radioligand	 binding	 assays.	 To	
quantify	 the	bound	marker	 in	MS	Binding	Assays,	 the	marker	has	to	be	 liberated	from	the	
target	protein.	This	can	be	achieved	by	denaturation	of	the	target	protein	under	the	influence	
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of	heat	and	an	organic	solvent.	Finally,	the	organic	solvent	is	used	to	elute	the	liberated	marker	
from	the	filter.	The	obtained	solution	containing	the	formerly	bound	marker	is	then	analysed	
by	LC-MS.	
	
1.1.3. Ligand	Binding	Experiments	
	
With	 radioligand	 as	 well	 as	 MS	 Binding	 Assays,	 a	 variety	 of	 binding	 experiments	 can	 be	
performed.	They	can	be	divided	into	three	subclasses,	i.e.	saturation,	as	well	as	competitive	
experiments	and	kinetic	studies.	All	three	assay	types	are	based	on	the	same	experimental	
protocol,	described	above	(see	1.1.1	Radioligand	Binding	Assays	and	1.1.2	MS	Binding	Assays).	
Since	 the	 specific	binding	of	 the	 reporter	 ligand	 towards	 the	 target	 cannot	be	determined	
directly	in	binding	experiments,	the	nonspecific	binding	(NSB)	and	the	total	binding	(TB)	have	
to	be	measured	instead.	Nonspecific	binding	is	the	amount	of	reporter	ligand,	that	is	bound	
to	nonspecific	binding	sites	in	the	binding	sample,	such	as	lipid	membranes	and	non-target-
proteins	in	the	target	preparation,	or	materials	used	to	carry	out	the	binding	experiment,	e.g.	
vessels	 used	 for	 the	 incubation	 or	 filter	materials	 required	 for	 the	 separation	 of	 reporter	
ligand-target	 complexes	 and	unbound	 reporter	 ligand.	 The	 sum	of	 the	 nonspecifically	 and	
specifically	 bound	 reporter	 ligand	 is	 the	 total	 binding.	 Hence,	 the	 specific	 binding	 can	 be	
calculated	as	the	difference	between	total	binding	and	nonspecific	binding	(2).	
	
	 SB	=	TB	–	NSB	 (2)	
	
Since	saturation	and	competition	experiments	were	performed	in	this	work,	only	these	two	
types	of	binding	experiments	will	be	discussed	in	the	following	in	detail.		
	
Saturation	Experiments	
	
In	 saturation	 experiments,	 the	 affinity	 of	 the	 reporter	 ligand	 towards	 the	 target	 –	 the	
equilibrium	dissociation	constant	(Kd)	–	can	be	determined.	For	this	purpose,	a	defined	target	
concentration	 [T]	 is	 incubated	 together	with	 the	 reporter	 ligand	 [L],	which	 is	 employed	at	
different	concentrations.	The	concentrations	of	the	reporter	ligand	should	cover	a	range	of	at	
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least	0.1	Kd	to	10	Kd	to	ensure,	that	the	resulting	saturation	isotherm	is	well	defined	by	the	
obtained	 data	 points.	 Furthermore,	 to	 avoid	 reporter	 ligand	 depletion,	 the	 target	
concentration	should	not	exceed	0.1	Kd	[23].	Reporter	ligand	depletion	is	an	effect,	where	a	
substantial	 fraction	 of	 the	 employed	 concentration	 of	 the	 reporter	 ligand	 is	 bound	 to	 the	
target	and	therefore	not	free	in	solution.	For	the	calculation	models,	the	concentration	of	free	
reporter	 ligand	is	required,	but	for	reasons	of	simplicity,	the	nominal	concentration	can	be	
used	as	long	as	the	marker	depletion	is	below	10	%.	The	incubation	time	should	be	chosen	
long	enough	to	guarantee	that	the	association	of	the	reporter	ligand-target	complexes	(k+1)	is	
in	equilibrium	with	the	dissociation	of	the	reporter	ligand-target	complexes	(k-1).		
	
Additionally	to	the	samples	for	the	determination	of	the	total	binding,	a	set	of	samples	for	the	
nonspecific	binding	are	needed.	In	these	samples,	the	target	and	the	different	reporter	ligand	
concentrations	are	typically	incubated	in	presence	of	a	large	excess	of	a	highly	potent	inhibitor	
for	 the	 specific	 binding	 site,	 but	 also	 other	 options	 to	 avoid	 specific	 binding,	 such	 as	
denaturation	of	the	target	by	heat	shock	are	possible.	Usually,	the	nonspecific	binding	can	be	
described	by	a	linear	regression	(see	figure	4	a)).	Based	on	the	two	data	sets	for	the	total	and	
the	 nonspecific	 binding,	 the	 specific	 binding	 can	 be	 calculated	 according	 to	 the	 equation,	
mentioned	above	(see	formula	2).	
	
	
	
Figure	 4:	 Simulated	 data	 for	 a	 saturation	 experiment.	 a)	 Concentration	 of	 bound	 reporter	
ligand	is	plotted	against	employed	nominal	concentration	of	the	reporter	ligand	for	nonspecific	
binding	()	and	total	binding	(●).	b)	Saturation	 isotherm	for	specific	binding	resulting	from	
data	shown	in	a).		
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From	the	saturation	isotherm,	which	is	defined	by	the	Langmuir	adsorption	model	(equation	
1),	the	affinity	of	the	reporter	ligand	and	the	maximum	amount	of	binding	sites	(Bmax)	can	be	
derived.	The	Bmax	is	represented	by	the	plateau	of	the	saturation	isotherm.	At	this	level,	all	
specific	 binding	 sites	 are	 occupied	 by	 the	 reporter	 ligand.	 The	 equilibrium	 dissociation	
constant	(Kd,	see	figure	4	b))	is	defined	by	the	reporter	ligand	concentration,	which	results	in	
a	target	occupancy	of	50	%.		
	
Competition	Experiments	
	
To	evaluate	the	binding	affinities	of	 large	numbers	of	substances,	competitive	experiments	
are	a	powerful	tool.	In	these	experiments,	the	displacement	of	the	reporter	ligand	from	the	
target	 caused	 by	 the	 addition	 of	 a	 competing	 test	 substance,	 is	 analysed.	 To	 perform	
competitive	 experiments,	 different	 concentrations	 of	 the	 test	 substance	 [C]	 are	 incubated	
with	the	target	in	presence	of	a	defined	concentration	of	the	reporter	ligand	(see	figure	5).	At	
the	equilibrium	state,	both	the	reporter	ligand	and	the	test	substance	are	in	competition	for	
the	specific	target	binding	sites,	which	can	be	expressed	by	equation	3.		
	
	 L 	+	 C 	+	 T 	⇄	 LT 	+	[CT]	 (3)	
	
	
	
Figure	5:	Schematic	depiction	of	a	competition	experiment.	The	target	(T)	is	incubated	together	
with	the	reporter	ligand	L	and	a	competing	test	substance	(C).	After	the	incubation,	reporter	
ligand-target	complexes	and	competitor-target	complexes	are	separated	from	the	unbound	
reporter	ligand	and	competitor	by	a	filtration	step	(adopted	from	de	Jong	[2]).		
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At	 increasing	 concentrations	 of	 the	 test	 substance,	 the	 reporter	 ligand	 will	 be	 gradually	
displaced	 from	 the	 complexes	 with	 the	 target	 and	 competitor-target	 complexes	 will	 be	
formed.	In	competition	experiments,	the	affinity	of	the	test	substance	is	determined	indirectly	
by	quantification	of	the	bound	reporter	ligand.	An	important	benefit	of	this	procedure	is	the	
circumstance,	that	it	is	not	required	to	quantify	the	bound	test	substance.	This	means,	that	in	
radioligand	binding	experiments,	unlabelled	compounds	can	be	used	as	test	substances	and	
in	case	of	MS	Binding	Assays,	only	one	quantification	method	for	the	marker	is	needed	instead	
of	quantification	methods	for	each	employed	test	compound.		
	
After	 the	 incubation	 of	 the	 test	 compound	 with	 the	 target	 and	 the	 reporter	 ligand,	 the	
reporter	 ligand-target	 complexes	 are	 separated	 together	 with	 the	 competitor-target	
complexes	 from	 the	 unbound	 reporter	 ligand	 and	 competitor.	 The	 data	 from	 the	
quantification	of	the	bound	reporter	ligand	allows	the	construction	of	a	competition	curve	as	
shown	in	figure	6.	The	left	side	of	the	competition	curve	is	fixed	to	100	%	which	represents	
the	concentration	of	bound	reporter	ligand	without	the	addition	of	the	competitor.	On	the	
other	 side	 of	 the	 competition	 curve,	 the	 amount	 of	 nonspecific	 reporter	 ligand	 binding	 is	
defined	as	0	%	specifically	bound	reporter	ligand.	The	inhibitory	effect	of	the	test	substance	is	
described	 by	 the	 IC50-value,	 the	 concentration	 of	 the	 competitor,	 which	 reduces	 the	
specifically	bound	marker	to	a	level	of	50	%	(see	figure	6).		
	
	
	
Figure	6:	Simulated	data	for	a	competition	experiment.	Concentration	of	bound	reporter	ligand	
is	plotted	against	employed	concentration	of	a	competitor.	
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To	calculate	the	affinity	of	the	test	substance,	the	IC50-value	has	to	be	transformed	into	the	
inhibition	constant	Ki	with	the	Cheng-Prusoff	equation	(4)	[24].	
	
	 -i	=	 IC;<1	+	 [L]-d 	 (4)	
	
For	this	equation,	the	Kd	of	the	reporter	ligand	has	to	be	known.	Similar	to	equation	(3)	for	the	
saturation	experiments,	[L]	represents	the	free	concentration	of	the	reporter	 ligand,	which	
can	be	substituted	by	the	nominal	concentration	of	the	reporter	ligand,	as	long	as	the	marker	
depletion	is	negligible.	Since	the	inhibition	constant	Ki	is	independent	from	binding	affinity	of	
the	 used	 reporter	 ligand	 and	 its	 concentration	 in	 the	 binding	 experiment,	 it	 allows	 the	
comparison	of	binding	affinities	of	different	test	substances,	determined	in	different	binding	
assays.	
	
Saturation	experiments	are	important	to	characterize	the	binding	affinity	of	a	reporter	ligand	
towards	a	target.	The	results	from	these	experiments	can	then	be	used	to	set	up	competition	
experiments	for	the	screening	of	large	numbers	of	test	compounds.	Hence,	these	two	binding	
experiments	 are	 effective	 tools	 for	 the	 characterization	 of	 the	 binding	 affinities	 of	 test	
compounds	in	the	modern	drug	development	process.		
	 	
Introduction	
	 	
11	
1.2. The	Neurotransmitters	Dopamine,	Norepinephrine,	and	Serotonin	
	
The	three	biogenic	monoamines	dopamine	(DA),	norepinephrine	(NE),	and	serotonin	(5-HT,	
see	 figure	 7	 for	 the	 structures	 of	 the	 three	monoamines)	 act	 as	 neurotransmitters	 in	 the	
human	brain	and	periphery.		
	
	
	
Figure	7:	Structures	of	dopamine,	norepinephrine,	and	serotonin	
	
As	 neurotransmitters,	 these	monoamines	 have	 distinct	 functions	 in	 different	 areas	 of	 the	
central	nervous	system	(CNS).		
	
1.2.1. Signal	Transmission	at	Monoaminergic	Neurons	
	
The	 function	 of	 the	mammalian	 CNS	 is	 based	 on	 neurons,	 which	 are	 able	 to	 receive	 and	
transmit	 the	 neuronal	 signals.	 This	 connection	 between	 neurons	 is	 usually	 achieved	 by	
neurotransmitters,	 like	 the	above-mentioned	monoamines.	 In	 the	presynaptic	neuron,	 the	
neurotransmitters	 are	 stored	 in	 vesicles,	where	 they	 are	 protected	 from	degradation	 (see	
figure	 8	 a)	 step	 1).	 To	 transmit	 the	 neuronal	 signal	 from	 one	 neuron	 to	 another,	 the	
monoamines	 are	 released	 from	 vesicles	 in	 the	 presynaptic	 neuron	 into	 the	 synaptic	 cleft	
initiated	 by	 the	 influx	 of	 calcium	 ions	 as	 a	 response	 to	 an	 action	 potential	 arriving	 at	 the	
synapse	 (see	 figure	 8	 a)	 step	 2)	 [25].	 Due	 to	 the	 storage	 of	 the	 neurotransmitters	 in	 the	
vesicles,	 a	 fast	 release	 of	 high	 neurotransmitter	 concentrations	 can	 be	 achieved.	 In	 the	
synaptic	cleft,	the	neurotransmitters	can	bind	to	receptors,	located	in	the	membrane	of	the	
postsynaptic	neuron	(see	figure	8	a)	step	3a).	Most	of	the	monoamine	receptors	are	G-protein-
coupled	 receptors,	 which	 are	 coupled	 to	 ion	 channels	 or	 enzymes.	 Only	 the	 serotonin	
receptor	3	(5-HT3	receptor)	is	a	ligand	gated	cation	channel	[26].	Activation	of	the	receptors	
can	lead	to	excitatory	or	inhibitory	effects	on	the	action	potential	of	the	postsynaptic	neuron.	
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Furthermore,	presynaptic	G-protein-coupled	monoamine	receptors	can	reduce	the	release	of	
the	 neurotransmitter,	 resulting	 in	 a	 negative	 feedback	 effect	 (see	 figure	 8	 a)	 step	 3b).	 To	
terminate	the	signal	transmission,	there	are	two	pathways	for	the	removal	of	the	released	
monoamines.	 They	 can	 either	 be	 degraded	 by	 the	monoamine	 oxygenase	 (MAO)	 and	 the	
catechol-O-methyltransferase	 (COMT),	or	 transported	back	 into	 the	presynaptic	neuron	by	
monoamine	transporters	(see	figure	8	a)	step	4).	When	transported	back	into	the	presynaptic	
neuron,	the	monoamines	are	taken	up	into	secretory	vesicles	through	vesicular	transporters	
(see	figure	8	a)	step	5),	where	they	are	stored	until	the	next	release	[26–28].	
	
	
	
Figure	8:	a)	Schematic	representation	of	the	monoaminergic	synapse.	The	monoamines	(e.g.	
dopamine,	norepinephrine,	or	serotonin)	are	stored	in	vesicles	(1).	Upon	arrival	of	an	action	
potential,	 the	neurotransmitters	are	released	 into	the	synaptic	cleft	 (2),	where	they	bind	to	
postsynaptic	receptors	(3a)	or	to	presynaptic	receptors,	triggering	a	negative	feedback	effect	
(3b).	 To	 mediate	 neurotransmission,	 the	 monoamines	 are	 transported	 back	 into	 the	
presynaptic	 neuron	 by	monoamine	 reuptake	 transporters	 (e.g.	 DAT,	NET,	 or	 SERT)	 (4)	 and	
stored	in	vesicles	again	(5).	b)	Depiction	of	dopamine,	norepinephrine,	and	serotonin	transport,	
with	 stoichiometry	 of	 sodium	 and	 chloride	 symport,	 as	 well	 as	 potassium	 antiport.	 Figure	
adopted	from	Kristensen	et	al.	[28].	
	
1.3. Monoamine	Transporters	
	
The	monoamine	transporters	are	part	of	the	solute	carrier	6	(SLC6)	family	of	transporters	[29].	
Besides	the	transporters	for	dopamine	(DAT),	norepinephrine	(NET),	and	serotonin	(SERT),	the	
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SLC6	transporter	family	consists	of	20	different	transporters,	among	those	are	transporters	
for	 the	neurotransmitters	 g-aminobutyric	 acid	 (GABA)	 and	glycine,	 as	well	 as	 amino	acids,	
betaine,	 taurine	 and	 creatine	 [30,31].	 SLC6	 transporters	 can	 be	 divided	 into	 subgroups,	
depending	on	the	transported	substrate.	The	neurotransmitter	transporters	(NTTs)	consist	of	
the	three	monoamine	transporters,	 the	GABA	transporters,	and	glycine	transporters.	Since	
the	transport	of	the	neurotransmitters	is	based	on	a	sodium	gradient,	the	neurotransmitter	
transporters	are	also	called	neurotransmitter-sodium-symporters	 (NSS)	 in	 the	“Transporter	
Classification	System”	from	Milton	Saier	[31,32].	The	cotransport	of	sodium	ions	enable	the	
neurotransmitter	 transporters	 to	 transport	 the	 substrate	 against	 large	 concentration	
gradients	[28].	In	addition	to	the	substrate	and	sodium,	a	chloride	ion	is	transported	into	the	
cell	by	the	monoamine	transporters	[33].	The	stoichiometry	of	the	transported	substrate	and	
ions	 differs	 for	 each	 of	 the	 three	 transporters.	 Generally,	 one	 substrate	 molecule	 is	
transported	together	with	one	sodium	ion	and	one	chloride	ion.	Differing	from	this,	the	DAT	
transports	two	sodium	ions,	while	an	additional	potassium	ion	is	transported	from	the	SERT	
against	 the	direction	of	 the	substrate	 (see	table	1	and	figure	8	b))	 [33].	There	 is	not	much	
variance	between	the	three	monoamine	transporters	in	the	turnover	rate,	all	three	of	them	
transport	between	1	and	3	substrate	molecules	per	second	[28].	Affinities	of	the	substrate	
towards	the	transporters	and	therefore	the	selectivity	of	the	transporters	for	the	substrate	is	
different	for	each	transporter.	Only	SERT	is	highly	selective	for	its	substrate	serotonin.	This	
can	be	explained	by	the	structure	of	serotonin,	which	is	very	distinct,	compared	to	dopamine	
and	norepinephrine	(see	figure	7).	The	dopamine	transporter	has	a	slightly	higher	affinity	for	
dopamine	than	for	norepinephrine,	while	unexpectedly,	the	norepinephrine	transporter	also	
shows	a	lower	affinity	for	norepinephrine	than	for	dopamine	(see	table	1)	[33].		
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Transporter	 Substrate	affinity	Ki	in	µmol/L	
a	
Turnover	
rate	in	
molecules	
per	s	b	
Substrate-ion	
stoichiometry	
(substrate	:	Na+	:	
Cl-)	b	
DA	 NE	 5-HT	
DAT	 6.40	±	0.59	 57.0	±	13.0	 549	±	96	 0.7	–	1.9	 1	:	2	:	1	
NET	 28.0	±	11.0	 160	±	33	 360	±	71	 1.7	–	2.5	 1	:	1	:	1	
SERT	 1110	±	180	 1470	±	110	 3.50	±	1.20	 1.0	–	3.1	 1	:	1	:	1	(:	1	K+	out)	
	
Table	1:	Characteristics	of	the	monoamine	transporters	DAT,	NET,	and	SERT.	a	Eshleman	et	al.	
[34].	b	Kristensen	et	al.	[28].	
	
1.3.1. Structure	and	Function	of	Monoamine	Transporters	
	
In	recent	years,	X-ray	structures	of	monoamine	transporters	were	published.	Until	then,	the	
crystal	structure	of	the	 leucine	transporter,	expressed	by	the	hyperthermophilic	bacterium	
Aquifex	aeolicus	(LeuTAa),	was	used	for	studies	on	the	structure	and	function	of	transporters	
from	the	SLC	6	family	[28,35].	With	a	sequence	identity	of	20	–	25	%	between	the	LeuTAa	and	
the	monoamine	transporters,	the	similarity	of	these	two	transporters	seem	to	be	quite	low,	
but	 the	homology	at	 the	substrate	binding	site	 is	76	%	 in	 the	LeuTAa	and	 the	human	SERT	
(hSERT),	which	explains	the	good	accordance	of	data,	obtained	from	experiments	with	the	
monoamine	transporter	and	from	predictions	based	on	the	LeuTAa	crystal	structure	[28,36,37].	
The	elucidation	of	crystal	structures	for	Drosophila	melanogaster	DAT	(dDAT)	and	hSERT	in	
the	 last	 years	 gave	 better	 insight	 into	 the	 structure	 and	 function	 of	 the	 monoamine	
transporters.	
	
Crystal	Structure	of	dDAT	
	
In	2013,	Penmatsa	et	al.	published	the	crystal	 structure	of	dDAT	 (see	 figure	9)	 [38].	When	
extracted	from	the	membrane	with	detergents,	wild-type	dDAT	loses	its	ligand-binding	activity	
and	is	therefore	hard	to	crystallize.	Crystallization	was	finally	achieved	by	the	insertion	of	five	
mutations,	which	resulted	in	a	loss	of	dopamine-transport	activity.	The	resolution	of	the	X-ray	
structure	was	further	enhanced	by	the	creation	of	a	complex	of	the	transporter	together	with	
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an	antibody	fragment.	In	the	crystal	with	nortriptyline,	the	transporter	is	in	an	outward-open	
conformation	[38].	A	 later	publication	describes	the	crystallization	of	dDAT	with	nisoxetine	
and	 reboxetine	 bound	 to	 the	 transporter	 (see	 figure	 10	 a)	 and	 b)).	 Crystallization	 of	 the	
nisoxetine-dDAT	was	achieved	with	the	previously	published	dDAT	construct,	containing	five	
mutations	(see	figure	9	a)),	while	reboxetine-dDAT	was	crystallized	with	a	dDAT	construct	with	
fewer	mutations,	which	possessed	a	reduced	dopamine-transport	activity	when	compared	to	
the	wild-type	[39].	In	each	case,	the	antidepressant	is	bound	in	the	cavity	halfway	across	the	
membrane	bilayer,	where	it	can	only	be	accessed	by	solvent	from	the	extracellular	side	of	the	
transporter.	 The	 structure	 of	 the	 crystallized	 dDAT	 (dDATcryst)	was	 in	 accordance	with	 the	
predictions	based	on	the	crystal	structure	of	 the	LeuTAa	 (LeuTcryst).	While	there	are	distinct	
differences	 in	 the	periphery	of	 structure	of	both	 transporters,	 the	core	of	dDATcryst	 closely	
resembles	the	one	of	LeuTcryst	[38].	
	
	
	
Figure	9:	Crystal	structure	of	dDAT	as	published	by	Penmatsa	et	al.	[38].	a)	Schematic	structure	
of	dDAT.	Mutations	are	labeled	by	red	circles.	b)	Architecture	of	dDAT	as	viewed	parallel	to	the	
membrane	with	bound	nortriptyline,	cholesterol,	sodium	and	chloride	ions.	c)	Architecture	of	
dDAT	as	viewed	from	the	extracellular	face.	
	
Both	transporters	consist	of	twelve	transmembrane	helices	(TMs)	with	intracellular	N	and	C	
termini.	TM	1,	3,	6,	and	12	can	be	subdivided	into	two	parts,	connected	by	non-helical	hinge-
like	 regions	 (see	 figure	 9).	 The	 arrangement	 of	 the	 TMs	 result	 in	 a	 C2-pseudosymmetry	
regarding	the	helices	1	–	5	and	6	–	10,	which	is	also	referred	to	as	the	5	+	5	inverted	repeat	
fold	[28,31,35,38,39].	As	previously	proclaimed	 in	chimeric	studies,	 the	drug-binding	site	 is	
localized	 between	 the	 helices	 1,	 3,	 6,	 and	 8,	 which	 corresponds	 to	 the	 position	 of	 the	
substrate-binding	pocket	 in	LeuT	 [40,41].	Close	 to	 the	nortriptyline	molecule	 in	 the	crystal	
structure,	 three	 locations	 with	 high	 electron	 densities	 were	 identified	 in	 the	 non-helical	
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regions	of	TMs	1	and	6.	Two	of	these	locations	are	identical	with	the	sodium	ion-binding	sites	
Na1	and	Na2	of	the	LeuT-structure.	The	third	location,	proclaimed	as	the	chloride	ion-binding	
site	 is	positioned	between	TMs	2,	6,	and	7.	Between	TMs	5	and	7,	a	cholesterol	molecule,	
modulating	the	movement	of	TM	1a,	which	takes	place	during	the	transport	of	the	substrate,	
is	positioned	(see	figure	9	b)	and	c)).	In	the	crystal	structure	of	dDAT,	the	ion	and	ligand	binding	
sites	are	accessible	to	solvent	from	the	direction	of	the	extracellular	side.	To	the	intracellular	
side	of	the	transporter,	polar	interactions	are	forming	a	barrier,	so	no	solvent	can	reach	the	
ligand	binding	site	from	this	direction.	The	bound	antidepressants	in	the	crystal	structures	of	
dDAT	sterically	prevent	a	movement	of	TMs	1b	and	6a	into	the	direction	of	TMs	3	and	8,	which	
is	proclaimed	to	be	necessary	for	closing	of	the	extracellular	gate	of	the	transporter	and	thus	
the	transport	of	the	substrate	(see	figure	10	c)).	This	shows	that	in	contrast	to	LeuT,	where	
antidepressants	bind	to	a	noncompetitive	binding	site	distant	from	the	substrate	binding	site,	
the	antidepressants	stabilize	the	outward-open	confirmation	of	 the	transporter	 in	the	DAT	
crystal	structure,	and	thereby	block	it	competitively	[38,39].	
	
	
	
Figure	 10:	 Inhibition	 of	 dDAT	 by	 antidepressants.	 a)	 Crystal	 structure	 of	 dDAT	with	 bound	
reboxetine.	b)	Surface	representation	of	dDAT	with	bound	reboxetine	(a)	and	b)	adopted	from	
Penmatsa	 et	 al.	 [39]).	 c)	 Schematic	 representation	 of	 bound	 nortriptyline	 in	 the	 substrate	
binding	site	of	dDAT	and	its	mode	of	action.	The	bound	antidepressant	prevents	movement	of	
TMs	1b	and	6a,	which	is	necessary	for	substrate	transport	(adopted	from	Penmatsa	et	al.	[38]).	
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Crystal	Structure	of	hSERT	
	
The	 first	 crystal	 structures	 of	 a	 human	 serotonin	 transporter	 were	 published	 in	 2016	 by	
Coleman	et	al.	(see	figure	11)	[42].	Together	with	a	recombinant	anti-SERT	antibody	fragment	
and	two	mutations	in	the	hSERT,	a	crystal	structure	of	the	functional	monoamine	transporter	
with	the	bound	antidepressant	paroxetine	was	obtained.	The	 introduction	of	an	additional	
mutation	 resulted	 in	 a	 better	 resolution	 of	 crystal	 structures	 of	 the	 hSERT	 with	 bound	
paroxetine	an	(S)-citalopram,	but	also	in	a	loss	of	transporter	activity.	According	to	the	crystal	
structures	of	LeuT	and	dDAT,	hSERT	consists	of	twelve	transmembrane	helices,	of	which	TMs	
1	–	5	and	6	–	10	are	arranged	around	a	pseudo-two-fold	axis	(see	figure	9	a)).	A	cavity	between	
TMs	1,	3,	6,	8,	and	10	represents	the	substrate	binding	site,	in	which	the	antidepressants	are	
bound	in	the	crystal	structures.	Additionally	to	the	substrate,	two	binding	sites	for	sodium	ions	
(of	which	only	one	is	transported)	and	one	binding	site	for	a	chloride	ion	were	identified	in	
the	same	locations,	as	the	ion	binding	sites	in	the	dDAT.	The	two	transmembrane	helices	1	
and	6	are	interrupted	by	non-helical	regions	and	contribute	residues	to	coordinate	a	sodium	
and	a	chloride	ion.	As	in	the	previously	described	dDAT	crystal	structure,	the	antidepressants	
lock	the	transporter	in	an	outward-open	configuration	(see	figure	10	c))	[42].		
	
	
Figure	 11:	 Architecture	 of	 hSERT	 with	 bound	 (S)-citalopram	 in	 central	 (dark	 green)	 and	
allosteric	(cyan)	binding	site	(NAG:	N-acetylglucosamine,	CHA:	Cholesterol	hemisuccinate).	a)	
hSERT	as	viewed	parallel	 to	the	membrane.	b)	hSERT	as	viewed	from	the	extracellular	 face	
(adopted	from	Coleman	et	al.	[42]).	
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In	addition	to	the	central	ligand	binding	site,	an	allosteric	binding	site	was	found	in	the	crystal	
structure	of	hSERT	between	TMs	1,	6,	8,	10	and	extracellular	loops	(ELs)	4	and	6.	A	molecule	
of	 (S)-citalopram,	 bound	 to	 this	 allosteric	 binding	 site,	 slowed	 down	 the	 off-rate	 of	 the	
inhibitor,	bound	to	the	central	binding	site	[42].	In	summary,	the	crystal	structure	of	hSERT	
confirms	the	findings	of	 the	crystal	structure	of	dDAT.	The	allosteric	binding	site	of	hSERT,	
which	was	not	identified	in	dDAT,	can	modulate	the	dissociation	of	the	bound	antidepressant	
in	the	central	binding	site.	
	
Transport	Mechanism	of	Monoamine	Transporters	
	
The	mechanism	of	 the	monoamine	transport	 is	described	by	the	alternating	access	model.	
This	model	states	that	the	substrate	binding	site	can	be	sealed	off	from	the	extracellular	or	
intracellular	side	by	the	transporter.	During	the	transport	cycle,	the	transporter	changes	its	
confirmation,	 initiated	 by	 the	 binding	 of	 the	 substrate	 and	 the	 ions.	 The	 monoamine	
transporter	can	shuttle	through	at	least	three	conformations,	of	which	one	is	the	outward-
open	conformation	(captured	in	the	above-mentioned	crystal	structures),	the	second	is	the	
occluded	conformation	in	which	the	substrate	binding	side	is	not	accessible	from	neither	side	
of	the	transporter,	and	the	third	is	the	inward-open	conformation,	allowing	the	substrate	to	
diffuse	 into	 the	cell.	 The	occluded	conformation	 itself	 can	be	 subdivided	 into	an	outward-
facing	occluded	state,	as	well	as	an	 inward-facing	occluded	state	 (see	 figure	12).	After	 the	
binding	of	the	substrate	and	the	ions	in	the	central	binding	site,	rearrangement	of	the	TMs	1,	
3,	6,	8,	2,	and	10	results	in	the	closing	of	the	cavity	to	the	extracellular	face	of	the	transporter.	
It	has	been	proclaimed,	that	the	non-helical	regions	in	TMs	1	and	6	act	as	hinges,	which	enable	
the	movement	 of	 the	 helical	 regions	 of	 these	 two	 TMs	 (see	 figure	 10	 c)).	 To	 release	 the	
substrate	into	the	cell,	TMs	1,	6,	and	8	form	a	cavity	to	the	intracellular	side,	through	which	
the	substrate	can	diffuse	[28,31,43].	In	an	alternative	model,	TMs	1,	2,	6,	and	7	form	a	bundle	
and	the	other	6	TMs	a	scaffold,	in	which	the	bundle	can	rock.	This	rocking	movement	is	then	
responsible	to	close	the	transporter	to	each	side	of	the	membrane	[31,44].	
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Figure	 12:	 Schematic	 representation	 of	 the	 alternating	 access	 model	 for	 the	 transport	 of	
monoamines	according	to	Kristensen	et	al.	[28].	
	
1.3.2. Localization,	Physiological	and	Pathophysiological	Implications	
	
Expression	 of	 the	 monoamine	 transporters	 seems	 to	 be	 exclusive	 to	 their	 respective	
monoaminergic	 neurons.	 There	 they	 are	 present	 in	 dendrites	 and	 axons	 of	 the	 neurons,	
predominantly	localized	in	the	extrasynaptic	regions	[26,28,45–48].	Each	of	the	monoamines	
and	 therefore	also	 the	monoamine	 transporter	has	distinctive	effects	on	a	variety	of	body	
functions,	but	they	are	all	involved	in	the	regulation	of	mood	(see	figure	13).	
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Figure	13:	Areas	of	action	for	the	monoamine	neurotransmitters	dopamine,	norepinephrine	
and	serotonin	(adapted	from	Guiard	[49]).	
	
DAT	
	
The	dopamine	transporter	is	mainly	expressed	in	the	substantia	nigra	of	the	brain,	but	it	can	
also	be	found	in	the	periphery,	especially	in	the	gut	and	the	adrenal	gland	[33,45].	Movement,	
mood,	pleasure,	cognition,	attention,	and	interest	is	mediated	by	the	dopaminergic	system	
[49,50].	In	experiments	with	knockout	mice,	deficiency	of	functional	dopamine	transporters	
resulted	 in	 hyperactivity,	 cognitive	 deficits,	 disrupted	 sensorimotor	 gating	 and	 sleep	
dysregulation	[51].	The	lack	of	response	to	psychostimulants	in	these	knockout	mice	supports	
the	role	of	DAT	in	the	mode	of	action	of	drugs	as	well	as	addiction	behaviour	[52,53].	This	
emphasizes	 the	 effect	 of	 the	 dopaminergic	 system	 on	motivation	 and	 reward.	 Uptake	 of	
released	dopamine	is	the	major	mechanism	for	the	removal	of	this	neurotransmitter	from	the	
synaptic	cleft	and	therefore	the	termination	of	the	neurotransmission	[54].		
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NET	
	
Norepinephrine	 transporters	 can	 be	 predominantly	 found	 in	 the	 central	 and	 peripheral	
nervous	system,	where	they	are	confined	to	the	membranes	of	axons,	somata	and	dendrites	
of	 noradrenergic	 neurons.	 The	 norepinephrinergic	 system	 is	 responsible	 for	 learning	 and	
memory,	as	well	as	the	regulation	of	mood,	attention,	interest,	anxiety,	alertness,	stress,	pain	
perception,	and	blood	flow	[33,48–50].	Knockout	of	the	NET	results	in	lower	body	weight	and	
reduced	locomotor	response	of	test	mice.	Furthermore,	heart	failure	can	be	associated	with	
lower	NET	expression	and	reverse	norepinephrine	transport	has	been	observed	during	cardiac	
ischemia	[33].	
	
SERT	
	
The	serotonin	transporter	is	distributed	in	the	brain	as	well	as	in	peripheral	tissue.	SERT	in	the	
brain	can	be	mainly	found	on	extrasynaptic	axonal	membranes	of	dendrites	[33].	Interestingly,	
SERT	 is	 located	 along	 the	 axonal	 membranes,	 distant	 to	 synaptic	 junctions	 [46].	 In	 the	
periphery,	 SERT	 is	 expressed	 in	 epithelial	 cells	 and	 platelets	 [28,31,33].	 Regulation	 of	 the	
serotoninergic	system	plays	a	role	in	mood,	impulsivity,	aggression,	appetite,	sleep,	cognition	
and	motor	 activity	 [49,50].	 Anxiety,	 depression,	 suicide,	 schizophrenia,	 autism,	 substance	
abuse	 and	 gastrointestinal	 disorders	 can	 be	 associated	 with	 variations	 in	 SERT	 activity	
[33,49,50].	
	
The	monoaminergic	neuronal	systems	play	a	role	in	a	variety	of	diseases	(see	figure	14).	They	
range	 from	 gastrointestinal	 disorders	 and	 cardiovascular	 diseases	 in	 the	 periphery	 of	 the	
body,	 to	 severe	CNS	diseases,	 like	Parkinson’s	 disease	 and	affective	disorders.	 In	 affective	
disorders,	 especially	 in	 depression	 (also	 called	 major	 depressive	 disorder	 (MDD)),	 a	
dysfunction	in	the	regulation	of	dopamine,	norepinephrine,	and	serotonin	is	involved.	
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Figure	14:	Diseases	linked	to	malfunctions	in	the	monoaminergic	systems	[33].	
	
1.3.3. Pathophysiology	and	Therapy	of	Depression	
	
Research	on	the	therapy	of	depression	started	in	the	1950s	by	the	accidental	discovery	of	the	
first	antidepressive	drugs.	The	discovery	of	these	drugs	resulted	in	insights	into	the	genesis	of	
major	 depressive	 disorders.	 Malfunctions	 in	 the	 regulation	 of	 both	 the	 serotonergic	 and	
norepinephrinergic	 neuronal	 system	 were	 identified	 as	 causes	 for	 the	 emergence	 of	
depression.	 This	 led	 to	 the	 formulation	 of	 the	 “catecholamine	 hypothesis	 of	 affective	
disorders”	and	the	“serotonin	hypothesis”,	which	identify	the	lack	of	free	norepinephrine	and	
serotonin	 as	 responsible	 for	 the	 genesis	 of	 depression	 [55,56].	 Later,	 also	 dopamine	 was	
considered	to	contribute	to	this	disease.		
	
Besides	 the	 minor	 role	 of	 electroconvulsive	 therapy	 in	 the	 treatment	 of	 depression,	
pharmacological	 therapy	 of	 depression	 is	 focussed	 on	 an	 increase	 of	 the	 monoamine	
concentration	in	the	synaptic	cleft.	For	this	purpose,	three	targets	have	been	identified,	which	
can	be	affected	by	a	variety	of	different	drugs.	Many	of	the	symptoms,	caused	by	malfunction	
of	 the	 monoaminergic	 neurotransmission,	 mentioned	 above	 (see	 1.3.2	 Localization,	
Physiological	and	Pathophysiological	Implications,	figure	13,	and	figure	14)	can	be	recognized	
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in	depressive	patients	and	allow	the	allocation	of	side	effects	to	the	treatment	with	certain	
drugs.	
	
MAO-Inhibitors	
	
The	 first	 target	 for	 the	 treatment	 of	 major	 depressive	 disorder	 was	 found	 by	 accident.	
Inhibitors	 of	 the	monoamine	 oxygenase	 (MAO)	 reduce	 the	 enzymatic	 degradation	 of	 the	
released	monoamines.	 In	 this	way,	 the	monoamines	 stay	 in	 the	 extracellular	matrix	 for	 a	
prolonged	 time,	which	 results	 in	 a	 longer	 activation	 of	 the	monoamine	 receptors.	 Due	 to	
severe	side	effects,	such	as	an	increased	risk	for	hypertensive	crisis	and	toxicity	in	overdose,	
today	the	role	of	MAO-inhibitors	in	the	treatment	of	depression	is	only	subordinate	[50].	
	
Monoamine	Autoreceptor	Antagonists	
	
Another	 strategy	 for	 the	 increase	 of	 the	 extracellular	 monoamine	 concentration	 is	 an	
inhibition	 of	 the	 negative	 feedback	 effect,	 induced	 by	 stimulation	 of	 the	 presynaptic	
monoamine	 receptors	 (see	 figure	 8	 a)	 step	 3b).	 The	 drugs	 trazodone,	 mianserin,	 and	
mirtazapine	 are	 antagonists	 for	 the	 norepinephrine	 and	 serotonin	 autoreceptors.	
Autoreceptors	occupied	by	these	drugs	do	not	inhibit	the	exocytosis	of	vesicles	containing	the	
monoamines,	 thus	 the	 release	 of	 the	 neurotransmitter	 is	 not	 reduced	 by	 the	 released	
monoamines	[50,57].	
	
Monoamine	Reuptake	Inhibitors	
	
Unlike	the	inhibition	of	the	monoamine	autoreceptors	and	in	analogy	with	MAO-inhibitors,	an	
inhibition	 of	 the	 monoamine	 reuptake	 transporters	 prolongs	 the	 residence	 time	 of	 the	
extracellular	 neurotransmitters.	 The	 first	monoamine	 reuptake	 inhibitors	were	 discovered	
during	research	on	the	therapy	of	schizophrenia.	The	tricyclic	antidepressants	(TCAs),	such	as	
imipramine,	 amitriptyline,	 and	 clomipramine	 possess	 antidepressant	 properties,	 but	 also	
severe	 side	 effects.	 These	 side	 effects	 are	 anticholinergic	 effects,	 toxicity	 and	 increased	
incidence	of	seizure	in	overdose.	The	broad	variety	of	side	effects	can	be	explained	by	a	lack	
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in	 selectivity	 of	 TCAs.	 Besides	 the	 SERT	 and	 NET,	 muscarinic,	 adrenergic,	 histaminic,	
noradrenergic	and	serotonergic	receptors	are	also	targeted	by	these	drugs	[50].	In	order	to	
reduce	side	effects,	more	selective	drugs	for	the	treatment	of	depression	were	developed	as	
a	 new	 generation	 of	 antidepressants.	 In	 the	 1980s	 selective	 serotonin	 reuptake	 inhibitors	
(SSRIs)	were	developed	and	introduced	to	the	market.	Fluoxetine,	paroxetine,	sertraline,	and	
citalopram	are	members	of	this	group	of	antidepressants,	which	are	still	widely	in	use	[58].	
These	drugs	 selectively	 inhibit	 the	 SERT,	 thus	 they	have	 considerably	 reduced	 side	 effects	
when	compared	to	TCAs.	Furthermore,	their	efficacy	for	anxiety	disorders	and	depression	is	
improved.	To	further	enhance	the	efficacy	of	antidepressants,	drugs	targeting	both	the	SERT	
and	NET	with	higher	selectivity	than	TCAs	have	been	developed.	These	so-called	serotonin-
norepinephrine	reuptake	inhibitors	(SNRIs),	such	as	venlafaxine,	milnacipran,	and	duloxetine	
have	a	mode	of	action	and	efficacy,	comparable	to	TCAs,	but	they	are	better	tolerated	due	to	
their	much-improved	side	effect	profile	[50].	An	additional	benefit	in	the	therapy	of	MDD	is	a	
faster	 onset	 of	 action,	 which	 is	 often	 a	 drawback	 of	 antidepressants.	 Reboxetine	 and	
nisoxetine	have	been	developed	as	selective	norepinephrine	reuptake	inhibitors	(NRIs).	These	
drugs	target	the	NET	selectively	without	an	effect	on	the	SERT.	Since	it	mimics	the	adrenergic	
tricyclics	to	some	extent,	reboxetine	has	an	activating	effect,	as	is	energizes	the	patients	and	
improves	 their	 attention	 [50].	 The	 norepinephrine-dopamine	 reuptake	 inhibitor	 (NDRI)	
bupropion	is	the	only	dual-action	antidepressant	with	affinity	for	the	DAT.	Bupropion	can	be	
used	 to	 augment	 SSRIs	 in	 the	 therapy	 of	 MDD	 [59].	 Today,	 inhibition	 of	 monoamine	
transporters	represents	the	mainstay	in	the	therapy	of	MDD	[60].	 	
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2. Aims	and	Scope	
	
For	 the	 identification	 of	 compounds,	which	 bind	 towards	 a	 target,	 binding	 studies	 are	 an	
essential	tool	in	drug	discovery.	The	aim	of	this	work	was	the	development	of	a	binding	assay,	
suitable	for	the	characterization	of	target-ligand	interactions	at	the	monoamine	transporters	
hDAT,	hNET,	and	hSERT.	These	newly	developed	binding	assays	should	follow	the	procedure	
of	MS	Binding	Assays,	established	in	our	group	for	various	targets	[16–22].	Furthermore,	the	
MS	Binding	Assays	should	enable	the	use	of	a	selective	marker	for	each	of	the	targets.	The	
possibility	to	simultaneously	quantify	multiple	markers	in	the	same	binding	experiment	is	a	
feature,	 unique	 for	 MS	 Binding	 Assays.	 In	 radioligand	 binding	 studies,	 typically	 only	 one	
radioligand	can	be	applied	 in	 the	binding	experiments,	 since	 the	detection	via	 scintillation	
counting	has	only	 limited	selectivity.	The	high	selectivity	of	mass	spectrometry	enables	the	
performance	of	simultaneous	MS	Binding	Assays,	in	which	an	individual	marker	for	each	of	
the	 employed	 targets	 can	 be	 used.	 To	 carry	 out	 simultaneous	 MS	 Binding	 Assays,	 two	
requirements	have	to	be	met.	Additionally,	to	the	use	of	a	selective	marker	for	each	of	the	
targets,	 a	 highly	 sensitive	 method	 for	 the	 quantification	 of	 all	 applied	 markers	 must	 be	
available.	
	
Affective	disorders	have	a	high	and	even	increasing	importance	in	global	economics.	Major	
depression	is	already	the	main	burden	of	disease	in	medium-	to	high-income	countries	and	
will	be	the	primary	burden	of	disease	globally	by	2030	[61].	Since	only	60	–	70	%	of	patients	
treated	with	antidepressants	respond	to	the	therapy,	the	development	of	new	drugs	targeting	
the	monoaminergic	neurotransmission	is	still	of	great	importance.		
	
Recently,	MS	Binding	Assays	targeting	the	hDAT,	hNET,	and	hSERT	have	been	developed	and	
published	by	Stefanie	Grimm	[19,62].	In	these	MS	Binding	Assays,	(1R,3S)-indatraline	is	used	
as	a	marker	for	the	three	monoamine	transporters.	The	advantage	resulting	from	the	use	of	
only	one	marker	 for	all	 three	 targets	 is	 the	 reduced	work	 that	has	 to	be	 invested	 into	 the	
method	development.	Additionally,	the	performance	of	the	binding	experiments	is	very	easy,	
since	binding	affinities	of	test	compounds	at	different	targets	can	be	performed	following	the	
same	procedure	with	different	target	materials.		
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The	 concept	 of	 Simultaneous	 Multiple	 MS	 Binding	 Assays	 provides	 some	 advantages	 in	
comparison	 to	 radioligand	 binding	 assays	 and	 classical	 MS	 Binding	 Assays	 (in	 which	 one	
marker	for	multiple	targets	is	applied),	as	demonstrated	recently	by	Schuller	et	al.	[22].	The	
ability	to	characterize	binding	affinities	at	multiple	targets	in	the	same	experiments	means,	
that	in	Simultaneous	Multiple	MS	Binding	Assays	only	one	binding	experiment	is	necessary,	
whereas	 in	 radioligand	 binding	 assays	 and	 classical	 MS	 Binding	 Assays,	 one	 binding	
experiment	 for	each	target	has	 to	be	performed	 individually.	This	 results	 in	a	considerably	
lower	number	of	samples,	which	have	to	be	prepared	and	analysed	in	Simultaneous	Multiple	
MS	Binding	Assays.	So,	 regarding	 the	effort	of	work	and	 time	required	 to	perform	binding	
studies,	 Simultaneous	 Multiple	 MS	 Binding	 Assays	 have	 a	 much	 higher	 efficiency	 than	
radioligand	binding	experiments	and	classical	MS	Binding	Assays.	The	 second	advantage	 is	
concerning	the	purity	of	the	used	target	material.	In	the	above-mentioned	(1R,3S)-indatraline	
MS	Binding	Assays,	 the	selectivity	 is	 limited	by	 the	purity	of	 the	 target	material,	 so	 it	 is	of	
fundamental	 importance	to	apply	target	material	only	containing	one	of	 the	three	targets.	
This	can	be	achieved	by	the	use	of	target	material	generated	from	cell	lines	stably	expressing	
each	 of	 the	 three	 targets	 individually.	 In	 radioligand	 binding	 studies	 addressing	 the	
monoamine	 transporters,	 often	 native	 target	 material,	 containing	 the	 three	 monoamine	
transporters,	 is	used	together	with	[3H]-WIN	35,428	(also	known	as	[3H]-b-CFT,	[3H]-(–)-2b-
carbomethoxy-3b-(4-fluorophenyl)tropane)	 or	 [125I]-RTI-55	 ([125I]-b-CIT,	 [125I]-(–)-2b-
carbomethoxy-3b-(4-iodophenyl)tropane)	as	the	radioligand.	Both	of	these	radioligands	have	
low	 selectivities,	which	makes	 it	 necessary	 to	 use	 them	 together	with	 selective	 inhibitors,	
blocking	 the	other	 targets	 in	 the	 target	preparation	 [63–67].	 In	 the	mentioned	radioligand	
binding	 studies,	 neither	 the	 target	 material,	 nor	 the	 used	 radioligand	 offers	 the	 needed	
selectivity,	so	the	selectivity	can	only	be	achieved	by	additional	agents,	blocking	the	targets	
which	should	not	be	addressed.	As	mentioned	above,	a	major	requirement	for	the	feasibility	
of	Simultaneous	Multiple	MS	Binding	Assays	is	the	application	of	a	selective	marker	for	each	
of	the	targets.	This	provides	the	selectivity,	which	enables	the	use	of	native	target	material,	
containing	multiple	monoamine	transporters,	without	the	addition	of	blocking	agents.		
	
As	a	 first	step	 for	 the	development	of	Simultaneous	Multiple	MS	Binding	Assays	 for	hDAT,	
hNET,	and	hSERT,	a	suitable	marker	for	each	of	the	three	targets	had	to	be	 identified.	The	
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markers	should	have	a	high	affinity	and	only	for	one	of	the	targets,	which	should	be	ideally	in	
the	low	nanomolar	range.	Fulfilling	these	requirements,	(R,R)-4-(2-benzhydryloxyethyl)-1-(4-
fluorobenzyl)piperidin-3-ol	((R,R)-D-84)	was	chosen	as	marker	for	hDAT,	(S,S)-reboxetine	for	
hNET	and	(S)-citalopram	for	hSERT	(see	second	publication	“Development	and	validation	of	
an	LC-ESI-MS/MS	method	for	the	quantification	of	D-84,	reboxetine,	and	citalopram	for	their	
use	in	MS	Binding	Assays	addressing	the	monoamine	transporters	hDAT,	hNET,	and	hSERT”).	
Since	 (R,R)-D-84	was	 not	 commercially	 available,	 a	method	 for	 the	 semipreparative	 chiral	
separation	 of	 rac-trans-4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol	 had	 to	 be	
developed	and	the	resulting	product	had	to	be	characterized	concerning	its	enantiomeric	and	
chemical	 purity	 (see	 first	 publication	 “Determination	 of	 the	 enantiomeric	 purity	 of	 the	
selective	 dopamine	 transporter	 inhibitor	 (+)-R,R-4-(2-benzhydryloxyethyl)-1-(4-
fluorobenzyl)piperidin-3-ol”).	 Additionally,	 rac-reboxetine	 was	 extracted	 from	 tablets	 and	
(S,S)-reboxetine	 was	 obtained	 after	 semipreparative	 resolution	 of	 the	 racemate	 (see	
supporting	information	in	the	second	publication).	Successive	to	the	choice	and	production	of	
the	 markers,	 a	 highly	 sensitive	 quantification	 method	 for	 the	 three	 markers	 had	 to	 be	
developed.	In	previously	published	MS	Binding	Assays,	LC-MS	proved	to	be	suitable	for	the	
quantification	 up	 to	 low	 picomolar	 concentrations	 of	 markers	 in	 samples	 obtained	 from	
binding	 experiments	 [17,21,22,62,68].	 During	 the	 LC-MS	 method	 development,	 MS-
conditions	had	to	be	found,	which	allowed	a	sensitive	detection	of	the	markers	and	a	HPLC	
method	 had	 to	 be	 developed,	 separating	 the	 markers	 from	 the	 matrix	 within	 a	 short	
chromatographic	run	time.	To	compensate	for	variations	 in	the	ionization	efficiency	and	of	
matrix	effects,	a	deuterated	internal	standard	for	each	marker	should	be	included	in	the	MS	
Binding	Assays.	The	binding	samples	should	be	prepared	according	to	the	previously	published	
MS	 Binding	 Assays,	 applying	 a	 filtration	 step	 for	 the	 separation	 of	 the	 target-marker	
complexes	and	the	unbound	marker.	To	prove	the	reliability	and	robustness,	the	developed	
LC-MS	 quantification	 method	 should	 be	 validated	 according	 to	 the	 CDER	 guideline	 for	
bioanalytical	 method	 validation	 [69],	 concerning	 its	 selectivity,	 validity	 of	 the	 calibration	
curve,	quantification	range	defined	by	the	lower	and	upper	limit	of	quantification	(LLOQ	and	
ULOQ),	precision	and	accuracy.	
	
In	 individual	 saturation	 experiments,	 performed	 with	 the	 newly	 established	 MS	 Binding	
Assays,	 the	 affinities	 and	 selectivities	 of	 the	 markers	 towards	 their	 targets	 should	 be	
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characterized.	For	these	experiments,	only	one	marker	and	one	target	should	be	used.	After	
these	 individual	 saturation	 experiments,	 the	 feasibility	 of	 simultaneous	 saturation	
experiments,	 applying	 all	 three	markers	 and	 targets	 in	 one	 binding	 experiment	 should	 be	
demonstrated.	Finally,	the	binding	affinities	and	selectivities	of	a	variety	of	known	monoamine	
inhibitors	should	be	characterized	 in	simultaneous	competition	experiments,	again	with	all	
three	markers	and	 targets	 in	a	 single	experiment,	 carried	out	as	 simultaneous	MS	Binding	
Assays.	 	
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3. Results	and	Discussion	
	
3.1. First	Publication	
Determination	 of	 the	 Enantiomeric	 Purity	 of	 the	 Selective	 Dopamine	 Transporter	
Inhibitor	(+)-R,R-4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol	
	
3.1.1. Summary	of	the	Results	
	
(R,R)-4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol	((R,R)-D-84)	is	one	of	the	most	
selective	inhibitors	for	the	DAT,	known	so	far	[19,70–72].	With	an	IC50	of	0.46	nM	towards	the	
DAT,	an	IC50	of	3600	nM	towards	the	SERT	and	an	IC50	of	1880	nM	towards	the	NET,	the	(R,R)-
enantiomer	has	a	much	higher	affinity	and	selectivity	for	the	DAT	than	the	(S,S)-enantiomer	
(IC50	of	57	nM	towards	DAT,	1550	towards	NET,	and	1830	towards	SERT)	[70].	In	an	MS	Binding	
Assay,	 (R,R)-D-84	 showed	 the	 best	 selectivity	 for	 the	 hDAT	 in	 comparison	 to	 other	 DAT	
inhibitors	[19].	The	combination	of	high	affinity	as	well	as	high	selectivity	for	the	hDAT	implies	
that	(R,R)-D-84	is	a	compound	of	great	interest	as	a	pharmacological	tool	for	studies	with	the	
DAT.	To	ensure	the	quality	of	this	compound	prior	to	its	use	in	pharmacological	studies,	the	
chemical	and	enantiomeric	purity	of	(R,R)-D-84	has	to	be	determined.	
	
In	 the	 original	 literature,	 both	 enantiomers	 of	 trans-4-(2-benzhydryloxyethyl)-1-(4-
fluorobenzyl)piperidin-3-ol	 are	 derivatized	 with	 (S)-camphanic	 acid	 chloride	 to	 obtain	
diastereomers,	which	were	then	separated	using	a	normal	phase	(NP)	HPLC	method.	After	the	
separation,	 the	 diastereomers	 were	 subjected	 to	 hydrolysis	 to	 liberate	 the	 enantiomers	
(R,R)-D-84	and	(S,S)-D-83	[70].	Since	this	method	is	not	suitable	to	determine	the	ee	of	the	
final,	underivatized	product,	a	method	for	the	characterization	of	its	enantiomeric	purity	had	
to	 be	 developed.	 A	 well-established	 method	 for	 the	 chromatographic	 separation	 of	 two	
enantiomers	is	the	use	of	a	chiral	stationary	phase	(CSP).	Therefore,	we	intended	to	develop	
and	 validate	 a	 CSP-HPLC	method	 for	 the	 separation	 and	 quantification	 of	 (R,R)-D-84	 and	
(S,S)-D-83.	 This	 method	 should	 further	 be	 used	 to	 separate	 both	 enantiomers	 on	 a	
semipreparative	scale.	As	there	is	no	reference	standard	for	(R,R)-D-84	and	(S,S)-D-83	with	a	
certified	purity	available,	 the	CSP-HPLC	method	cannot	be	used	to	determine	the	absolute	
Results	and	Discussion	
	 	
30	
concentrations	and	chemical	purities	of	the	enantiomers.	This	requires	an	alternative	method	
to	 assess	 the	 chemical	 purity	 of	 (R,R)-D-84	 and	 (S,S)-D-83,	 for	which	 quantitative	 1H	NMR	
(qNMR)	was	selected.	
	
During	the	method	development,	 the	 influence	of	 the	mobile	phase	composition,	 the	flow	
rate	and	the	temperature	on	the	chromatographic	separation,	retention	and	peak	shapes	of	
(R,R)-D-84	and	 (S,S)-D-83	was	 investigated.	 In	 the	 final	analytical	method,	a	Lux	Celluose-1	
column	 (250	 x	 4.6	mm,	5	µm,	Phenomenex)	was	used	 in	normal	 phase	 (NP)	mode	with	 a	
mobile	 phase	 consisting	 of	 n-hexane/propan-2-ol/ethanol/trifluoroacetic	 acid	
(TFA)/diethylamine	(DEA)	(85/13.5/1.5/0.5/0.1;	v/v/v/v/v)	at	a	flow	rate	of	2.0	mL/min.	The	
temperature	of	the	column	was	40	°C,	the	injection	volume	20	µL	and	260	nm	was	used	as	the	
wavelength	 for	 the	 detection	 of	 the	 analytes.	With	 these	 chromatographic	 parameters,	 a	
separation	 of	 both	 enantiomers	 within	 a	 run	 time	 of	 7	 min	 was	 achieved.	 The	 analytical	
method	was	then	validated	regarding	its	specificity,	linearity,	and	range,	resulting	in	a	linear	
range	from	25	µg/mL	to	30	mg/mL.	For	the	analysis	of	(R,R)-D-84	and	(S,S)-D-83,	samples	with	
a	concentration	not	lower	than	25	mg/mL	of	the	major	enantiomer	were	analysed,	thus	the	
analytical	 CSP-HPLC	method	was	 able	 to	 determine	 an	 ee	 of	 up	 to	 99.8	%.	 Based	 on	 the	
analytical	CSP-HPLC	method,	a	CSP-HPLC	method	which	 is	suitable	 for	the	semipreparative	
separation	of	(R,R)-D-84	and	(S,S)-D-83	was	established.	Since	there	were	concerns	about	the	
stability	of	the	enantiomers	during	the	evaporation	of	the	mobile	phase,	containing	TFA	as	a	
strong	 acid,	 TFA	 was	 substituted	 with	 formic	 acid.	 Using	 a	 mobile	 phase	 consisting	 of	
n-hexane/propan-2-ol/ethanol/formic	 acid/DEA	 (85/13.5/1.5/1.0/0.1;	 v/v/v/v/v)	 at	 a	 flow	
rate	 of	 2.0	mL/min	 in	 combination	with	 the	 Lux	Celluose-1	 column	 (250	 x	 4.6	mm,	 5	µm,	
Phenomenex)	at	a	temperature	of	5	°C,	a	good	separation	of	large	amounts	of	rac-trans-4-(2-
benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol	was	achieved.	With	this	method,	80	µL	
of	a	solution	of	100	mg/mL	of	the	racemic	compound	were	separated	per	run,	resulting	 in	
137.3	 mg	 (R,R)-D-84	 and	 148.8	 mg	 (S,S)-D-83	 after	 multiple	 chromatographic	 runs	 and	 a	
purification	 step,	 performed	 by	 column	 chromatography.	 The	 enantiomeric	 purity	 of	
(R,R)-D-84	was	characterised	with	the	analytical	CSP-HPLC	method	as	an	ee	>	99.8	%.	Analysis	
by	qNMR	resulted	in	a	chemical	purity	of	96.95	%	for	(R,R)-D-84.	The	high	enantiomeric	and	
chemical	purity	means,	that	the	produced	(R,R)-D-84	has	a	quality,	which	is	sufficient	for	its	
use	in	pharmacological	studies.	
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3.1.2. Declaration	of	Contributions	
	
Racemic	 trans-4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol	was	 synthesized	by	
Lars	Allmendinger	and	Gerd	Bauschke.	The	bachelor	thesis	“Entwicklung	einer	Methode	für	
die	Analytik	und	semipräparative	Trennung	des	Racemates	D-83/D-84“	[73]	by	Jan	Stöckl	was	
prepared	under	my	supervision.	Results	from	this	bachelor	thesis	were	valuable	as	preliminary	
experiments	for	the	method	development	performed	by	myself.	I	developed	an	HPLC	method	
for	the	determination	of	the	ee	of	(R,R)-D-84	as	well	as	(S,S)-D-83,	respectively.	Furthermore	
the	analytical	HPLC	method	was	modified	to	develop	a	semipreparative	HPLC	method	for	the	
chiral	 separation	 of	 large	 amounts	 of	 a	 racemic	mixture	 of	 (R,R)-D-84	 and	 (S,S)-D-83.	 This	
semipreparative	 HPLC	 method	 was	 used	 by	Markus	 Stöckelhuber	 to	 obtain	 enantiomeric	
purified	 (R,R)-D-84	 and	 (S,S)-D-83,	 which	 were	 subsequently	 subjected	 to	 additional	
purification	by	column	chromatography.	Validation	of	the	analytical	HPLC	method	as	well	as	
analysis	 of	 the	 purified	 enantiomers	 was	 performed	 by	 myself.	 Quantitative	 1H	 NMR	
experiments	for	the	characterization	of	the	chemical	purities	of	(R,R)-D-84	and	(S,S)-D-83	were	
performed	by	Lars	Allmendinger	and	me.	I	wrote	the	manuscript	and	prepared	the	graphics	
and	tables,	assisted	by	Georg	Höfner	and	Lars	Allmendinger.	Klaus	T.	Wanner	corrected	the	
manuscript.	
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Abstract
(+)‐R,R‐D‐84 ((+)‐R,R‐4‐(2‐benzhydryloxyethyl)‐1‐(4‐fluorobenzyl)piperidin‐3‐ol)
is a promising pharmacological tool for the dopamine transporter (DAT), due to
its high affinity and selectivity for this target. In this study, an analytical method
to ascertain the enantiomeric purity of this compound was established. For this pur-
pose, a high‐performance liquid chromatographic (HPLC) method, based on a cel-
lulose derived chiral stationary phase (CSP) was developed. The method was
characterized concerning its specificity, linearity, and range. It was shown that the
method is suitable to determine an enantiomeric excess of up to 99.8%. With only
a few adjustments, this analytical CSP‐HPLC method is also well suited to separate
(+)‐R,R‐D‐84 from its enantiomer in a semipreparative scale.
KEYWORDS
cellulose tris‐(3,5‐dimethylphenylcarbamate), CSP‐HPLC, enantiomeric excesss, selective DAT inhibitor,
validation
1 | INTRODUCTION
Dopamine (DA) is an important neurotransmitter in the
human brain and periphery, controlling physiological func-
tions, such as voluntary movement, reward, hormonal regula-
tion as well as hypertension.1 After its release from the
presynaptic neuron, DA can bind to dopamine receptors to
transmit the signal to the postsynaptic neuron. To terminate
the neurotransmission, dopamine in the synaptic cleft can
be transported back into the presynaptic neuron by the dopa-
mine transporter (DAT), where it can be enzymatically
degraded or stored in vesicles. Dysregulation of the dopami-
nergic neurotransmission is associated with disorders like
Parkinson's disease and schizophrenia.1
Besides therapy for the mentioned diseases, dopaminer-
gic neurotransmission is considered a possible target to
treat addiction, due to its regulation of the reward system.
Since it is believed that the reinforcing effect of cocaine
is mainly mediated by its binding to the DAT,2,3 research
was focused to develop ligands, binding selectively to this
transporter.4 In addition to their potential for therapy of
cocaine addiction, such compounds are also of interest as
pharmacological tools.
Many groups addressing the structure–activity relation-
ships of DAT ligands have synthesized huge numbers of
compounds with a broad variety of structural motifs,5,6 such
as tropane derivatives,7,8 benztropine derivatives,9,10 or
piperazine derivatives, such as 1‐[2‐[bis(4‐fluorophenyl)
methoxy]ethyl]‐4‐(3‐phenylpropyl)piperazin (GBR 12909)
and 1‐[2‐(Diphenylmethoxy)ethyl]‐4‐(3‐phenylpropyl)piper-
azine (GBR 12935)11-13 and corresponding analogs derived
from these selective DAT inhibitors, to name only a few.
Despite the enormous efforts in the search for DAT
ligands, no highly potent and selective compounds that may
serve as reporter ligands to label DAT binding sites are com-
mercially available to date. There are, however, several
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compounds described that are claimed to be highly selective
for DAT in relation to the serotonin (SERT) and the norepi-
nephrine transporter (NET), respectively.
Binding affinities are usually characterized by
radioligand binding assays. As a powerful alternative to these
radioligand binding assays, MS Binding Assays have been
developed by our group.14-18
In DAT radioligand binding assays, typically [3H]WIN
35,428 (also known as [3H]CFT) or [125I]RTI‐55 are used
as reporter ligands.19-22 Studies on the selectivity of [3H]
WIN 35,428 show only a low selectivity for DAT against
SERT, while [125I]RTI‐55 has even a slightly higher affinity
towards SERT against DAT23,24 and is therefore used in com-
bination with agents blocking the binding to NET and
SERT.22 Also in MS Binding Assays, the reporter ligand rep-
resents an essential tool. As for radioligand binding assays, it
should exhibit high affinity for the respective target. In addi-
tion, it should be highly selective for the individual target to
avoid the need of blocking agents, in order to offer the per-
spective to perform simultaneous binding assays on multiple
targets. Another important requirement of a compound to be
used as a reporter ligand in MS Binding Assays is that it
should be easily accessible by synthesis, including the option
to synthesize a deuterated analog as internal standard for
liquid chromatography / electrospray ionization / mass spec-
trometry (LC‐ESI‐MS) quantification.
Taking these criteria into account, 4‐(2‐benzhydry‐
loxyethyl)‐1‐(4‐fluorobenzyl)piperidin‐3‐ol, which was
mentioned and characterized for the first time in 2003 by
Dutta's group,25 is a promising reporter ligand for DAT.
Based on (GBR 12935), the introduction of a polar hydroxy
group in the piperidine ring resulted in an elevated binding
affinity towards DAT, especially for the (+)‐R,R enantiomer
of 4‐(2‐benzhydryloxyethyl)‐1‐(4‐fluorobenzyl)piperidin‐
3‐ol (rac‐1), which was named (+)‐R,R‐D‐84 in further
publications (see Figure 1).26,27 Both enantiomers differ sub-
stantially in their binding affinities towards the three mono-
amine transporters. With an IC50 of 0.46 nM measured at
the DAT in rat striatum determined in radioligand binding
assays, (+)‐R,R‐D‐84, is 122‐fold more potent than (−)‐S,S‐
D‐83 (IC50 56.7 nM) towards this target. Furthermore,
radioligand binding assays targeting SERT and NET in rat
striatum showed better affinities for (−)‐S,S‐D‐83, than for
(+)‐R,R‐D‐84.
Overall, (+)‐R,R‐D‐84 exhibits higher affinity for DAT
as compared to (−)‐S,S‐D‐84, and at the same time a higher
subtype selectivity at this transporter with regard to SERT
and NET.
Uptake assays for all three monoamine transporters con-
firmed the high potency and selectivity of (+)‐R,R‐D‐84
towards DAT.26 In an MS Binding Assay, which was
established by our group, a set of DAT inhibitors containing
commercially available, as well as compounds described in
the literature of diverse structural classes, was pharmacolog-
ically characterized.17 Here again, (+)‐R,R‐D‐84 was shown
to be the most potent and subtype‐selective compound,
concerning its affinity for the human DAT (hDAT) as com-
pared to hSERT and hNET.
According to the data published for (+)‐R,R‐D‐84, this
compound offers high affinity (sub‐nanomolar Ki) in combi-
nation with the highest selectivity towards DAT (vs. NET and
SERT). In summary, these findings indicate that (+)‐R,R‐D‐
84 is a promising tool for pharmacological assays, targeting
selectively DAT and thus as a reporter ligand in MS Binding
Assays.
However, when used as a tool in pharmacological assays
and also as a reporter ligand in MS Binding Assays, the cor-
responding compound samples of (+)‐R,R‐D‐84 have to fulfil
high demands with regard to chemical and enantiomeric
purity. In the original publication, (−)‐S,S‐D‐83 and (+)‐R,
R‐D‐84 were obtained by chiral resolution.25 Derivatization
with S‐(−)‐camphanic acid chloride resulted in a mixture of
diastereomeric esters that were separated using a
semipreparative normal phase high‐performance liquid chro-
matographic (HPLC) method. Final hydrolysis of these esters
led to the pure enantiomers (−)‐S,S‐D‐83 and (+)‐R,R‐D‐
84.25 The obtained enantiomers have been characterized by
their optical rotations, but their enantiomeric purity has not
been finally determined. Since, for the MS Binding Assays
to be developed, only the highly selective (+)‐R,R‐D‐84
enantiomer should be used as a reporter ligand, it had to be
assured that the respective samples of the compound are not
contaminated by the (−)‐S,S‐D‐83 distomer. So far, however,
no method for the determination of the enantiopurity of (+)‐
R,R‐D‐84 has been published.
The aim of the present study was to develop an
enantioselective UV‐HPLC method with cellulose tris‐(3,5‐
dimethylphenylcarbamate) as a chiral stationary phase
(CSP) that allows the characterization of the enantiopurity
of (+)‐R,R‐D‐84 and (−)‐S,S‐D‐83 at the stage of the final
product without any need for derivatization.28 To be able to
rule out any substantial contamination with the minor enan-
tiomer, the method should work for very high enantiomeric
FIGURE 1 Chemical structures of (‐)‐S,S‐D‐83 and (+)‐R,R‐D‐84.
The racemate of both enantiomers together correspond to rac‐1
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excess (ee) values. To show its applicability for the determi-
nation of the enantiopurities of both enantiomers, the method
should be validated with regard to specificity, linearity, and
quantification range for both enantiomers. Furthermore, the
method for the analytical separation should also be examined
with regard to its suitability for semipreparative resolution of
the enantiomers. A CSP‐HPLC method, capable of separat-
ing reasonable amounts of rac‐1, would facilitate the prepara-
tion of (+)‐R,R‐D‐84, and thus be of high value. In addition,
the characterization of samples of enantiopure (+)‐R,R‐D‐84
by CSP‐HPLC, their chemical purity should also be deter-
mined by quantitative 1H nuclear magnetic resonance
(qNMR) spectroscopy.29,30 Both methods would be helpful
tools to ascertain the suitability of samples of this compound
as reporter ligand in future DAT MS Binding Assays and
possibly also as a probe in pharmacological assays.
2 | MATERIALS AND METHODS
2.1 | Chemicals and reagents
HPLC‐grade n‐hexane (95%) and propan‐2‐ol were pur-
chased from VWR International (Darmstadt, Germany), and
ethanol (100%) was bought from Brüggemann (Heilbronn,
Germany). Additives for the CSP‐HPLC were diethylamine
(DEA, >99.5%, Sigma‐Aldrich, St. Louis, MO),
trifluoroacetic acid (TFA, 99%, Acros Organics, Geel, Bel-
gium), and formic acid (98–100%, Merck, Darmstadt, Ger-
many). Ethyl acetate (pur.), heptane (puriss.) and diethyl
ether (p.a.) were distilled prior to use. Sodium
hydrogencarbonate was purchased from Fisher Scientific
(Loughborough, UK) in analytical reagent grade. For 1H
qNMR, dimethyl sulfoxide‐d6 (d6‐DMSO; 99.9 atom %D),
D2O (99.9 atom %D), and maleic acid (99.94%, TraceCERT
CRM for qNMR) were obtained from Sigma‐Aldrich. DCl
(99.5 atom %D, 36–38% in D2O) was purchased from
Deutero (Kastellaun, Germany). All mixtures of solvents
used as mobile phases (including additives) or sample sol-
vents are specified as volume fractions (v/v) if not indicated
otherwise.
2.2 | Instrumentation
Chromatography was carried out with an Agilent 1100 HPLC
system, consisting of a vacuum degasser, a binary pump with
solvent selection valve, autosampler, column oven, and UV–
Vis‐detector (Agilent, Waldbronn, Germany) under control
of EZChrom software (Agilent). As CSP, a Lux Cellulose‐1
column (250 x 4.6 mm, 5 μm, Phenomenex, Aschaffenburg,
Germany) was used, which was protected with a
SecurityGuard precolumn (Lux Cellulose‐1, 4 x 3 mm,
5 μm, Phenomenex) and an inline filter (0.5 μm, stainless
steel, IDEX, Lake Forrest, IL). For the determination of the
calibration functions, GraphPad Prism 6.03 (GraphPad,
La Jolla, CA) was employed. Calculations regarding valida-
tion parameters and enantiomeric purity were done in
Microsoft Excel (Microsoft, Redmond, WA).
Chemical purity determination by NMR (qNMR) was
performed with an Advance III HD 400 MHz NMR spec-
trometer equipped with a 5 mm PABBO broadband probe
head with z‐gradients (Bruker BioSpin, Billerica, MA).
2.3 | Solutions for analytical CSP‐HPLC
For establishment of a calibration function, a stock solution
of 60 mg/ml rac‐1 (purity: 97.6%, determined by 1H–
NMR) in propan‐2‐ol/DEA (9/1) was prepared resulting in
a concentration of 30 mg/ml per enantiomer. Calibration
standards in concentrations of 25 μg/ml to 20 mg/ml per
enantiomer in propan‐2‐ol/DEA (9/1) were diluted from this
stock solution.
The samples used for the determination of enantiomeric
purity were prepared by dissolving the enantiomer to be ana-
lyzed in propan‐2‐ol/DEA (9/1) at a concentration of
~27.5 mg/ml. The resulting solutions were directly subjected
to HPLC analysis.
2.4 | Analytical CSP‐HPLC method
Enantioseparation of (−)‐S,S‐D‐83 and (+)‐R,R‐D‐84 with
the Lux Cellulose‐1 column (250 x 4.6 mm, 5 μm) as station-
ary phase was performed with a mobile phase consisting of n‐
hexane/propan‐2‐ol/ethanol/TFA/DEA (85/13.5/1.5/0.5/0.1)
at a flow rate of 2.0 ml/min at 40 °C. Twenty μl of the sample
solutions were injected for analysis; for detection, a wave-
length of 260 nm was used.
Quantification was carried out according to the external
standard calibration method. Resulting peak areas (y) were
investigated as a function of the analyte concentrations (x)
of each enantiomer, separately. To obtain a calibration func-
tion, calibration standards in 11 concentrations reaching from
0.025 mg/ml up to 30 mg/ml of the free base of each enantio-
mer (employing the rac‐1, see above, “solutions for analytical
CSP‐HPLC”) were measured in triplicate. For calculation of
the calibration function, linear regression was used. The stan-
dards were used to validate the method concerning its linear-
ity and range. Furthermore, specificity (by comparison of the
response of a solvent blank at the expected retention times
with the standards) was investigated.
2.5 | Semipreparative enantioseparation of
trans‐4‐(2‐benzhydryloxyethyl)‐1‐(4‐
fluorobenzyl)piperidin‐3‐ol
Resolution of (−)‐S,S‐D‐83 and (+)‐R,R‐D‐84 with the Lux
Cellulose‐1 column (250 x 4.6 mm, 5 μm) as stationary phase
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was carried out with a mobile phase consisting of n‐hexane/
propan‐2‐ol/ethanol/formic acid/DEA (85.0/12.4/1.5/1.0/
0.1) at a flow rate of 2.0 ml/min at 5 °C using a detection
wavelength of 260 nm. For semipreparative
enantioseparation, 80 μl of a 100 mg/ml solution of the rac‐
1 in propan‐2‐ol/DEA (9/1) were injected onto the column.
All fractions collected during multiple chromatographic runs
that corresponded to (−)‐S,S‐D‐83 or (+)‐R,R‐D‐84, respec-
tively (for details see Supporting Information), were pooled.
After evaporation of the solvent, both residues (containing
(−)‐S,S‐D‐83 or (+)‐R,R‐D‐84, respectively) were subjected
to flash chromatography, using silica gel (Merck 60,
40–63 μm) as stationary phase and ethyl acetate, heptane,
and trimethylamine (49.5/49.5/1) as mobile phase. All frac-
tions containing (−)‐S,S‐D‐83 and (+)‐R,R‐D‐84 were col-
lected. After evaporation of the solvent, each enantiomer
was dissolved in diethyl ether and washed with a saturated
aqueous sodium hydrogencarbonate solution. The aqueous
phase was reextracted 3 times with diethyl ether. Finally, all
diethyl ether phases from one enantiomer were combined
and dried (MgSO4). Subsequent to filtration, the solvent
was removed in vacuo.
2.6 | Quantitative 1H NMR
(−)‐S,S‐D‐83 or (+)‐R,R‐D‐84 were weighed out separately
to a mass of ~15 mg, then an exact amount (~5 mg) of maleic
acid was added as an internal calibrant to each glass vial. The
mixture of the respective analyte and the internal calibrant
were dissolved in 600 μl d6‐DMSO and DCl (2 M in D2O,
1.5 equivalents referred to the analyte) was added. This solu-
tion was quantitatively transferred into a 5‐mm NMR‐tube
and directly subjected to qNMR measurement.
The measurement and data processing were performed
according to the literature.31 A standard pulse program
(“zg” with 90° pulse) from the Bruker pulse program library,
utilizing a single pulse without carbon decoupling, was used
and the following settings were made: a relaxation delay (D1)
of 60 sec, an acquisition time (AT) of 4 sec, and a spectral
width (SW) of 30 ppm with a transmitter offset at 7.5 ppm.
During acquisition the temperature was maintained at 25 °C.
After the acquisition of four dummy scans (DS), the spectrum
was acquired with 64 scans of 64 K data points. Prior to FT a
line‐broadening factor of 0.1 Hz and a zero‐filling to 256 K
data points were applied in MestReNova. After a manual
phase correction followed by a 5th order polynomial fit as
baseline correction, the signal of the internal calibrant
(δ = 6.3 ppm) as well as chosen signals of the analyte
[δ = 5.4 (CH(Ph)2), 2.8 (H‐6eq), 2.1 ppm (CH2CH2O)] were
manually integrated. Based on the absolute integrals, the
chemical purity of the analyte was calculated with the Purity
Calculator Tool of the MestReNova‐Software.
3 | RESULTS AND DISCUSSION
3.1 | CSP‐HPLC
The main goal for the method to be developed was at first
to enable reliable enantiopurity determination of highly
enantioenriched samples of (−)‐S,S‐D‐83 and (+)‐R,R‐D‐
84. Accordingly, the method should allow the quantifica-
tion of both enantiomers in a wide linear range, i.e., pos-
sess a lower limit of quantification (LLOQ) as low as
possible for the minor enantiomer and an upper limit of
quantification (ULOQ) as high as possible for the major
enantiomer. Furthermore, the resolution of the two chro-
matographic peaks resulting from the enantiomers should
be sufficient to guarantee a reliable separation of the small
peak of the minor enantiomer from the large peak of the
major enantiomer even when the major enantiomer elutes
before the minor one. When having this feature, it should
also be tested whether the method is suitable for a
semipreparative resolution of (−)‐S,S‐D‐83 and (+)‐R,R‐D‐
84. In that case, it should tolerate high loadings of the race-
mate onto the column, even in the mg range, distinctly sur-
passing the amounts typically applied to analytical
columns. Favorably, the mobile phase should not contain
any nonvolatile components to be able to easily isolate
the enantiopure compounds by vaporization of the solvent.
As the pure enantiomers (−)‐S,S‐D‐83 and (+)‐R,R‐D‐84
were not available for the development of the desired
CSP‐based separation method, the racemate synthesized
according to the literature was employed.25
3.2 | Development of the analytical CSP‐
HPLC method
Experiments were started with a column containing a chiral
stationary phase based on cellulose tris‐(3,5‐
dimethylphenylcarbamate) (Lux Cellulose‐1, 250 x 4.6 mm,
5 μm), as this CSP is known to enable enantiomeric resolu-
tion of a broad variety of different classes of chemical com-
pounds.32,33 Furthermore, this material proved to be
successful in semipreparative applications. Therefore, it was
assumed to be appropriate for our purpose, including the res-
olution of large amounts of rac‐1.33,34
Development of the CSP‐HPLC‐method on an analyti-
cal scale was started—as mentioned—using the racemate.
In preliminary experiments a resolution of (−)‐S,S‐D‐83
and (+)‐R,R‐D‐84 could be achieved with a mobile phase
consisting of n‐hexane, propan‐2‐ol, ethanol, and TFA.
Thereby, it was observed that addition of 0.1% DEA
improved peak symmetry substantially. Therefore, a mobile
phase, consisting of n‐hexane/propan‐2‐ol/ethanol/TFA/
DEA (80/14/6/0.5/0.1; all mobile phase compositions or
sample solvent compositions are given as v/v/v/v/v; n‐
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hexane, propan‐2‐ol and ethanol were mixed to 100%, TFA
and DEA were added to this mixture) at a flow rate of
1.0 ml/min was selected as the starting point for further
method optimization.
In a first step, the fraction of n‐hexane vs. the fixed
combination of propan‐2‐ol and ethanol (7/3) was varied
(see Table 1, no. 1a to 1c). It was observed that a higher
proportion of n‐hexane in the mobile phase results in better
resolution and longer run times. The mixture of n‐hexane/
propan‐2‐ol/ethanol/TFA/DEA (85/10.5/4.5/0.5/0.1) was
found to be the best compromise concerning a sufficient
resolution and a tolerable run time. Keeping this mobile
phase composition constant, next the flow rate was raised
from 1.0 ml/min to 2.0 ml/min (see Table 1, no. 2a to
2c). This resulted in shorter run times, with a minimum
of 4.21 and 5.53 min, respectively, and an increased back
pressure of up to 180 bar. At the same time, the resolution
declined from 4.48 to 3.55 (Table 1, no. 2a and 2c). Using
the conditions given in Table 1, no. 1b [mobile phase com-
position: n‐hexane/propan‐2‐ol/ethanol/TFA/DEA (85/10.5/
4.5/0.5/0.1)], the flow rate of 2.0 ml/min, which had deliv-
ered considerably shorter run times with only a minor loss
in resolution, the influence of the ratio of propan‐2‐ol vs.
ethanol in the mobile phase on the chromatography results
was investigated. To this end, the respective ratios were set
to 7.5/7.5 (Table 1, no. 3a), 9/6 (Table 1, no. 3b), 10.5/4.5
(Table 1, no. 3c), 12/3 (Table 1, no. 3d) and 13.5/1.5 (see
Table 1, no. 3e). With increased propan‐2‐ol and reduced
ethanol contents, retention times became longer and resolu-
tion increased. The mobile phase composition of n‐hexane/
TABLE 1 Effects of different mobile phase parameters (ratio of n‐hexane/propan‐2‐ol/ethanol (v/v/v), flow rate, ratio propan‐2‐ol/ethanol and
fraction of TFA)
No. (na)
Mobile phase: n‐hexane/
propan‐2‐ol/ethanol/
TFA/DEA (v/v/v/v/v)
Flow rate
(ml/min) RS
tR (min) AS
(−)‐S,S‐D‐83 (+)‐R,R‐D‐84 (−)‐S,S‐D‐83 (+)‐R,R‐D‐84
Variation of the ratio of n‐hexane and the sum of alcohols, ratio of propan‐2‐ol/ethanol kept constant at 7/3 (v/v), fraction of TFA kept constant at
0.5%. Flow rate kept constant at 1.0 ml/min.
1a (3) 80/14/6 /0.5/0.1 1.0 4.08 7.11 9.14 1.32 1.25
1b (4) 85/10.5/4.5/0.5/0.1 1.0 4.46 8.74 11.6 1.37 1.30
1c (2) 90/7/3/0.5/0.1 1.0 14.7 13.3 18.4 1.50 1.38
Variation of the flow rate. Mobile phase composition kept constant at n‐hexane/propan‐2‐ol/ethanol/TEA/DEA 85/10.5/4.5/0.5/0.1
2a (1) ≙ 1bb 85/10.5/4.5/0.5/0.1 1.0 4.48 8.62 11.4 1.30 1.29
2b (1) 85/10.5/4.5/0.5/0.1 1.5 3.89 5.72 7.54 1.25 1.24
2c (1) 85/10.5/4.5/0.5/0.1 2.0 3.55 4.21 5.53 1.24 1.17
Variation of the ratio of propan‐2‐ol and ethanol, ratio of n‐hexane/alcohols kept constant at 85/15 (v/v), fraction of TFA kept constant at 0.5%,
fraction of DEA kept constant at 0.1%. Flow rate kept constant at 2.0 ml/min.
3a (1) 85/7.5/7.5/0.5/0.1 2.0 2.82 3.82 4.80 1.39 1.37
3b (4) 85/9/6 /0.5/0.1 2.0 3.01 3.98 5.03 1.22 1.21
3c (3) ≙ 2cb 85/10.5/4.5/0.5/0.1 2.0 3.50 4.28 5.57 1.10 1.10
3d (3) 85/12/3/0.5/0.1 2.0 3.72 4.64 6.21 1.11 1.13
3e (3) 85/13.5/1.5/0.5/0.1 2.0 3.85 4.84 6.54 1.13 1.14
Variation of the fraction of TFA, composition of n‐hexane/propan‐2‐ol/ethanol/DEA kept constant at 85/13.5/1.5/0.1. Flow rate kept constant at
2.0 ml/min.
4a (3) 85/13.5/1.5/0.1/0.1 2.0 3.57 4.30 5.67 1.11 1.02
4b (3) 85/13.5/1.5/0.2/0.1 2.0 3.62 4.32 5.71 1.12 1.09
4c (3) 85/13.5/1.5/0.3/0.1 2.0 3.65 4.34 5.75 1.12 1.09
4d (3) 85/13.5/1.5/0.4/0.1 2.0 3.69 4.34 5.76 1.11 1.11
4e (3) ≙ 3eb 85/13.5/1.5/0.5/0.1 2.0 3.72 4.35 5.80 1.10 1.09
The varied parameters are indicated as bold characters. On resolution, retention times and peak symmetries of (−)‐S,S‐D‐83 and (+)‐R,R‐D‐84. All chromatograms were
acquired, using a Lux Cellulose‐1 (250 x 4.6 mm, 5 μm) column at 20 °C with a detection wavelength of 260 nm.
aNumber of replicates, which were acquired for each No. The values for RS, tR and AS represent the mean values.
bData were acquired with the same chromatographic conditions in different experimental series.
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propan‐2‐ol/ethanol/TFA/DEA amounting to 85/13.5/1.5/
0.5/0.1 (Table 1, no. 3e) was considered the most suitable
for the intended purpose, as it resulted in chromatograms
with the highest resolution in this test series. Finally, the
effect of the fraction of TFA in the eluent on the chroma-
tography results was studied. Varying its percentage from
0.1–0.5% had only negligible effects on resolution and
retention (Table 1, no. 4a to 4e). Due to a slight tendency
towards better resolution at higher TFA contents in the elu-
ent, the mobile phase with 0.5% of TFA was chosen for
further experiments. Because of the high back pressure in
the chromatographic system, the effects of temperature on
the chromatography results and on the back pressure were
also studied. When varying temperature from 5 °C to
50 °C, in line with expectations, a higher temperature
resulted in a lower system back pressure, but also in
reduced retention times and peak widths. Resolution had
a maximum at 30 °C and declined slightly at lower as well
as at higher temperatures. This might be explained by the
decrease of retention time and peak width at higher temper-
atures. From 5 °C to 30 °C, the reduction of peak width
results in an increasing resolution, although the retention
times for both peaks are decreasing. After having reached
optimum resolution at 30 °C, the decrease of retention
times seems to become more dominant than the reduction
in peak width, leading to a lower resolution (Figure 2).
For the final conditions, a temperature of 40 °C was cho-
sen, as it appears to provide a good compromise between
a reasonable resolution and a not too high system back
pressure (~160 bar).
Accordingly, the parameters for the final chromatogra-
phy method at the chosen stationary phase (Phenomenex
Lux Cellulose‐1, 250 x 4.6 mm, 5 μm) were as follows:
The mobile phase consisted of a mixture of n‐hexane/
propan‐2‐ol/ethanol/TFA/DEA in a ratio of 85/13.5/1.5/
0.5/0.1. The flow rate was set to 2.0 ml/min, the column
compartment to 40 °C, and the injection volume to 20 μl.
For detection, a wavelength of 260 nm was chosen (for
details, see Supporting Information).
FIGURE 2 Effect of the temperature on the chromatography of (‐)‐S,
S‐D‐83 and (+)‐R,R‐D‐84 in the method development of the analytical
CSP‐HPLC method. A, Effect on the retention times and the peak
widths (10 %) of (‐)‐S,S‐D‐83 and (+)‐R,R‐D‐84. B, Effect of the
temperature on the resolution of (‐)‐S,S‐D‐83 and (+)‐R,R‐D‐84
FIGURE 3 Chromatograms from the analytical CSP‐HPLC method,
using a Lux Cellulose‐1 (250 x 4.6 mm, 5 μm) column as stationary
phase in combination with a mixture of n‐hexane/propan‐2‐ol/ethanol/
TFA/DEA (85/13.5/1.5/0.5/0.1; v/v/v/v/v) as mobile phase at a flow rate
of 2.0 mL/min at 40 °C, an injection volume of 20 μl at a detection
wavelength of 260 nm. A, solvent blank; B, 25 μg/ml of (‐)‐S,S‐D‐83
and (+)‐R,R‐D‐84; C, 5 mg/ml of (‐)‐S,S‐D‐83 and (+)‐R,R‐D‐84
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These conditions resulted in retention times of 4.0 min for
(−)‐S,S‐D‐83 and 5.0 min for (+)‐R,R‐D‐84* and a resolution
of more than 2.0 (see Figure 3C for a chromatogram with a
concentration of 5 mg/ml) even for the highest concentrations
of 30 mg/ml per enantiomer and a run time of 7 min.
3.3 | Development and application of the
semipreparative CSP‐HPLC method
It was intended to adjust the analytical CSP‐HPLC method
described above in a way that it would allow the
semipreparative resolution of rac‐1.
As TFA is a very strong acid, it was worried that the sam-
ples of the enantiomers might be prone to degradation, e.g.,
by elimination of H2O when during their isolation by evapo-
ration of the solvent the TFA concentration increases. There-
fore, TFA should be substituted by a weaker acid. Formic
acid proved to be a good alternative to TFA, allowing a good
separation of the enantiomers when present in a concentra-
tion of 1% in the mobile phase instead of TFA.
As expected, injection of large amounts of rac‐1 onto the
column caused severe peak broadening. At high tempera-
tures, the resolution tended to decrease; therefore the temper-
ature for the semipreparative method was set to 5 °C. It may
be assumed that this massive overloading results in a chro-
matographic behavior that does not follow the observations
described for the analytical method. Nevertheless, these chro-
matographic conditions were suited for the semipreparative
resolution of rac‐1 (at a still tolerable back pressure of around
180 bar). For these reasons, no further optimization of the
semipreparative method was needed.
With a 100 mg/ml solution of rac‐1 in propan‐2‐ol/DEA
(9/1), the effects of injection volumes in a range from
10–100 μl on the chromatography results were studied
(see Figure 1 in the Supporting Information). Eighty μl was
found to be the highest injection volume still allowing a
sufficient separation of the two enantiomers of rac‐1
(resolution >1.5) (see Figure 4). Accordingly, 8 mg of
rac‐1 could be resolved within a single chromatographic run.
With this modification of the analytical CSP‐method, we
separated ~300 mg racemic (−)‐S,S‐D‐83/(+)‐R,R‐D‐84 mix-
ture. The eluents representing the peaks containing (−)‐S,S‐
D‐83 and (+)‐R,R‐D‐84 were collected separately and
concentrated in vacuo. 1H–NMR spectroscopy revealed that
there were still residual amounts of formic acid and DEA in
the fractions of both enantiomers. Therefore, the fractions
containing the individual enantiomers were further purified
by column chromatography and thereafter also by base treat-
ment (NaHCO3) of diethylether solutions of the individual
enantiomers. That way, 148.8 mg (−)‐S,S‐D‐83 and 137.3 mg
(+)‐R,R‐D‐84 could be obtained as the final products. Their
purities were determined later on by quantitative 1H–NMR.
3.4 | Validation and quantification of the
enantiomeric excess
The analytical CSP‐HPLC method was validated concerning
specificity, linearity, and range. For validation, blank samples
and calibration samples at 11 concentration levels were
prepared from rac‐1 (corresponding to concentrations of
25–30 mg/ml of each enantiomer) and analyzed in triplicate.
To ascertain the specificity of the method, blank samples
(propan‐2‐ol/DEA; 9/1) were injected to the chromatographic
system (see Figure 3A). Absence of any peaks at the expected
retention times characteristic for (−)‐S,S‐D‐83 and (+)‐R,R‐
D‐84 indicated that there are no compounds present that
would interfere with the analytes and thus affect their
quantification.
Based on the data obtained from calibration standards,
calibration functions for both enantiomers were established
by modelling the relation of the analyte peak areas (y) as a
function of the concentrations (x) of corresponding calibra-
tion standards applying a linear regression (1/x weighting).
Both calibration functions showed excellent linearity with r2
of 1.000 in the investigated range. The LLOQ and ULOQ
of the calibration curve were defined as the lowest and
*These retention times differ slightly from the ones observed during method
development, as the column was employed in the meantime in another pro-
ject with a different mobile phase.
FIGURE 4 Chromatogram from the
semipreparative CSP‐HPLC method, using a
Lux Cellulose‐1 (250 x 4.6 mm, 5 μm)
column as stationary phase in combination
with a mixture of n‐hexane/propan‐2‐ol/
ethanol/formic acid/DEA (85/13.5/1.5/1.0/
0.1; v/v/v/v/v) as mobile phase at a flow rate
of 2.0 ml/min at 5 °C. For this chromatogram
80 μl of a 100 mg/ml solution of racemic (‐)‐
S,S‐D‐83 and (+)‐R,R‐D‐84 was injected and
detected at a wavelength of 260 nm
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highest concentration of analyte, respectively, which can be
quantified accurately and precisely. The criterion for
accuracy defined as recovery was limited to a range from
98–102%, the criterion for precision defined as the relative
standard deviation (RSD) of three injections was limited to
≤2%. For both enantiomers and all calibration levels, the
recovery was between 99.12% and 101.74%. Precision is
given as the RSD of the triplicates for each concentration
level and did not exceed a value of 1.72% and 1.37% for
(+)‐R,R‐D‐84, and for (−)‐S,S‐D‐83, respectively (see
Table 2). In addition, based on the data obtained, a concentra-
tion of 25 μg/ml could be defined as the LLOQ of the calibra-
tion curve (see Figure 3B) and 30 mg/ml as the ULOQ.
Another parameter, investigated for the series of racemic
calibration standards, was the ratio of the peak areas of both
enantiomers. The peak area ratios of (−)‐S,S‐D‐83 vs. (+)‐
R,R‐D‐84 for all concentration levels were between 1.006
and 0.980, thus indicating that both enantiomers show
almost identical peak areas in the whole concentration
range. This indicates that there are no chromatographic
interferences affecting one of both enantiomers exclusively.
For the quantification of the ee of an analyte, first the
concentration of both enantiomers in the sample has to be
determined. Based on these concentrations, the ee can be
calculated.
To allow ee‐determinations of highly enantioenriched
samples, the concentrations of the major enantiomer in
the sample should be as high as possible with regard to
the ULOQ of the method (30 mg/ml). Using, for example,
a sample with an overall concentration of 25 mg/ml, in
which the minor enantiomer is present at a concentration
equal to the LLOQ, the area ratio of the minor enantiomer
at the LLOQ (25 μg/ml) vs. the major enantiomer reaches
almost 1:1000 (exactly 1:999). This means that the
established method is capable for reliable determination of
ee values up to 99.8% when the sample to be characterized
is employed at concentrations between 25 and 30 mg/ml
(overall concentration).
FIGURE 5 Chromatogram of 27.5 mg/ml
(+)‐R,R‐D‐84, using a Lux Cellulose‐1 (250
x 4.6 mm, 5 μm) column as stationary phase
in combination with a mixture of n‐hexane/
propan‐2‐ol/ethanol/TFA/DEA (85/13.5/1.5/
0.5/0.1; v/v/v/v/v) as mobile phase at a flow
rate of 2.0 ml/min at 40 °C, a detection
wavelength of 260 nm and an injection
volume of 20 μl
TABLE 2 Results from the validation
Concentration
(mg/ml per
enantiomer)
(−)‐S,S‐D‐83 (+)‐R,R‐D‐84
Peak area
(−)‐S,S‐D‐83/
(+)‐R,R‐D‐84
Determined
concentration
(mg/ml) Recovery (%) RSD (%)
Determined
concentration
(mg/ml) Recovery (%) RSD (%)
30 29.85 99.50 0.15 30.01 100.05 0.14 0.995
20 20.09 100.43 0.41 20.12 100.60 0.60 0.998
10 10.06 100.61 0.43 10.10 101.02 0.16 0.996
5 4.995 99.89 0.85 5.017 100.34 0.81 0.996
2.5 2.512 100.48 0.86 2.522 100.89 0.66 0.996
1 0.9940 99.40 0.21 0.9974 99.74 0.44 0.997
0.5 0.4969 99.39 0.30 0.5071 101.74 0.66 0.980
0.25 0.2490 99.61 0.41 0.2500 100.00 1.40 0.996
0.1 0.09912 99.12 0.76 0.1011 101.14 1.72 0.981
0.05 0.05060 101.20 1.37 0.05028 100.56 0.59 1.006
0.025 0.02507 100.27 0.75 0.02494 99.78 0.84 1.004
All samples were measured in triplicate and are indicated as means.
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3.5 | Determination of the enantiomeric purity
of (−)‐S,S‐D‐83 and (+)‐R,R‐D‐84
The enantiomeric purity of (−)‐S,S‐D‐83 and (+)‐R,R‐D‐84,
obtained from the semipreparative separation, was determined
with the established analytical CSP‐HPLC method. For this,
(−)‐S,S‐D‐83 and (+)‐R,R‐D‐84 were dissolved in propan‐2‐
ol/DEA (9/1) to yield a final concentration of ~27.5 mg/ml.
Both solutions were injected and analyzed three times. A rep-
resentative chromatogram obtained for (+)‐R,R‐D‐84 is
depicted in Figure 5. The concentrations of the enantiomers
were calculated from the calibration functions determined
before (see above). For (−)‐S,S‐D‐83 as well as for (+)‐R,R‐
D‐84, the signal intensities of the minor enantiomers were
below the LLOQ and the concentrations of the major enantio-
mer were 28.8 mg/ml ((−)‐S,S‐D‐83) and 26.4 mg/ml ((+)‐R,
R‐D‐84), the ee‐values of (−)‐S,S‐D‐83 and (+)‐R,R‐D‐84
(see Figure 5) being accordingly >99.8%.
3.6 | Determination of the chemical purity of
(+)‐R,R‐D‐84 and (−)‐S,S‐D‐83
Due to the fact that neither a reference standard for (−)‐S,S‐D‐
83, (+)‐R,R‐D‐84 nor the corresponding racemate was com-
mercially available, the CSP‐HPLC method was not useable
for the determination of the chemical purity of the enantio-
mers. Therefore, to obtain the chemical purities of (−)‐S,S‐
D‐83 and (+)‐R,R‐D‐84, quantitative 1H–NMR experiments
with maleic acid as internal calibrant were performed.31 Either
enantiomer (−)‐S,S‐D‐83 and (+)‐R,R‐D‐84 yielded only
poorly resolved 1H–NMR spectra signals being severely
broadened (in d6–DMSO). As this was assumed to be due to
salt formation between the enantiomers and the internal stan-
dard used, maleic acid, 1H–NMR probes were supplemented
with DCl in D2O (2 M, 1.5 equiv. of DCl with respect to the
analyte). Thereupon, the resolution of the 1H–NMR spectra
was distinctly improved. The calculation of the chemical
purity of the analytes was performed based on the integrals
of the signals at δ = 6.3 ppm, (maleic acid) and at
δ = 5.4 ppm, 2.8 ppm and 2.1 ppm (all from analytes). This
led to a chemical purity of 91.18% for (−)‐S,S‐D‐83 and
96.95% for (+)‐R,R‐D‐84.
4 | CONCLUSION
In the present study, we developed an analytical CSP‐HPLC
method for the determination of the enantiomeric purity of
(−)‐S,S‐D‐83 and (+)‐R,R‐D‐84. For this method, a
Phenomenex Lux Cellulose‐1 column (250 x 4.6 mm,
5 μm) was used in combination with a mixture of n‐hexane/
propan‐2‐ol/ethanol/TFA/DEA (85/13.5/1.5/0.5/0.1) as
mobile phase. The flow rate was set to 2.0 ml/min, the
temperature in the column oven to 40 °C, and the injection
volume was 20 μl, while the detection was done at a wave-
length of 260 nm. Using these chromatographic parameters,
we obtained chromatograms where the two enantiomers were
sufficiently separated within a run time of 7 min. The method
was successfully validated with regard to the parameters
specificity, linearity, and range for both enantiomers. The
achieved excellent range reached for both enantiomers from
25 μg/ml to 30 mg/ml enabled the determination of
enantiopurities of up to 99.8% ee for each enantiomer. With
minor changes, the method could also be applied to quantita-
tive separation of up to 8 mg of racemate per run. Both, the
analytical and the semipreparative CSP‐HPLC method repre-
sent a substantial improvement in comparison to the pub-
lished methods. Enantiomerically pure compounds have so
far been accessible by intermediate formation of
diasteromers. And an analytical CSP‐HPLC method based
on the determination of the enantiopurity of (−)‐S,S‐D‐83
or (+)‐R,R‐D‐84 has not been available at all. The highly
enantioenriched sample of (+)‐R,R‐D‐84 with an
enantiopurity of >99.8% and a chemical purity of 96.95%,
obtained in this study, will be of great value for the future
development of MS Binding Assays for the dopamine trans-
porter using this compound as reporter ligand.
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Figure 1: Comparison of chromatograms resulting from varying injection volumes of a 100 mg/mL solution of racemic (-)-S,S-D-
83 and (+)-R,R-D-84, analyzed with the semipreparative CSP-HPLC method (Lux Cellulose-1 (250 x 4.6 mm, 5 µm) column as 
stationary phase in combination with a mixture of n-hexane/propan-2-ol/ethanol/formic acid/DEA (85/13.5/1.5/1.0/0.1; v/v/v/v/v) 
as mobile phase at a flow rate of 2.0 ml/min at 5 °C). 
 
 
Choice of the detection wavelength 
 
An UV-spectrum recorded for rac-1 showed a shoulder at 224 nm and a local maximum at 260 nm. In preliminary 
experiments, we observed a better linear range due to the higher selectivity for 260 nm. Due to the higher selectivity 
expected for 260 nm, this wavelength was selected for analyte detection. 
 
 
Collection of fractions in the semi-preparative HPLC method 
 
Collection of the fractions for (-)-S,S-D-83 and (+)-R,R-D-84 was started as soon as the slope of the first peak was 
visible (at approximately 5.5 min) and the collection container was changed when the slope of the first peak changed 
from a negative to a positive slope (at approximately 7.6 min). The second fraction was collected for approximately 3 
min. 
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3.2. Second	Publication	
Development	and	Validation	of	an	LC-ESI-MS/MS	Method	for	the	Quantification	of	D-84,	
Reboxetine,	 and	 Citalopram	 for	 their	 Use	 in	 MS	 Binding	 Assays	 Addressing	 the	
Monoamine	Transporters	hDAT,	hSERT,	and	hNET	
	
3.2.1. Summary	of	the	Results	
	
In	 the	 last	years,	MS	Binding	Assays	have	been	developed	and	established	 for	a	variety	of	
targets.	MS	Binding	Assays	represent	an	alternative	to	radioligand	binding	assays	and	enable	
the	implementation	of	experiments	to	determine	reporter	 ligand-target	 interactions	hardly	
feasible	with	radioligand	binding	assays.	Due	to	the	complex	interactions	regarding	the	action	
of	 antidepressant	drugs	with	 the	 three	monoamine	 transporters	DAT,	NET,	 and	SERT,	 it	 is	
important	to	characterize	the	binding	of	such	drugs	at	all	of	these	targets.	The	aim	of	this	work	
was	to	develop	an	LC-ESI-MS/MS	quantification	method	for	the	three	monoamine	reuptake	
transporter	 inhibitors	 (R,R)-D-84,	 (S,S)-reboxetine,	 and	 (S)-citalopram,	 which	 were	 chosen	
because	of	their	high	selectivity	for	each	of	the	targets	((R,R)-D-84	for	hDAT,	(S,S)-reboxetine	
for	hNET,	and	(S)-citalopram	for	hSERT).	This	method	should	be	suitable	for	the	quantification	
of	the	three	markers	down	to	low	pM	concentrations	in	samples	generated	from	a	biological	
matrix	 within	 a	 single	 and	 fast	 chromatographic	 run.	 The	 use	 of	 one	 method	 for	 the	
quantification	 of	 all	 three	 markers	 is	 an	 important	 requirement	 for	 the	 intended	 use	 in	
Simultaneous	Multiple	MS	Binding	Assays,	which	were	to	be	established	in	a	subsequent	step.	
To	 demonstrate	 the	 selectivity,	 accuracy,	 precision,	 sensitivity,	 and	 linearity,	 the	 LC-ESI-
MS/MS	method	should	be	validated	according	to	the	CDER	guideline	for	bioanalytical	method	
validation.	 The	 implementation	 of	 the	method	 for	 saturation	 experiments	 of	 the	markers	
towards	 their	particular	 targets,	 should	show	the	suitability	of	 the	method	 for	MS	Binding	
Assays.	
	
For	 the	 chromatographic	 separations	 of	 the	 three	 markers	 from	 the	 matrix,	 a	 Luna	
pentafluorophenyl	(PFP(2),	50	x	2.0	mm,	3	µm,	Phenomenex)	column	was	used	in	combination	
with	a	mobile	phase	consisting	of	acetonitrile/ammonium	formate	buffer	(0.75	mg/mL;	85/15;	
v/v)	at	a	flow	rate	of	800	µL/min.	The	column	temperature	was	set	to	20	°C	and	a	volume	of	
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30	µL	 of	 the	 sample	was	 injected.	 For	 the	 detection	 of	 the	 analytes	 and	 their	 deuterated	
internal	standards,	an	AB	Sciex	API	5000	mass	spectrometer	with	an	electrospray	ionization	
(ESI)	ion	source	was	used	in	multiple	reaction	monitoring	(MRM)	mode,	acquiring	two	MRM	
transitions	for	each	analyte	and	one	for	every	internal	standard.	During	a	chromatographic	
run	time	of	1.5	minutes,	the	three	markers	were	separated	and	isolated	from	the	matrix.		
	
The	procedure	used	for	the	binding	experiments	was	adopted	and	adjusted	from	previously	
published	MS	Binding	Assays.	Binding	samples	containing	the	marker,	target	protein,	and	–	if	
needed	 –	 an	 inhibitor	 to	 block	 specific	 binding	 sites	 in	 samples	 for	 the	 determination	 of	
nonspecific	 binding	 in	 an	 HEPES	 (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic	 acid)	
buffer,	supplemented	with	NaCl	and	KCl,	were	incubated	for	2	hours	at	20	°C.	As	an	inhibitor	
in	 the	 samples	 for	 the	 determination	 of	 the	 nonspecific	 binding,	 rac-[2H3]-indatraline	was	
used,	due	 to	 the	ability	of	 indatraline	 to	efficiently	block	 specific	binding	 sites	 at	 all	 three	
targets.	 To	 avoid	 interferences	 with	 another	MS	 Binding	 Assay	 based	 on	 non-deuterated	
indatraline,	running	on	the	same	LC-MS	system,	the	deuterated	compound	was	used.	After	
the	incubation,	the	binding	samples	were	filtrated	through	glass	fiber	filters	and	subsequently	
washed	with	ammonium	formate	buffer	to	separate	the	target-marker	complexes	from	the	
unbound	marker.	The	glass	fiber	filters	were	then	dried	before	the	markers	were	eluted	from	
the	 target	 proteins	 with	 acetonitrile.	 Finally,	 the	 concentration	 of	 the	 marker	 in	 the	
acetonitrile	eluates	was	determined	with	the	developed	LC-MS	method.		
	
During	the	method	development	and	preliminary	saturation	experiments,	an	adsorption	of	
D-84	to	polypropylene	reaction	vessels	and	the	glass	fiber	filters	was	observed.	Addition	of	
dimethylacetamide	(DMA)	to	the	aqueous	solutions	of	D-84	and	to	the	washing	buffer	was	
effective	to	prevent	adsorption	as	well	as	to	remove	adsorbed	D-84	from	the	glass	fiber	filters	
without	affecting	the	formation	and	stability	of	the	target-marker	complexes.	
	
To	 demonstrate	 that	 the	 markers	 are	 sufficiently	 separated	 from	 the	 matrix	 during	 the	
chromatographic	step,	post-column	infusion	experiments	were	performed	with	the	final	assay	
procedure.	According	to	the	results	of	these	experiments	the	markers	are	not	co-eluting	with	
matrix	components	which	appeared	to	cause	multiple	zones	of	signal	suppression.	Since	one	
of	these	matrix	suppression	zones	occurs	after	the	elution	of	the	last	analyte	peak,	the	effect	
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of	 the	 matrix	 on	 the	 following	 chromatograms	 was	 investigated.	 These	 experiments	
demonstrated,	that	no	signal	suppression	is	caused	due	to	late-eluting	matrix	components	in	
successive	 chromatograms.	 Therefore,	 the	 chosen	 chromatographic	 conditions	 warrant	 a	
good	separation	of	the	markers	from	all	interfering	matrix	components.		
	
The	final	LC-ESI-MS/MS	quantification	method	was	validated	according	to	the	CDER	guideline	
for	bioanalytical	method	validation	in	regard	to	selectivity,	accuracy,	precision,	sensitivity,	and	
linearity.	 For	 the	 validation,	matrix	 samples	 from	 all	 three	 target	 proteins	were	 prepared	
under	the	procedure	of	the	binding	assays.	All	requirements	of	the	guideline	were	fulfilled	for	
concentrations	from	2.5	pM	to	1	nM	for	(R,R)-D-84,	from	1	pM	to	2.5	nM	for	(S,S)-reboxetine,	
and	from	2.5	pM	to	2.5	nM	for	(S)-citalopram.		
	
Saturation	 experiments	 performed	 under	 the	 established	 assay	 conditions	 utilizing	 the	
validated	LC-ESI-MS/MS	quantification	method	resulted	 in	Kd–values	of	3.66	±	1.35	nM	for	
(R,R)-D-84	 towards	hDAT,	 3.06	±	 0.46	nM	 for	 (S,S)-reboxetine	 towards	hNET,	 and	0.411	±	
0.003	nM	for	(S)-citalopram	towards	hSERT.	These	binding	affinities	are	in	good	agreement	
with	 data	 published	 in	 literature,	 thus	 demonstrating	 the	 suitability	 of	 these	MS	 Binding	
Assays	for	a	reliable	characterization	of	reporter	ligand-target	interactions.	
	
	
3.2.2. Declaration	of	Contributions	
	
[2H4]-4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol	 and	 rac-[2H3]-indatraline	
were	synthesized	by	Lars	Allmendinger	and	Gerd	Bauschke.	Racemic	reboxetine	was	extracted	
from	tablets.	The	CSP-HPLC	method	for	the	semipreparative	separation	of	rac-reboxetine	was	
developed	and	applied	by	Anna	Ramershoven	to	obtain	(S)-reboxetine.	Furthermore,	Anna	
Ramershoven	 developed	 an	 analytical	 CSP-HPLC	 method	 for	 the	 determination	 of	 the	
enantiomeric	 purity	 of	 reboxetine	 and	 characterized	 the	 ee	 of	 the	 final	 products.	 The	
extraction,	 semipreparative	 enantioseparation	 and	 ee-determination	 is	 described	 in	 the	
bachelor	 thesis	 “Semipräparative	 Trennung	 des	 racemischen	 Antidepressivums	 Reboxetin	
sowie	 Entwicklung	 und	 Validierung	 einer	 HPLC-Methode	 zur	 Bestimmung	 der	
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Enantiomerenreinheit”	 by	 Anna	 Ramershoven,	which	was	 prepared	 under	my	 supervision	
[74].	Characterization	of	MRM	transitions	for	the	markers	and	method	development	of	the	
LC-ESI-MS/MS	quantification	method	was	done	by	myself.	Experiments	for	the	final	method	
optimization,	the	validation,	and	the	saturation	experiments	were	performed	by	Angela	De	
Simone	and	myself.	I	wrote	the	manuscript	and	prepared	the	graphics	and	tables,	assisted	by	
Georg	 Höfner,	 Lars	 Allmendinger,	 and	 Angela	 De	 Simone.	 Klaus	 T.	Wanner	 corrected	 the	
manuscript.	
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Abstract 
 
MS Binding Assays represent a label free alternative to radioligand binding assays. In this 
study, we present an LC-ESI-MS/MS method for the quantification of (R,R)-4-(2-
benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol ((R,R)-D-84, (R,R)-1), (S,S)-reboxetine 
((S,S)-2), and (S)-citalopram ((S)-3) employed as highly selective nonlabelled reporter ligands 
in MS Binding Assays addressing the dopamine (DAT, (R,R)-D-84), the norepinephrine 
(NET, (S,S)-reboxetine), and the serotonin transporter (SERT, (S)-citalopram), respectively. 
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The developed LC-ESI-MS/MS method uses a pentafluorphenyl (PFP) stationary phase in 
combination with a mobile phase composed of acetonitrile and ammonium formate buffer for 
chromatography and a triple quadrupole mass spectrometer in the multiple reaction 
monitoring (MRM) mode for mass spectrometric detection. Quantification is based on 
deuterated derivatives of all three analytes serving as internal standards. The established LC-
ESI-MS/MS method enables fast, robust, selective, and highly sensitive quantification of all 
three reporter ligands in a single chromatographic run. The method was validated according to 
the CDER guideline for bioanalytical method validation regarding selectivity, accuracy, 
precision, calibration curve, and sensitivity. Finally, filtration based MS Binding Assays were 
performed for all three monoamine transporters based on this LC-ESI-MS/MS quantification 
method as read out. The affinities determined in saturation experiments for (R,R)-D-84 
towards hDAT, for (S,S)-reboxetine towards hNET, and for (S)-citalopram towards hSERT, 
respectively, were in good accordance with results from literature, clearly demonstrating that 
the established MS Binding Assays have the potential to be an efficient alternative to 
radioligand binding assays widely used for this purpose so far. 
 
Introduction 
 
According to the World Health Organization (WHO), an estimated 300 million people 
worldwide suffer from depression. This makes depression a leading cause of disability and 
can lead to suicide of the patient in the worst case (World Health Organization, 2017). The 
genesis of depressions is often explained with the catechol hypothesis (Lapin & Oxenkrug, 
1969; Schildkraut & Kety, 1967), which links the dopaminergic, norepinephrinergic, and 
serotoninergic neuronal system to the emergence of this disease. In accord with this 
hypothesis, a lack of these monoamine neurotransmitters at corresponding synapses can be 
counteracted by the inhibition of the monoamine transporters, which terminate the neuronal 
signal transmission by removing the neurotransmitters out of the synaptic cleft. The inhibition 
of the monoamine transporters can be achieved by selective inhibitors of the serotonin 
transporter (SERT) or the norepinephrine transporter (NET) as well as by dual reuptake 
inhibitors targeting the SERT and NET or the NET and the dopamine transporter (DAT). 
These classes of monoamine transporter inhibitors are often used in the therapy of depression, 
but they inherit a few insufficiencies. It has to be noted that the therapy with these 
antidepressants has a considerable lag between the administration of the drug and the onset of 
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the therapeutic effect. A second shortcoming of these antidepressants is that only 60 – 70 % 
of the treated persons respond to the therapy (Ferrari & Villa, 2016). Thus, there is still a 
strong demand for the development of new drugs, targeting the monoamine transporters with 
an improved therapeutic profile. 
To identify new potential drugs, screening methods are necessary for identification of 
compounds which can act at predefined targets. Such test systems can either detect a 
functional activity or affinity of a test compound at a target. Radioligand binding assays were 
performed for the first time in the 1970s (Lefkowitz, Roth, & Pastan, 1970) and have been 
extensively used to characterize binding affinities (R. Zhang & Xie, 2012). To apply this 
technique, a radiolabelled reporter ligand, which can be quantified by means of scintillation 
counting, is incubated together with the target. After the incubation, the target-radioligand 
complexes are separated from the unbound radioligand (e.g. by filtration) and the bound 
radioligand is quantified based on the radioactivity in the sample. Various types of binding 
experiments can be carried out following this strategy, such as the determination of the 
radioligand’s equilibrium dissociation constant Kd towards the target in saturation assays or 
the determination of the inhibitory constant Ki of test compounds incubated together with the 
radioligand and the target in competition experiments. The challenge of quantification of low 
bound radioligand concentrations due to the low concentrations of the target is met by the 
high sensitivity offered by scintillation counting. But the radioactivity in radioligand binding 
assays also causes multiple problems associated with legal restrictions for the handling of the 
radioisotope labelled compounds as well as with complicated and expensive regulations 
regarding the disposal of the radioactive waste. To circumvent these issues, MS Binding 
Assays have been established and proven to be a powerful alternative to radioligand binding 
assays (Grimm, Höfner, & Wanner, 2015a; Hess, Höfner, & Wanner, 2011; Massink et al., 
2015; Neiens, Höfner, & Wanner, 2015; Zepperitz, Höfner, & Wanner, 2006). MS Binding 
Assays follow the procedure of radioligand binding assays, but as a reporter ligand, a 
nonlabelled ligand, also referred to as MS marker, is used. The utilization of mass 
spectrometry (MS) as a detection principle allows the quantification of the reporter ligand 
with a sensitivity that can reach low picomolar concentrations (Grimm et al., 2015a; Hess et 
al., 2011; Neiens et al., 2015). As in radioligand binding assays, MS Binding Assays can use a 
filtration step for the separation of the formed target-marker complexes from the nonbound 
marker. After this separation, the target protein is denatured to liberate the formerly bound 
MS marker, which is then eluted to generate a sample that is subjected to marker 
quantification by LC-ESI-MS/MS. For the use in MS Binding Assays, the quantification 
Page 3 of 61
http://mc.manuscriptcentral.com/bmc
Biomedical Chromatography
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 
 
method has to fulfil an important criterion, regarding its sensitivity. To carry out saturation 
assays, samples with nominal marker concentrations ranging from 0.1 Kd up to 10 Kd should 
be analysed (Hulme, 1992). According to the calculation, described in a previously published 
work, the quantification method used in MS Binding Assays should be able to determine 
concentrations down to 0.0091 Kd (Grimm, Höfner, & Wanner, 2015b). Since the affinity of 
markers used in MS Binding Assays is in the low nM range, the quantification method to be 
developed should enable quantification of low picomolar concentrations of each marker in 
samples obtained from the binding experiment. As mentioned above, LC-ESI-MS/MS is a 
suitable analytical technique to quantify such low concentrations of nonlabelled substances, 
nevertheless, this can be still a very challenging task. Besides its high sensitivity, LC-MS/MS 
provides the possibility to analyse multiple analytes simultaneously, even if they are not 
chromatographically separated. In this study, we wanted to develop a single quantification 
method, which enables the quantification of the three selective markers (one for each target) 
under the same chromatographic conditions. This would allow us to develop the MS Binding 
Assays further to multiple simultan ous MS Binding assays, like the ones recently published 
for the dopamine D1 and D5 receptors (Schuller, Höfner, & Wanner, 2017). Due to the ability 
to perform binding experiments at multiple targets simultaneously, Multiple Simultaneous 
MS Binding Assays have huge advantages regarding their efficiency, compared to radioligand 
binding assays. Furthermore, it is worth to mention that the efforts made for LC-ESI-MS/MS 
method development can be considered as particularly efficient, as the established method can 
be applied for MS Binding Assays addressing three different targets in this case. In this study, 
we aimed at developing an LC-ESI-MS/MS quantification method for markers of the biogenic 
amine transporters hSERT, hDAT, hNET as the basis for the establishment of Multiple MS 
Binding Assays for the aforementioned targets. 
The robustness of this LC-ESI-MS/MS quantification method and its suitability for the 
desired Multiple MS Binding Assays, we intended to develop, were considered to be best 
verified by its validation according to the CDER guideline for bioanalytical method validation 
(FDA, 2013). Finally, this established LC-ESI-MS/MS method should be applied for the 
quantification of all three markers in MS Binding Assays addressing hDAT, hNET, and 
hSERT, respectively. Accordingly, saturation experiments of each marker towards its specific 
target should be performed. For the control of the obtained binding affinities, the latter should 
be compared with published literature data. As in radioligand binding assays, and many 
related techniques also for MS Binding Assays the concentration of specifically bound marker 
in binding samples may be determined only indirectly. Two sets of experiments have to be 
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performed, one for the determination of the total binding (TB, entire bound marker in a 
binding sample), a second set of samples for the determination of nonspecific binding (NSB, 
marker bound to nonspecific binding sites), the difference of which provides the specific 
binding (SB) (SB = TB – NSB). 
At first, markers suitable for the selective labelling of the monoamine transporters hDAT, 
hNET, and hSERT had to be chosen. In contrast to previously published MS Binding Assays 
using (1R,3S)-indatraline as a nonselective marker for all three targets (Grimm et al., 2015a), 
the MS Binding Assays to be developed in this study should be based on selective markers 
each selectively addressing DAT, NET, and SERT, respectively. As already indicated, this 
approach has the potential that the MS Binding Assays can determine the affinity of test 
compounds simultaneously at all three targets, a procedure which is hardly feasible with 
radioligand binding assays. Provided selective reporter ligands are employed such an 
approach would also allow the use of native target material in which the different monoamine 
transporters are present. An ideal marker for an MS Binding Assay should have a high affinity 
for its target, preferable a Kd in the low nM range. Furthermore, the marker should be 
commercially available in its native as well as its deuterated form or the latter should be at 
least synthetically easily accessible. Well characterized ligands such as radioligands used in 
radioligand binding assays, may also be a good choice for MS Binding Assays, which of 
course, were to be employed in their native, i.e. unlabelled form.  
For the hDAT, [3H]-WIN 35,428 (also known as [3H]-CFT) or [125I]-RTI-55 are often applied 
in radioligand binding assays (Dersch et al., 1994; Gracz & Madras, 1995; Reith, de Costa, 
Rice, & Jacobson, 1992; Richard B Rothman et al., 2002). However, [3H]-WIN 35,428 
possesses only a low selectivity for DAT against NET and SERT, whilst the affinity of [125I]-
RTI-55 for DAT is even lower than for NET and SERT (Eshleman et al., 1999; R B Rothman 
et al., 1994), requiring additional ligands blocking the binding to NET and SERT when this 
ligand is used (Richard B Rothman et al., 2002). This apparent lack of selective DAT 
inhibitors that are expected to possess a high potential in the treatment of cocaine dependence 
has spurred an intensive search for these compounds (Ritz, Lamb, Goldberg, & Kuhar, 1987; 
Wilcox, Paul, & Woolverton, 1999). Thus, a wide variety of compounds from different 
structural classes (Gryzło, Zaręba, Malawska, Jakubowska, & Kulig, 2015; Singh, 2000), like 
tropane (F I Carroll et al., 1992; F Ivy Carroll et al., 1991), benztropine (Agoston et al., 1997; 
Newman, Allen, Izenwasser, & Katz, 1994), or piperazine derivatives such as 1-[2-[bis(4-
fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazin (GBR 12909) and 1-[2-
(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine (GBR 12935) (Hsin et al., 2002; R B 
Page 5 of 61
http://mc.manuscriptcentral.com/bmc
Biomedical Chromatography
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
6 
 
Rothman et al., 1993; Van der Zee, Koger, Gootjes, & Hespe, 1980) have been synthesized 
and tested for their selectivity as DAT inhibitors. This led to the identification of the (+)-R,R 
enantiomer of 4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol ((R,R)-D-84, (R,R)-
1, see figure 1) as a highly selective and highly potent DAT inhibitor (Ghorai et al., 2003). In 
radioligand binding assays for DAT in crude rat striatum with [3H]-WIN 35,428 as 
radioligand, for this compound an IC50 of 0.46 nM was found. For the two other monoamine 
transporters, an IC50 of 3,600 nM at SERT and an IC50 of 1,880 nM at NET were determined 
in studies with crude rat cerebral cortex with [3H]-citalopram for SERT and [3H]-nisoxetine 
for NET as radioligand. According to these results, (R,R)-D-84 ((R,R)-1) has a 7,800-fold 
lower affinity for the SERT compared to DAT and a 4,100-fold lower affinity for NET versus 
DAT (Ghorai et al., 2003). In MS Binding Assays for hSERT, hNET, and hDAT based on 
(1R,3S)-indatraline as MS marker, a series of commercially available and resynthesized DAT 
inhibitors selective for DAT from literature were analysed regarding their affinity and 
selectivity towards the human monoamine transporters. From all analysed compounds, (R,R)-
D-84 ((R,R)-1) appeared to possess the highest selectivity for hDAT as compared to hSERT 
and hNET and a relatively low nM affinity thus allowing target concentrations in the low 
µg/mL-range in the planned MS Binding Assays (Grimm et al., 2015b). This and the easy 
synthetic accessibility of this compound allowing the synthesis of deuterated derivatives 
required as an internal standard made this compound appear to be well suited as an MS 
marker in multiple simultaneous MS Binding Assays for hSERT, hNET, and hDAT. 
For NET, several selective and potent inhibitors have been published. Nisoxetine has been 
applied in radioligand binding assays (Ghorai et al., 2003; Meyers & Kritzer, 2009; Zavosh, 
Schaefer, Ferrel, & Figlewicz, 1999), while reboxetine was reported to be a potential PET 
radioligand (Zeng et al., 2008). In addition, talopram was found to have a high selectivity 
towards hNET (Andersen et al., 2011). Finally, according to data from the (1R,3S)-indatraline 
MS Binding Assays out of these three compounds rac-reboxetine has the highest selectivity 
for hNET (Grimm et al., 2015b). In addition, published data for (S,S)-reboxetine ((S,S)-2) 
state that this enantiomer has a binding affinity of 0.2 nM towards NET and one of 2,900 nM 
for SERT. For racemic reboxetine, a binding affinity of 1.1 nM towards NET and 129 nM 
towards SERT, respectively, has been published (Hajós, Fleishaker, Filipiak-Reisner, Brown, 
& Wong, 2004). Accordingly, (S,S)-reboxetine ((S,S)-2) can be considered well-suited for its 
use as a selective marker in MS Binding Assays which is even more true as deuterated form 
of reboxetine is commercially available that could serve as an internal standard. 
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For hSERT, a variety of drugs selectively targeting this protein are on the market commonly 
termed selective serotonin reuptake inhibitors (SSRIs). Examples are fluoxetine, paroxetine, 
sertraline, and citalopram, to name only a few. In radioligand binding assays (S)-citalopram 
((S)-3) yielded Ki values of 0.28 nM towards SERT and 28,200 nM towards NET (Deupree, 
Montgomery, & Bylund, 2007), respectively, in one study, or Ki values of 1.1 nM towards 
hSERT, 27,410 nM towards hDAT, and 7,841 nM towards hNET, respectively, in another 
one (Owens, Knight, & Nemeroff, 2001). Thus, (S)-citalopram ((S)-3) displays the desired 
high selectivity for the hSERT in combination with an affinity in the low nM to high pM 
range. Moreover, as enantiopure (S)-citalopram ((S)-3) as well as deuterated citalopram are 
commercially available, this ligand seems to be an ideal marker for hSERT. 
Based on the above given considerations, (R,R)-D-84 ((R,R)-1), (S,S)-reboxetine ((S,S)-2), 
and (S)-citalopram ((S)-3) were chosen as markers for the MS Binding Assays to be 
developed. 
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Figure 1: Structures of markers, internal standards and the inhibitor employed for 
determination of non-specific binding in MS Binding Assays. a Deuterated substances were 
used as racemates, but only one enantiomer is depicted in the figure. For the sake of 
simplicity, the racemic mixture of (R,R)-D-84 and (S,S)-D-83 (the enantiomer of (R,R)-D-84) 
is referred to as rac-D-84 and the racemic mixture of (R,R)-[2H4]-D-84 and (S,S)-[2H4]-D-83 
is called rac-[2H4]-D-84 throughout this work. 
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Experimental 
 
Chemicals 
 
HPLC grade acetonitrile (for use at the API 3200) and LC-MS grade solvents (acetonitrile, 
methanol, water, for use at the API 5000) were purchased from VWR Prolabo (Darmstadt, 
Germany). HPLC grade methanol (for use at the API 3200) was bought from Fisher 
(Loughborough, UK). Water used for the preparation of mobile phase (for the API 3200), 
incubation and wash buffers had been purified by distillation of demineralized water (reverse 
osmosis) followed by filtration using a 0.45 µm filter. Additives for mobile phase buffers 
(ammonium formate, ammonium bicarbonate, formic acid, ammonium hydroxide solution 
≥ 25 %; for mass spectrometry), were bought from Fluka (Teufelskirchen, Germany). rac-
Citalopram (rac-3) HBr was purchased from Enzo Life Chemicals (Lörrach, Germany), (S)-
citalopram oxalate  ((S)-3) was bought from TCI (Eschborn, Germany), [2H6]-citalopram 
oxalate (rac-[2H6]-3) from Alsachim (Illkirch, France), and [2H5]-reboxetine mesylate (rac-
[2H5]-2) was bought from TRC (North York, ON, Canada), all in the best commercially 
available quality. 
4-(2-Benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol (rac-D-84, rac-1) was 
synthesized and purified according to Ghorai (Ghorai et al., 2003). For the sake of simplicity, 
the racemic mixture of (R,R)-D-84 and (S,S)-D-83 (the enantiomer of (R,R)-D-84) is referred 
to as rac-D-84 throughout this work. The enantiomer (R,R)-D-84 ((R,R)-1) was obtained after 
semipreparative enantioseparation of rac-D-84 (Neiens, Höfner, & Wanner, 2017). rac-
Reboxetine (rac-2) was extracted from Edronax tablets (4 mg, Pfizer Europe, Kent, UK) as a 
racemate which was further used to perform a semipreparative CSP-HPLC to obtain (S,S)-
reboxetine ((S,S)-2, see supporting information). The enantiopurities were determined by 
CSP-HPLC. Enantiomeric excesses amounted to ≥ 99.8 % for (R,R)-D-84 ((R,R)-1) and 
99.3 % for (S,S)-reboxetine ((S,S)-2). [2H4]-4-(2-benzhydryloxyethyl)-1-(4-
fluorobenzyl)piperidin-3-ol (rac-[2H4]-D-84, rac-[2H4]-1) was synthesized utilizing an H/D 
exchange reaction (Allmendinger & Wanner, 2014) (total synthesis is to be published soon). 
rac-[2H3]-Indatraline (rac-[2H3]-4) HCl was synthesized according to Grimm et al. (for 
synthesis see supporting information) (Grimm, Allmendinger, Höfner, & Wanner, 2013).  
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Polyethylenimine (PEI) solution (50 % in H2O) was bought from Fluka, HEPES and roti-
quant (5 x concentrated) from Roth (Karlsruhe, Germany). 
All percentages and ratios refer to v/v if not indicated otherwise. 
 
Solutions for marker and internal standard 
 
Marker and internal standard solutions for the performance of MS Binding Assays were 
prepared as follows. Stock solutions with a concentration of 1 mM of each marker and each 
internal standard in H2O/dimethylacetamide (DMA; 80/20) were prepared separately and 
stored at -20 °C. For the binding samples, calibration standards and the quality control (QC) 
samples, solutions with the 100-fold concentration (regarding the concentration in the final 
sample) were prepared in H2O/DMA (80/20) based on these stock solutions. For the binding 
samples, the 100-fold concentrated marker solutions in H2O/DMA (80/20) were used to 
obtain the binding samples (see “MS Binding Assay”). A 10 nM solution with all three 
internal standards in H2O/DMA (80/20) was diluted with acetonitrile to yield a 100 pM 
internal standards solution. Based on this internal standard solution, elution solutions for the 
validation and the MS Binding Assays were prepared. For the validation (see “Method 
validation”), 10-fold concentrated marker solutions (generated by dilution of a solution 
containing all three markers at 100-fold concentration with acetonitrile) were spiked to the 
100 pM internal standard solution (1 part 10-fold concentrated marker solution + 9 parts 100 
pM internal standard solution), resulting in a set of solutions containing the three marker at 
the final concentration for the calibration sample or QC sample and 90 pM of the three 
internal standards. To elute the bound marker in the MS Binding Assays (see “MS Binding 
Assay”), the 100 pM internal standard solution was diluted with acetonitrile (9 parts 100 pM 
internal standard solution + 1 part acetonitrile) to obtain a solution containing all three 
internal standards at a concentration of 90 pM (elution solution). All solutions were prepared 
in micro tubes (1.5 mL, polypropylene, Sarstedt, Nürmbrecht, Germany) and for the pipetting, 
non-coated pipet tips without filters (quality tips without filters, 20 µL neutral, 200 µL yellow 
300 µL neutral, 1000 µL blue, and 1250 µL neutral, Sarstedt, Nürmbrecht, Germany) were 
used. 
 
Instrumentation 
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HPLC method development was carried out on an API 3200 triple quadrupole mass 
spectrometer (AB Sciex, Darmstadt, Germany) with a Turbo V Ion Source, which was 
coupled with an Agilent 1200 HPLC system (vacuum degasser, binary pump, column oven; 
Agilent Waldbronn, Germany) and a Shimadzu SIL-HTA autosampler (Shimadzu, Duisburg, 
Germany). Mass spectrometric measurements for the optimization of the binding assay, 
validation, and the saturation experiments were performed on an API 5000 triple quadrupole 
mass spectrometer (AB Sciex) equipped with a pneumatically assisted Turbo V Ion Source, 
coupled to an Agilent 1200 HPLC system (vacuum degasser, binary pump, column oven) and 
a HTS-PAL autosampler (50 µL sample loop, 50 µL syringe; CTC Analytics, Zwingen, 
Switherland). For infusion experiments at the API 5000 a syringe pump (model 11 Plus MA 
170-2208, Harvard Apparatus Inc., Holliston, MA, USA) in combination with a 1 mL syringe 
(Hamilton, Cinnamonson, NJ, USA) was used and connected to the ion source via a T-piece. 
In all mass spectrometric measurements, the resolution of Q1 and Q3 was set to unit 
resolution. The LC-MS systems were controlled with Analyst 1.6 software (AB Sciex). 
As stationary phases a YMC Triart PFP column (50 x 2.0 mm, 3 µm, YMC Europe GmbH, 
Dinslaken, Germany) with a YMC Triart precolumn (10 x 2.0 mm, 3 µm) and a Luna PFP(2) 
column (50 x 2.0 mm, 3 µm, Phenomenex, Aschaffenburg, Germany), protected by a Luna 
PFP(2) security guard cartridge (4 x 2.0 mm, 3 µm, Phenomenex) were used. Furthermore, 
Amino, Diol NP, Polyamine, PVA SIL, and Silica (all 50 x 3.0 mm, 5 µm, YMC Europe 
GmbH, Dinslaken, Germany) were used as polar stationary phases. In all experiments, the 
stationary phase was additionally protected by two successive inline filters (IDEX, Wertheim-
Monfeld, Germany) of 0.5 µm (stainless steel) and 0.2 µm (titanium) porosity. 
 
Identification and tuning of MRM mass transitions 
 
Identification of mass transitions and optimization of compound-dependent parameters for the 
operation in MRM mode was done with the Quantitative Optimization tool of the Analyst 
software. For this purpose, solutions with a concentration of 400 nM (for the API 3200) or 
20 nM (for the API 5000) of each marker and internal standard separately dissolved in 
methanol/formic acid (0.1 %; 50/50) was infused (5 µL/min) directly into the ESI-source of 
the mass spectrometer (positive mode).  
 
Development of the LC-MS/MS method 
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During the method development, the HPLC parameters were evaluated at the API 3200 with 
solvent samples containing rac-D-84 (rac-1), rac-reboxetine (rac-2), and rac-citalopram (rac-
3) in acetonitrile. Detection was based on the mass transitions m/z 420.3/167.0 for rac-D-84 
(rac-1), m/z 314.2/176.1 for rac-reboxetine (rac-2), and m/z 325.2/109.1 for rac-citalopram 
(rac-3). 
 
Flow injection analysis 
 
A solution of (R,R)-D-84 ((R,R)-1), (S,S)-reboxetine ((S,S)-2), (S)-citalopram ((S)-3), rac-
[2H4]-D-84 (rac-[2H4]-1), rac-[2H5]-reboxetine (rac-[2H5]-2), and rac-[2H6]-citalopram (rac-
[2H6]-3), each in a concentration of 100 pM in acetonitrile containing the matrix (for 
preparation see “MS Binding Assay” below) was prepared for the flow injection analysis 
(FIA).  For each run an injection volume of 10 µL of this solution was used and analysed with 
the FIA option in the Compound Optimization Tool of the Analyst software. The source-
dependent parameters, such as ionization voltage, ion source temperature, and gas pressures 
were optimized in repeated chromatographic runs with the final HPLC method (see “LC-ESI-
MS/MS quantification method). 
 
Investigation of the matrix effect by post-column infusion experiments 
 
Thirty µL of samples containing rac-[2H4]-D-84 (rac-[2H4]-1), rac-[2H5]-reboxetine (rac-
[2H5]-2), and rac-[2H6]-citalopram (rac-[2H6]-3) in a concentration of 100 pM, dissolved in 
blank matrix (preparation see “MS Binding Assay” below) were injected into the 
chromatographic system. The flow rate of the HPLC was set to 200 µL/min. The optimized 
source dependent parameters (determined with the FIA option of the Compound Optimization 
Tool of the Analyst software, see above) were as following: ion source temperature (TEM) 
300 °C, ion spray voltage (IS) 5,000 V, nebulizing gas (GS1) 20 psi, and auxiliary gas (GS2) 
50 psi. The acquisition time was set to 15 min. All other method parameters were identical to 
the final method, described in LC-ESI-MS/MS quantification method (see below). A solution 
of 300 pM (R,R)-D-84 ((R,R)-1), 2 nM (S,S)-reboxetine ((S,S)-2), and 600 pM (S)-citalopram 
((S)-3) in mobile phase was infused at a flow rate of 100 µL/min into the eluent of the HPLC 
by means of a syringe pump with a Hamilton Gastight 5 mL syringe coupled to a 3-way-
connector between the HPLC-column and the MS.  
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LC-ESI-MS/MS quantification method 
 
For the quantification of the MS markers, a Luna PFP(2) column was used in combination 
with a mobile phase consisting of acetonitrile/ammonium formate buffer (0.75 mg/mL; 85/15) 
at a flow rate of 800 µL/min at a temperature of 20 °C. The injection volume was 30 µL. For 
the run time of the first 0.4 min the eluent was directed to waste. With positive polarity, the 
markers and internal standards were analysed under pneumatically assisted ESI conditions, 
using an ion source temperature of 650 °C, an ion spray voltage of 1,500 V, a curtain gas 
(CUR) pressure of 25 psi, a collision gas (CAD) of 5 psi, a nebulizing gas of 30 psi, and an 
auxiliary gas of 60 psi. For each marker two mass transitions were acquired (the first one with 
a dwell time of 50 ms the other one as a qualifier with a dwell time of 10 ms) in multiple 
reaction monitoring (MRM) mode. One mass transition with a dwell time of 50 ms was 
acquired for each internal standard. The mass transitions at the API 5000 were m/z 
420.2/167.1 and m/z 420.2/109.1 for (R,R)-D-84 ((R,R)-1), m/z 314.1/176.2 and m/z 
314.1/91.1 for (S,S)-reboxetine ((S,S)-2), m/z 325.2/109.2 and m/z 325.2/262.2 for (S)-
citalopram ((S)-3), m/z 424.2/167.1 for rac-[2H4]-D-84 (rac-[2H4]-1), m/z 319.2/176.2 for rac-
[2H5]-reboxetine (rac-[2H5]-2) and m/z 331.2/109.0 for rac-[2H6]-citalopram (rac-[2H6]-3). 
 
Method validation 
 
For validation six series, each containing blank samples, zero samples, calibration standards, 
and QC samples were investigated. In every validation series, matrix samples containing all 
three markers and internal standards were analysed. All standards (excluding the solvent 
blanks) were prepared similar to the binding samples (“MS Binding Assay”, see below) but 
without markers during the incubation. Elution solutions for the validation samples 
(“Solutions for marker and internal standard”, see above), which were transferred through the 
96-well filter plate containing the membrane fractions, were spiked with the markers in 
varying concentrations and 90 pM of the internal standards.  
For matrix blanks and zero samples (containing the matrix and the internal standards at 
90 pM), six replicates were prepared and analysed. 
The calibration curve was established with calibration standards in eleven concentration 
levels, ranging from 1 pM to 2.5 nM concentrations of each marker (the lower three 
concentrations in six replicates, all other concentrations in triplicates). The resulting area 
ratios (y, peak area MS marker/peak area internal standard) of each marker was plotted 
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against the concentration of the marker (x) and a linear regression with a weighting of 1/x was 
applied to obtain the calibration functions. To determine the intra- and inter-batch accuracy as 
well as the precision, QC samples at four concentration levels (2.5 pM, 10 pM, 100 pM, 
1 nM) were prepared and analysed in six replicates for each level.  
As a system suitability check, a 90 pM internal standard solution in acetonitrile was analysed 
prior to each series of measurements. The chromatogram obtained from this sample was 
evaluated in regard to the retention time (retention time of rac-[2H6]-citalopram (rac-[2H6]-3): 
1.15 – 1.25 min), the peak symmetry (no visible tailing or fronting for rac-[2H6]-citalopram 
(rac-[2H6]-3)) and the intensity (given as peak heights, not less than 30,000 cps for rac-[2H4]-
D-84 (rac-[2H4]-1), not less than 10,000 cps for rac-[2H5]-reboxetine (rac-[2H5]-2), and not 
less than 20,000 cps for rac-[2H6]-citalopram (rac-[2H6]-3)) of each internal standard.  
 
MS Binding Assay 
 
MS Binding Assays were carried out, using membrane preparations of HEK293 cells, stably 
expressing hDAT, hNET or hSERT, respectively (Grimm et al., 2015a). Aliquots of the 
membrane preparations, stored at -80 °C were thawed on the day of the assay. For saturation 
assays of (R,R)-D-84 ((R,R)-1) towards hDAT, 1 mL of the hDAT membrane preparation was 
diluted in 20 mL cold assay buffer (50 mM HEPES, 120 mM NaCl, 5 mM KCl, pH 7.4), 
centrifuged (20 min, 20,000 rpm, 4 °C, Sorvall Evolution, SS-34 rotor, Thermo Fisher 
Scientific, Dreieich, Germany) and the supernatant was discarded. The pellet was resuspended 
in 15 mL cold assay buffer and diluted with 10 mL assay buffer additionally to a final volume 
of 25 mL protein preparation. Membrane preparations for saturation experiments of the other 
two markers were prepared like described above, but with the following deviations: to 
perform saturation assays of (S,S)-reboxetine ((S,S)-2) towards hNET, 1 mL of the hNET 
membrane preparation was centrifuged in 20 mL assay buffer, the pellet was resuspended in 
15 mL assay buffer and finally diluted with assay buffer to yield a volume of 50 mL protein 
preparation. For saturation assays of (S)-citalopram ((S)-3) towards hSERT, 2.5 mL of the 
hSERT membrane preparation was centrifuged in 20 mL assay buffer and the pellet was 
resuspended in 30 mL assay buffer without further dilution. 
In a polypropylene 96-deep-well plate (1.2 mL, polypropylene, Sarstedt, Nürmbrecht, 
Germany), binding samples for the determination of the total binding were prepared in 32 
marker concentration levels as triplicates for each concentration level in assay buffer to a 
volume of 200 µL. The incubation was started by addition of 50 µL membrane preparation to 
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give a final sample volume of 250 µL resulting in final marker concentrations of 25 pM to 
500 nM and a protein content of 1.0 µg protein per well. The samples were then incubated at 
20 °C in a shaking water bath for 2 h. To terminate the incubation, 200 µL of each sample 
was transferred to a 96-well glass fiber filter plate (AcroPrep Advance, glass fiber, 1.0 µm, 
350 µL, Pall, Dreieich, Germany) which had been pretreated for 2 h with 150 µL 0.5 % (m/v) 
PEI solution per well at 4 °C. To transfer the samples row after row, a 12-channel pipette 
(25 µL - 300 µL, Eppendorf, Hamburg, Germany) was used. The filtration was carried out 
with a multi well plate vacuum manifold (Pall). After filtration of the samples row by row 
(i.e. 12 wells), the filters - with the membrane fragments containing the bound marker - were 
washed three times with 150 µL ice cold washing buffer (0.75 mg/mL ammonium formate, 
pH 7.4 + 10 % DMA) and finally one time with 150 µL ice cold washing buffer without 
DMA (0.75 mg/mL ammonium formate, pH 7.4) before the next row was transferred. 
Subsequent to the filtration of all samples, the 96-well filter plate was dried at 60 °C for 2 h. 
The bound marker was then liberated by the elution with 3 times 70 µL acetonitrile containing 
90 pM of the three internal standards (rac-[2H4]-1, rac-[2H5]-2, and rac-[2H6]-3, elution 
solution, see "Solutions”) into a 96-deep-well plate, leaving the elution solution each time on 
the filter for 20 s prior to aspiration under vacuum. The plates with the sample solutions were 
sealed with aluminium foil and centrifuged (10 min, 2000 rpm, 4 °C; Biofuge Stratos, Rotor: 
#3048, Heraeus, Germany) before they were analysed with the LC-MS/MS method.  
Samples for the determination of the nonspecific binding were prepared by spiking of the 
binding samples with rac-[2H3]-indatraline (rac-[2H3]-4) prior to the addition of the target, to 
obtain a concentration of 10 µM of rac-[2H3]-indatraline in the final binding samples. 
Preparation of these samples was performed according to the procedure described above. All 
the other parameters (e.g. replicates, marker concentrations, incubation time) were kept the 
same. 
Every day, when an MS Binding Assay was performed, at least one set of samples, containing 
all blanks, calibration standards, and QC samples described in the section “Validation”, was 
prepared and analysed together with the binding samples. Based on this calibration, binding 
samples were quantified. 
Matrix samples, used in the method development, for the determination of the matrix effect 
and for the validation were prepared analogously, in the same way as the incubation samples, 
except that no marker was added.  
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Data analysis 
 
All chromatograms for method development, validation as well as marker quantification in 
saturation experiments were acquired with Analyst 1.6 software. The Analyst 1.6 software 
was further used to generate the calibration functions and the calculations for the accuracy of 
calibration and QC samples. In Prism 6 software (GraphPad Software, San Diego, CA, USA) 
the area ratios (peak area MS marker/peak area internal standard), obtained from the binding 
samples were transformed into the concentrations of bound markers. Only samples with a 
bound marker concentration within the quantification limits of the LC-MS/MS quantification 
method were used for the further data analysis. Specific binding was calculated as the 
difference between total binding and nonspecific binding and used for the construction of 
saturation isotherms. Nonspecific binding was analysed for all marker concentrations, but 
only marker concentrations ≥ LLOQ were used to calculate a line of best fit for the 
nonspecific binding, using a linear regression (forced through the origin). Based on the 
function of this line of best fit, the nonspecific binding for all marker concentrations (binding 
samples with a nonspecifically bound marker concentration < LLOQ as well as binding 
samples for which the nonspecifically bound marker concentration was ≥ LLOQ) was 
determined. The equilibrium dissociation constant (Kd) and the maximum number of binding 
sites (Bmax) were obtained by nonlinear regression analysis (“one site – specific binding”, 
Prism 6) of the data points for the specific binding. 
 
Results 
 
LC-MS/MS Method development 
 
To quantify the amount of bound marker in an MS Binding Assay, an LC-ESI-MS/MS 
method had to be developed. LC-MS methods for the quantification of reboxetine and 
citalopram are already described in literature. Most of these methods are aimed at therapeutic 
drug monitoring of a variety of drugs, including either reboxetine (Zoerner et al., 2013) or 
citalopram (Amundsen, Øiestad, Ekeberg, & Kristoffersen, 2013; Licata et al., 2016) or both 
(Montenarh et al., 2014; Sempio, Morini, Vignali, & Groppi, 2014; Viette et al., 2011). 
Retention times in the published LC-MS methods are between 2.6 min (Zoerner et al., 2013) 
and 9.3 min (Viette et al., 2011) for reboxetine and range from 2.76 min (Amundsen et al., 
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2013) to 9.2 min (Licata et al., 2016) for citalopram. All of the mentioned LC-MS methods 
have lower limits of quantification (LLOQs) not below 1 ng/mL (3.2 nM) for reboxetine 
(Zoerner et al., 2013) and not lower than 3.2 ng/mL (9.9 nM) for citalopram (Amundsen et al., 
2013; Sempio et al., 2014). For D-84, no analytical method for the quantification is known at 
all. The method to be developed should enable us to quantify the markers with a sufficient 
sensitivity, so the LLOQ should be in the low pM range (see introduction), which is by a 
factor of approximately 1000 lower than the most sensitive quantification methods for 
reboxetine and citalopram known so far. Furthermore, the markers should be sufficiently 
separated from matrix components. Additionally, a separation of the three markers during the 
LC run appeared desirable as a mutual interaction of the coeluting compounds might be 
associated with signal suppression, thus falsifying the quantification which might be 
eventually true for a component present only in very low concentration coeluting with another 
compound present in very high concentration. Finally, the LC conditions should be optimized 
for short run times to obtain a method, capable of analysing samples with a high throughput. 
The published quantification methods for reboxetine and citalopram have retention times of at 
least 2.6 min for reboxetine and 2.8 min for citalopram, whereas the method to be developed 
was aimed to have a chromatographic run time of less than 2 min.  
 
ESI-MS/MS 
 
Since rac-D-84 [(rac-1, for the sake of simplicity, the racemic mixture of (R,R)-D-84 and 
(S,S)-D-83 (the enantiomer of (R,R)-D-84) is referred to as rac-D-84 throughout this work] 
was analysed by LC-ESI-MS/MS for the first time, mass transitions suitable for quantification 
were not known. Infusing a solution of rac-D-84 (rac-1) into the mass spectrometer 
(API 3200, ESI positive, for details the experimental section) the [M+H]+ precursor ion for D-
84 with m/z 420.3 could be observed as expected. Based on this precursor ion, the 5 most 
intensive fragment ions (m/z 167.0, 109.2, 152.2, 165.1, 121.2, see SI-figure 1) were 
identified and subsequently, the compound dependent parameters optimized with the 
Compound Optimization Tool of the Analyst software. Analogously, the mass transitions for 
rac-reboxetine (rac-2) m/z 314.2/176.1 and for rac-citalopram (rac-3) and m/z 325.2/109.1 
were found to be in accordance with literature (Amundsen et al., 2013; Licata et al., 2016; 
Montenarh et al., 2014; Sempio et al., 2014; Zoerner et al., 2013) and used later on for 
method development at the API 3200.  
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For final method development with the API 5000 (API 5000, ESI positive, for details see 
experimental section) compound optimization was repeated with the markers as pure 
enantiomers and in each case the two most intensive mass transitions were selected for final 
method development: for (R,R)-D-84 ((R,R)-1) m/z 420.2/167.1 and m/z 420.2/109.1, for 
(S,S)-reboxetine ((S,S)-2) m/z 314.1/176.2 and m/z 314.1/91.1 as well as for (S)-citalopram 
((S)-3) m/z 325.2/109.2 and m/z 325.2/262.2. In the same way, the mass transitions for the 
internal standards were analysed and optimized at the API 5000. For rac-[2H4]-D-84 (rac-
[2H4]-1, the [M+H]+ precursor ion with m/z 424.2 could be observed as expected. Based on 
this precursor ion, again (as described above for the nondeuterated compound) the 5 most 
intensive fragment ions (m/z 176.1, 113.2, 168.2, 152.1, 165.2) were identified. Expected 
mass transitions for rac-[2H5]-reboxetine (rac-[2H5]-2) and rac-[2H6]-citalopram (rac-[2H6]-3) 
were found in agreement with published data (Licata et al., 2016; Sempio et al., 2014; 
Zoerner et al., 2013). For LC-MS/MS at the API 5000 m/z 424.2/167.1 for rac-[2H4]-D-84 
(rac-[2H4]-1), m/z 319.2/176.2 for rac-[2H5]-reboxetine (rac-[2H5]-2), and m/z 331.2/109.0 for 
rac-[2H6]-citalopram (rac-[2H6]-3) were chosen.  
 
LC 
 
The aims of LC method development were to find chromatographic conditions that enable 
fast and robust quantification of all markers. Furthermore, a chromatographic separation of 
the markers from matrix components was intended in order to minimize matrix effects in the 
quantification of samples from MS Binding Assays via LC-ESI-MS/MS and to reach high 
ESI-MS/MS responses for all three analytes.  
Under reversed-phase conditions in isocratic mode, we could not find conditions (even in the 
basic pH range up to 11) resulting in sufficient retention of the markers in a mobile phase 
consisting of at least 50 % acetonitrile (data not shown). An increase of the portion of the 
aqueous component in the mobile phase in order to enhance retention was not considered, due 
to the loss of sensitivity typically arising under LC-ESI-MS conditions from an enhanced 
water content (Naidong, 2003; Nguyen & Schug, 2008). Therefore, a set of distinctly more 
polar stationary phases (Amino, Diol NP, Polyamine, PVA SIL, Silica, all 50 x 3.0 mm, 
5 µm, for detailed specification see experimental section) operated under HILIC conditions 
(Hemström & Irgum, 2006) as well as a pentafluorophenyl (PFP) stationary phase were 
investigated under various mobile phase compositions, with various additives and pH values 
in order to obtain an appropriate retention behaviour of the analytes. The PFP stationary phase 
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material has an enhanced selectivity in comparison to C8 and C18 stationary phases due to its 
dipole-dipole, π-π, charge transfer, and ion exchange retention mechanisms and turned out to 
be the most promising one for the intended purpose (Bell, Cramer, & Jones, 2005; Euerby, 
McKeown, & Petersson, 2003; Reta, Carr, Sadek, & Rutan, 1999). On a Triart PFP 
(50 x 2.0 mm, 3 µm, YMC), a method applying ammonium formate buffer (1.0 mg/mL) in 
combination with acetonitrile (15/85) at a flow rate of 800 µL/min resulted in a separation of 
all three markers. As an alternative to this stationary phase, chromatography on a Luna 
PFP(2) column (50 x 2.0 mm, 3 µm, Phenomenex) was also investigated. With the above 
mentioned mobile phase parameters, both stationary phases were compared concerning 
chromatographic parameters for the three markers (rac-1, rac-2 and rac-3) by analysis of a 
solution containing each marker at a concentration of 1 nM (see table 1 and SI-figure 2). With 
the Luna PFP(2) column, reduced retention times in combination with lower peak widths 
were observed for all three markers in comparison to the chromatograms from the Triart PFP. 
This resulted in considerably higher peak intensities and signal-to-noise ratios (S/N). 
Furthermore, the peak asymmetry obtained with the Luna PFP(2) was closer to 1 for all three 
analytes. For this reason, the Luna PFP(2) column was chosen for the final LC-ESI-MS/MS 
method. Since the Luna PFP(2) showed a lower retention for all three markers than the Triart 
PFP, the mobile phase was slightly adjusted to an ammonium formate buffer concentration of 
0.75 mg/mL, which was observed to prolong retention under these chromatographic 
conditions during the method development. All other method parameters were kept 
unchanged, resulting in retention times of 0.6 min for (R,R)-D-84 ((R,R)-1, k = 1.4), 0.78 min 
for (S,S)-reboxetine ((S,S)-2, k = 2.1), and 1.1 min for (S)-citalopram ((S)-3, k = 3.4, see figure 
7d) while the results for peak height, S/N, peak width, and peak asymmetry were still better 
than for the Triart PFP column. It is also worth to mention that this LC-method is compatible 
with samples dissolved in pure acetonitrile, thus no addition of aqueous buffer is needed prior 
to analysis, which would dilute the samples resulting after elution of the bound marker from 
the filters (see also figure 3) and therefore reduce the sensitivity of the method. 
 
For the developed LC method, the source dependent parameters of the mass spectrometer 
were optimized (for details see experimental section). The flow injection analysis (FIA) 
resulted in an optimal ion spray voltage (IS) of 1500 V, an ion source temperature (TEM) of 
650 °C, a nebulizer gas (GS1) of 30 psi, and a heater gas (GS2) of 60 psi. In preliminary 
experiments, we found that a low pressure for the curtain gas (CUR) leads to higher 
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intensities, but since the CUR protects the mass spectrometer from contaminations, a low 
CUR also has huge disadvantages. As a compromise, the CUR was set to 25 psi. 
 
 
Adsorption of the markers towards the container material 
 
During LC-MS method development, it was observed that a freshly prepared aqueous solution 
of rac-D-84 (rac-1) resulted in considerably higher LC-ESI-MS/MS responses than a solution 
that was stored overnight. For a stock solution of rac-D-84 (rac-1) in water kept in a 
polypropylene tube, the peak area for the mass transition m/z 420.3/167.0 in LC-ESI-MS/MS 
analyses decreased by more than a half on the consecutive day when stored overnight (in each 
case prior to analysis the sample was subsequently diluted in acetonitrile. In contrast, when 
rac-D-84 (rac-1) was stored as a solution in acetonitrile, in a polypropylene tube such a loss 
of intensity was not apparent in corresponding MRM chromatograms. Nuclear magnetic 
resonance analysis of the rac-D-84 (rac-1) solution after varying storage durations showed no 
change in the 1H-NMR spectrum (data not shown), indicating that the loss of compound is not 
due to degradation. Furthermore, storage of the aqueous rac-D-84 (rac-1) solution at different 
temperatures did not alter the loss of signal intensity, but it was noticed that this loss of signal 
intensity could be dependent on the materials, the container was made from. Therefore, a 
variety of containers from different manufacturers including coated and non-coated 
polypropylene tubes as well as glass vials were investigated. The adsorption and therefore 
loss of D-84 in aqueous solutions could not be sufficiently avoided with the tested materials. 
Hence, we did not pursue this strategy furthermore, as it seemed to be a hopeless endeavour to 
find suitable material (and corresponding containers) for all sample preparation steps of the 
MS Binding Assays (including e.g. pipetting, incubation, LC-MS analysis etc., see also figure 
3). In this context, it is worth to mention that water as solvent is inevitable for incubation in 
the desired MS Binding Assays, so replacing water by an organic solvent was no alternative 
solution to overcome this problem.  
The adsorption of analytes towards container material is an occasionally observed issue also 
described for analytical studies dealing with urine samples (Heinig, Wirz, Yuan, Tingler, & 
Mylott, 2011; Ji et al., 2010; Li, Luo, Smith, & Tse, 2010). Interestingly, in a publication by 
S. Sylvester and F. Zang (Silvester & Zang, 2012) adsorption of a test compound (AZD9164, 
(R)-1-(4-fluorophenethyl)-3-(((S)-2-phenyl-2-(piperidin-1-yl)propanoyl)oxy)quinuclidin-1-
ium), which shares some structural features with D-84, towards plastic material of containers 
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in urine samples is reported. Several types of additives (such as proteins, detergents or 
cosolvents) are known to overcome this problem. Due to concerns that addition of proteins 
may lead to undesired interferences in the binding experiments and addition of detergents 
may cause severe matrix problems in LC-ESI-MS/MS based marker quantification, we 
decided to make use of dimethylacetamide (DMA), which has already been described to 
prevent adsorption of AZD9164 in urine samples in the above-mentioned study (Silvester & 
Zang, 2012). For investigation of the effect of DMA on the adsorption of rac-D-84 (rac-1) to 
the container, dilution series at six concentration levels between 500 pM and 25 nM were 
prepared in water without and with the addition of DMA. Each concentration level was 
prepared by dilution of the higher concentrated solution, thus every decrease in D-84 
concentration was achieved by using a new container and pipet tip, on which adsorption could 
occur. These aqueous solutions were finally spiked with rac-reboxetine (rac-2) as internal 
standard (as the deuterated analogue of rac-1 was not yet available at this time) and diluted 
tenfold in acetonitrile prior to analysis, to obtain solutions with 50 pM to 2.5 nM of rac-1 
with 2.5 nM rac-2. In the dilution series prepared in water without the addition of DMA, it 
could be seen that the relative response factors (RRF) decrease with each dilution step, 
illustrating a consecutive loss of analyte due to dilution in water (see figure 2). Preparation of 
the dilution series in water with 20 % DMA resulted generally in higher RFFs than for the 
dilution series in pure water and no decrease in RRFs during the course of the dilution series. 
This demonstrates that rac-D-84 (rac-1) stays at least largely dissolved in an aqueous solution 
with 20 % DMA. In this context, it is worth to mention that this conclusion is also supported 
by the excellent linear calibration functions obtained for (R,R)-1 over a wide range of 
concentrations, which were prepared as a dilution series in DMA/water (20/80) prior to 
dilution in acetonitrile as described below (see “Validation”). It has to be noted that these 
adsorption-issues would also have been a major problem for the use of (R,R)-D-84 ((R,R)-1) 
as reporter ligand in radioligand binding assays. In the case of MS Binding Assays, these 
effects can be easily investigated and targeted during the method development in contrast to 
radioligand binding assays, where such problems may be overlooked.  
In the MS Binding Assays to be developed, a high DMA content was expected to perturb a 
reliable affinity determination. Therefore, the DMA concentration in the binding samples had 
to be much lower. For this purpose, stock solutions were prepared in DMA/water (20/80) and 
diluted with the same solvent to obtain 100-fold concentrated marker solutions. The 100-fold 
concentrated marker solutions were diluted on the day of the assay with binding buffer to 
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generate the binding samples, resulting in the desired final marker concentrations. In this way, 
the DMA concentration in the final binding samples was reduced to 0.2 %.  
 
 
 
Figure 2: Relative response factors (RRF) for rac-D-84 (rac-1) calculated as, !"#$	#&"#	'()*+*,-./0."01&#12/0	'()*+*,-	!"#$	#&"#	'()*&"3/4"120"./0."01&#12/0	'()*&"3/4"120" , (mean ± SD, n = 3). Dilution series of rac-D-84 (rac-1, 500 pM – 
25 nM) in pure water (circles) and 20 % DMA in water (triangles) were prepared, spiked with 
rac-reboxetine, subsequently diluted tenfold in acetonitrile and analysed. Stationary phase: 
Triart PFP (50 x 2.0 mm, 3 µm), mobile phase: acetonitrile / ammonium formate buffer 
(1.0 mg/mL, 85/15), 800 µL/min, detection at the API 3200: rac-D-84 (rac-1): m/z 
420.3/167.0, rac-reboxetine (rac-2): m/z 314.2/176.1. 
 
Binding assay 
 
It was intended to perform MS Binding Assays according to the setup, previously published 
for targets like the γ-aminobutyric acid transporter GAT1 (Zepperitz et al., 2006), monoamine 
transporters (Grimm et al., 2015a; Hess et al., 2011), and dopamine receptors (Neiens et al., 
2015) (see also figure 3 for the procedure of the established MS Binding Assays). For the 
formation of target-marker complexes, all of these MS Binding Assays consist of an 
incubation step under controlled conditions in a 96-well format. After an incubation time 
sufficient for equilibration, the target-marker complexes are then separated from the unbound 
marker by a vacuum filtration step employing a 96-well filterplate, followed by the washing 
of the filters with the entrapped membrane fragments to further reduce the presence of 
unbound and non-specifically bound marker. In successive steps, the target protein is 
denatured by the influence of heat and organic solvent, leading to a liberation of the bound 
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marker. The formerly bound marker - now dissolved in the organic solvent - can be eluted by 
filtration, resulting in a sample, which is finally analysed by LC-MS/MS.  
Conditions for the incubation should be – as far as possible - chosen based on published 
binding assays for the corresponding targets and markers. Therefore, a HEPES buffer 
supplemented with NaCl and KCl (50 mM HEPES, 120 mM NaCl, 5 mM KCl, pH 7.4) was 
used for incubation as described by Grimm et al. (Grimm et al., 2015a) for MS Binding 
Assays addressing hDAT, hNET, and hSERT with (1R,3S)-indatraline as marker. With 
respect to incubation time and temperature, only information from radioligand binding 
experiments for rac-[3H]-citalopram (rac-[3H]-2) towards SERT was available. Chen et al. 
and Goulet et al. described incubation times from 1 h to 2 h at 4 °C for the mentioned 
radioligand binding experiments (Chen et al., 2005; Goulet et al., 2001). Since the affinities of 
(R,R)-D-84 ((R,R)-1) towards DAT and (S,S)-reboxetine ((S,S)-2) towards NET were 
expected to be in a similar range as the one of (S)-citalopram ((S)-3) towards hSERT, binding 
of all markers towards their targets was assumed to reach equilibrium within an incubation 
time of 2 h at 20 °C.  
For the determination of the nonspecific binding, the triple reuptake inhibitor rac-indatraline 
(rac-4)) was intended to be used in a concentration of 10 µM in the binding assay to block 
specific binding sites of the markers at hDAT, hNET, and hSERT (Bøgesø, Vibeke 
Christensen, Hyttel, & Liljefors, 1985; Grimm et al., 2015b). Preliminary experiments using 
10 µM rac-indatraline (rac-4) as an inhibitor enabled the reliable determination of the 
nonspecific binding. Since an MS Binding Assay using (1R,3S)-indatraline as a marker 
(Grimm et al., 2015a) was analysed on the same instrument, we wanted to avoid introducing 
high concentrations of indatraline into the MS, which could interfere with the (1R,3S)-
indatraline MS Binding Assays. As an alternative to native indatraline, rac-[2H3]-indatraline 
(rac-[2H3]-4) was previously synthesized in our group (according to the procedure published 
in the supporting information of Grimm et al. (Grimm et al., 2013), synthesis is described in 
detail in the supporting information of this publication) for an earlier project. When used as 
inhibitor for the determination of the nonspecific binding in the newly developed MS Binding 
Assays, rac-[2H3]-indatraline (rac-[2H3]-4) did not interfere with the (1R,3S)-indatraline-MS 
Binding Assays, allowing its use in this project. It is, however, important to mention that the 
use of a deuterated indatraline species for this purpose is basically not imperative at all. There 
is a wealth of commercially available high affinity ligands for DAT, NET, and SERT that can 
be considered as alternatives as inhibitors for the determination of nonspecific binding in MS 
Binding Assays as well.  
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Commonly, the separation of nonbound marker from the target-marker complexes can be 
easily achieved by rapid filtration of the binding samples through a glass fiber filter. 
Pretreatment of the filters with polyethyleniminie (PEI) is known to reduce filter binding in 
radioligand binding assays in many cases (Bruns, Lawson-Wendling, & Pugsley, 1983; 
Hampton, Medzihradsky, Woods, & Dahlstrom, 1982; Roche, Bergert, & Ryan, 1985) and 
was e.g. applied to [3H]-citalopram binding assays (Chen et al., 2005; Goulet et al., 2001). 
After the filtration, the target material and the filters should be washed with ice cold 
ammonium formate washing buffer to remove remaining solution of the binding samples and 
loosely, nonspecifically bound marker from the target preparation and the filters. The filters 
with the target-marker complexes should be stored in the drying cabinet, before a solution of 
the internal standard in acetonitrile is applied to each filter and aspirated in the vacuum in 
order to elute the formerly bound marker. In this way, the formerly bound marker would be 
dissolved in the organic solvent of the mobile phase, which can then be used as the sample for 
LC-MS/MS analysis without any further sample preparation (e.g. solvent evaporation or 
addition of buffer). 
 
  
 
 
 
Figure 3: Workflow of the developed MS Binding Assays  
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Matrix effect 
 
In LC-ESI-MS, the matrix of a sample can lead to signal suppression (Dams, Huestis, 
Lambert, & Murphy, 2003; Fu, Woolf, & Matuszewski, 1998; King, Bonfiglio, Fernandez-
Metzler, Miller-Stein, & Olah, 2000; Matuszewski, Constanzer, & Chavez-Eng, 1998; Taylor, 
2005). To compensate matrix effects, the use of stable isotopically labelled internal standards 
is typically advised and followed in LC-ESI-MS/MS quantification methods (Stokvis, Rosing, 
& Beijnen, 2005; Wang, Cyronak, & Yang, 2007; G. Zhang & Wujcik, 2009). Since we 
aimed for a high sensitivity, which is usually limited by the S/N ratio and therefore the 
intensity of the analyte signal in the chromatogram, we tried to reduce matrix suppressions 
that affect the performance of the method. To analyse the matrix effect, we tried to uncover 
possible matrix-effects that may be caused by the target material (i.e. hDAT, hNET, and 
hSERT membrane preparations), the buffers used for incubation and washing as well as by 
the glass fiber filter material (including its pretreatment with PEI) in post-column infusion 
experiments (Bonfiglio et al., 1999). At first, matrix from binding samples was generated 
according to the intended procedure for the binding experiments (for details see experimental 
section). After incubation of the target material (in absence of the markers) in HEPES buffer 
(50 mM HEPES, 120 mM NaCl, 5 mM KCl, pH 7.4) 200 µL of the binding samples were 
filtrated through PEI pretreated filter plates. Subsequently, the filters were washed with 
ammonium formate buffer (0.75 mg/mL, pH 7.4) and dried. Afterwards the filter plates were 
eluted with a solution of all three deuterated internal standards, each in a concentration of 100 
pM, in acetonitrile. These matrices containing the internal standards were subjected to the 
developed LC-ESI-MS/MS method. In contrast to the standard conditions of the developed 
LC-MS/MS method, now a solution of 300 pM (R,R)-D-84 ((R,R)-1), 2 nM (S,S)-reboxetine 
((S,S)-2), and 600 pM (S)-citalopram ((S)-3) in the mobile phase was infused into to the eluent 
leaving the column via a T piece before reaching the mass spectrometer by means of syringe 
pump at a flow rate of 100 µL/min. Furthermore, due to the pressure of the LC eluent directed 
into the syringe pump, the LC flow rate had to be reduced to 200 µL/min (and as a 
consequence, the source-dependent MS parameters were also adjusted for this purpose by 
FIA, for details see experimental section). 
In the MRM chromatograms obtained in this way (see figure 5), the retention times of the 
markers under the altered flow rate were clearly indicated by the peaks of the internal 
standards (rac-[2H4]-1: m/z 424.2/167.1, 2.4 min, rac-[2H5]-2: m/z 319.2/176.2, 3.0 min, rac-
[2H6]-3: m/z 331.2/109.0, 4.4 min). The void time is indicated by a peak in the traces of all 
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three markers ((R,R)-1: m/z 420.2/167.1, (S,S)-2: 314.1/176.2, (S)-3: m/z 325.2/109.2 at 
1.1 min, which is assumed to be caused by higher acetonitrile content from the sample solvent 
eluting from the LC, leading to better volatility of the mobile phase and increased ionization 
efficiency. Furthermore, several suppression zones in the MRM traces of the markers could 
be recognized. The first one, directly after the void time and a second matrix suppression 
from 2.5 min to approximately 4.0 min can be clearly seen. After these suppression zones, 
which are located near or at the retention times of the markers, there was a third one after the 
peak of (S)-citalopram ((S)-3) visible in the chromatogram of the post-column infusion 
experiment (6.0 min – 8.0 min, see figure 5).  
The third matrix suppression could be an issue, as it may affect successive chromatographic 
runs. An easy way to avoid this, would be a chromatographic run time, long enough to ensure 
that all the matrix is eluted from the column. Since short chromatographic run times were an 
important aim in our method development, we did not favour a solution in this way. Instead, 
we tried to determine, if there is indeed a significant suppression due to a matrix effect of the 
late-eluting matrix components onto successive chromatographic runs under the original 
conditions of the developed LC-ESI-MS/MS quantification method (with a flow rate of 
800 µL/min). Therefore, a matrix standard with all three markers at a concentration of 
100 pM was prepared according to the procedure of the MS Binding Assays (incubation, 
filtration of binding sample, washing with ammonium formate buffer, elution with solution 
containing 100 pM markers in acetonitrile, for details see experimental section) and analysed 
in a sequence together with a solvent standard containing the three markers ((R,R)-1, (S,S)-2, 
(S)-3) also in a concentration of 100 pM in acetonitrile (see figure 6). The sequence of the 
injections was chosen on the basis of the publication from S. Sylvester and F. Zang (Silvester 
& Zang, 2012), to determine signal suppressions on up to two solvent samples, which are 
analysed after a matrix sample, as well as an additional effect in a series of six matrix 
samples. In the first five injections of the solvent standard (see figure 5, injection no. 1 – 5), 
the peak intensities of the three markers ((R,R)-1, (S,S)-2, (S)-3) show a constant level for the 
peaks of the markers ((R,R)-1: m/z 420.2/167.1, ca. 800,000 cps (S,S)-2: 314.1/176.2, ca. 
250,000 cps (S)-3: m/z 325.2/109.2), ca. 500,000 cps). In the six successive sequences of 
injections consisting of one matrix standard followed by two solvent standards (injection no. 6 
– 23), no signs of suppression of the marker peaks due to preceding matrix samples could be 
observed. In the following series of six injections of the matrix standard (injection no. 24 – 
29), the signal intensities of the peaks in all six chromatograms are at the same level, showing 
no effects of matrix accumulation over multiple injections caused by the matrix standards. A 
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lack of suppression on marker peaks caused by the matrix of preceding samples is further 
demonstrated by the successive solvent standards (injection no. 30 – 36), in which the peaks 
have the same level of intensity as in the solvent standards at the start of the sequence. As a 
result, this experiment shows, that under the standard method parameters (see experimental 
section “LC-ESI-MS/MS quantification method”) the chromatographic cycle time including 
the time period necessary for the injection of the successive sample is long enough for the 
elution of the complete matrix before the next chromatographic run is started.  
 
 
 
Figure 4:  Schematic workflow of the post-column infusion experiment. 
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Figure 5:  MRM Chromatogram from a post-column infusion experiment for the 
determination of matrix effects resulting from binding samples, as described in the 
experimental section (“Investigation of the matrix effect by post-column infusion 
experiments”). 300 pM (R,R)-D-84 ((R,R)-1, blue signal), 2 nM (S,S)-reboxetine ((S,S)-2, red 
signal), and 600 pM (S)-citalopram ((S)-3, green signal) were infused continuously, while 
blank matrix, containing 100 pM rac-[2H4]-D-84 (rac-[2H4]-1, blue dotted peak), rac-[2H5]-
reboxetine (rac-[2H5]-2, red dotted peak), and rac-[2H6]-citalopram (rac-[2H6]-3, green dotted 
peak at a retention time of 4.5 min; peak at 1.5 min is caused by matrix components, 
generating a signal with the same MRM transition as rac-[2H6]-3), which was subjected to the 
chromatography. 
 
  
 
Figure 6: Plot of marker peak intensities for a series of injections of solvent standards (full 
symbols) and matrix standards (100 pM of each marker, empty symbols, obtained from a 
simulated binding experiment, for details on the sample preparation and analysis see 
experimental section); (R,R)-D-84 ((R,R)-1): blue dots, (S,S)-reboxetine ((S,S)-2): red squares, 
(S)-citalopram ((S)-3): green triangles. 
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Nonspecific binding of markers to glass fiber filters 
 
In MS Binding Assays as well as in radioligand binding assays, separation of the target-
marker complexes from nonbound marker is typically achieved by filtration (Chen et al., 
2005; Grimm et al., 2015a; Hess et al., 2011; Neiens et al., 2015; Zepperitz et al., 2006; R. 
Zhang & Xie, 2012). In contrast to radioligand binding assays, where the whole filter with the 
remaining target material and the bound marker is subjected to measurement of radioactivity, 
in MS Binding Assays the target bound marker remaining on the filter has to be eluted by 
means of an organic solvent to enable its quantification by LC-MS (see also figure 3). Due to 
the adsorption problems observed for D-84 (see above), we found it worth to examine the 
adsorption of all three markers ((R,R)-1, (S,S)-2, (S)-3) when diluted in acetonitrile towards 
the glass fiber filters. Therefore, a 100 pM solution of all three markers ((R,R)-1, (S,S)-2, and 
(S)-3) in acetonitrile was filtered through pretreated glass fiber filters. The pretreatment of the 
glass fiber filters should be the same as in the final MS Binding Assays. Filters were 
incubated with 200 µL 0.5 % PEI solution or 200 µL water as a negative control for 1 h and 
afterwards washed three times with 150 µL ammonium formate buffer (0.75 mg/mL, pH 7.4). 
Additionally to the filtrated marker solutions, reference samples with unfiltrated marker 
solution (in the same nominal concentration) were prepared. Finally, all samples were spiked 
with a 100 pM solution of the three internal standards (rac-[2H4]-1, rac-[2H5]-2, rac-[2H6]-3) 
to compensate matrix effects. In comparison to the signals of the unfiltrated reference sample 
(100 % for each marker), the signals of the samples, which were passed through filters not 
pretreated with PEI are considerably decreased ((R,R)-1: 78.2 %, (S,S)-2: 35.0 %, and (S)-3: 
9.6 %, see figure 7). Surprisingly, the adsorption of the markers towards the filter material is 
much higher for (S,S)-reboxetine and (S)-citalopram, than for (R,R)-D-84, when the markers 
are dissolved in acetonitrile. The comparison of the signals obtained from the samples 
filtrated through the PEI-coated filters (peak area ratios of (R,R)-1: 87.5 %, (S,S)-2: 91.1 %, 
and (S)-3: 89.6 %) shows that the pretreatment with PEI effectively reduces the loss of 
markers during liberation and elution (see figure 3) even though the filters are washed 
repeatedly after the pretreatment with PEI. 
In preliminary saturation experiments performed for each of the three markers ((R,R)-1, (S,S)-
2, (S)-3) in presence of their targets, an extraordinarily high nonspecific binding of (R,R)-D-
84 was apparent. The proportion of the nonspecifically bound marker concentration for (R,R)-
D-84 was between 1.4 and 2.8 % of the nominal marker concentration in the binding sample, 
whereas the nonspecifically bound marker concentrations of (S,S)-reboxetine and (S)-
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citalopram were considerably lower with proportions between 0.025 and 0.030 % for (S,S)-2 
and between 0.054 and 0.074 % for (S)-3 , respectively (see figure 8, filled symbols). It was 
assumed, that the high nonspecific binding of (R,R)-D-84 ((R,R)-1) may be mainly caused 
again by adsorption of the marker towards the filter material during the filtration step of the 
aqueous binding samples (see figure 3), which is not sufficiently reduced by the pretreatment 
with PEI.  
Reliable determination of specific binding is typically hampered when the portion of 
nonspecific binding is high. Attempts to reduce the nonspecific binding of (R,R)-D-84 ((R,R)-
1) by the use of other filter materials (hydrophilic polypropylene and polyethersulfone) 
resulted in even higher nonspecific filter binding when aqueous solutions of the markers 
(without target preparation) were filtrated (data not shown). Since the addition of DMA to the 
aqueous marker solutions proved to reduce the adsorption of D-84 towards the container 
surface, it was assumed that the nonspecific binding of (R,R)-D-84 ((R,R)-1) to the glass fiber 
filters could also be reduced by the addition of DMA to the washing buffer. Addition of DMA 
during incubation above 0.2% was avoided, as high concentrations of DMA were expected to 
affect the stability of the target-marker complexes. An alternative strategy was to remove 
nonspecifically bound D-84 from the filter material by the use of a washing buffer, which is 
supplemented with DMA. Therefore, 10 % DMA was added to the pure ammonium formate 
buffer (0.75 mg/mL, pH 7.4) This washing buffer was used for repeated washing of the filters 
(three times with 150 µL) after filtration of the binding samples. To reduce the DMA content 
in the filters prior to drying, a fourth washing step with pure ammonium formate buffer 
(0.75 mg/mL, pH 7.4) was implemented. In this way, the proportion of nonspecifically bound 
(R,R)-D-84 ((R,R)-1) in relation to the nominal marker concentration in the binding sample 
could be distinctly reduced to values between 0.31 and 0.40 % (see figure 7, blue empty 
symbols). This reduction of nonspecific binding enabled reliable determination of specific 
binding for (R,R)-D-84 ((R,R)-1) as shown below. In order to examine the suitability of these 
filtration and washing conditions, preliminary saturation experiments were exemplarily 
performed for (S)-citalopram ((S)-3) towards hSERT, as the results of these experiments 
could be easily validated by comparision with results published for [3H]-(S)-citalopram 
binding experiments. The good agreement of the Kd values found for (S)-citalopram ((S)-3) 
with those obtained in radioligand binding assays (see supporting information) demonstrated 
that the established filtration, washing, and elution procedure enables a reliable determination 
of affinities.  
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Figure 7: Recovery of markers ((R,R)-D-84 ((R,R)-1, blue), (S,S)-reboxtine ((S,S)-2, red), and 
(S)-citalopram ((S)-3, green, all at 100 pM) dissolved in acetonitrile after filtration through 
glass fiber filters. Reference sample was not filtrated, filtrated samples were filtrated through 
filters, pretreated with 200 µL water (“filter not pretreated with PEI”) or 200 µL 0.5 % PEI 
solution (“filter pretreated with PEI”) for 1 h and washed with 3 x 150 µL ammonium formate 
buffer (0.75 mg/mL, pH 7.4) prior to filtration. All non-filtrated reference and filtrated 
samples were spiked with internal standards (rac-[2H4]-1, rac-[2H5]-2, rac-[2H6]-3) at a 
concentration of 100 pM in acetonitrile prior to analysis. Bars represent means of recovery (% 
relative to reference sample) ± SD (n = 6). 
 
 
 
Figure 8: Nonspecific binding (mean ± SD, n = 3) derived from preliminary saturation 
experiments using different washing procedures. Binding samples were prepared according to 
the general procedure for the MS Binding Assays (see experimental section). After 
incubation, binding samples were filtrated over the glass fiber filters. Subsequently, the filters 
were washed with ammonium formate buffer (0.75 mg/mL, pH 7.4, filled symbols, (R,R)-1: 
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blue, (S,S)-2: red, (S)-3: green) or 10 % DMA in ammonium formate buffer (0.75 mg/mL, 
pH 7.4, only shown for (R,R)-1: empty blue symbols). Marker elution and analysis was 
carried out according to the procedure and with the LC-ESI-MS/MS quantification method, 
described in the experimental section. 
 
Validation 
 
The final LC-ESI-MS/MS quantification method was validated according to the CDER 
guideline for bioanalytical method validation (FDA, 2013) regarding selectivity, accuracy, 
precision, calibration curve, and sensitivity. 
Calibration standards at eleven concentration levels in a range from 1 pM to 2.5 nM for each 
marker ((R,R)-1, (S,S)-2, and (S)-3) and quality control samples (QCs) at four concentration 
levels between 2.5 pM and 1 nM were prepared for the validation experiments. Matrix blanks, 
zero samples, calibration standards for the concentrations 1 pM, 2.5 pM, and 5 pM, as well as 
all concentration levels of the QC samples were prepared in six replicates for each 
concentration level. The other concentration levels for the calibration samples were prepared 
as triplicates. For all of these standards and samples, matrix blanks were prepared according 
to the procedure for the binding samples (but without the addition of marker and internal 
standard) and spiked with markers and internal standards at the elution step employing an 
acetonitrile solution containing the corresponding marker concentration and the internal 
standards each at a concentration of 90 pM. Sample series taken for the validation, were 
prepared at different days with membrane preparations for each of the three targets. In each 
series, the quantification for all three markers was validated. 
To demonstrate the selectivity of the LC-MS/MS quantification method, matrix blanks, and 
zero samples were prepared with matrices of all three target materials. For each marker and 
internal standard, no interfering signals (i.e. no signals with an intensity of more than 20 % of 
the LLOQ) could be detected in the blanks at the estimated retention times of the analytes (see 
figure 9a). Furthermore, the absence of such peaks in the traces of the markers in the 
chromatogram of the zero samples shows, that there is no contamination of the markers 
originating from non-deuterated internal standards (data not shown). 
To determine accuracy and precision of the method, QC samples were used. For the accuracy, 
the mean of the concentrations measured with the quantification method was compared to the 
actual concentration of the standard. The back-calculated concentration was between the 
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limits of the guideline (85 % and 115 % of the nominal concentration) for all three markers 
(see table 2 “Accuracy”).  
The precision is defined as the coefficient of variance or relative standard deviation (RSD) of 
multiple samples at each concentration level. It can be differentiated between intra-batch 
(within one validation run) or inter-batch (within all validation runs). In accordance to the 
guideline, the RSDs of the QCs were below 15 % for intra- as well as inter-batch precision 
(see table 2 “Precision”).  
For each of the three markers ((R,R)-1, (S,S)-2, and (S)-3), also calibration functions were 
established. The sensitivity defined by the lower limit of quantification (LLOQ) is the lowest 
analyte concentration, which can be determined accurately and precisely. For (R,R)-D-84 
((R,R)-1) and (S)-citalopram ((S)-3) the data for an analyte concentration of 2.5 pM (see 
figure 9c) met the criteria of the guideline in regard to signal-to-noise ratio (S/N ≥ 5), as well 
as precision (RSD ≤ 20 %) and accuracy (80 % - 120 %) of the calibration standards (see 
table 2 “LLOQ”). The LLOQ of (S,S)-reboxetine ((S,S)-2) was at a concentration of 1 pM (see 
figure 9b), where all criteria of the guideline were fulfilled. 
The upper limit of quantification (ULOQ) is the highest concentration of the calibration 
function. For (R,R)-D-84 ((R,R)-1) the ULOQ was at 1 nM, for (S,S)-reboxetine ((S,S)-2) and 
(S)-citalopram ((S)-3) the ULOQ was at 2.5 nM. At these concentrations all requirements of 
the guideline regarding precision (RSD ≤ 15 %) and accuracy (85 % - 115 %) were met (see 
table 2 “ULOQ”)).  
The calibration functions were defined by a linear regression of peak area ratios (peak area 
marker/peak area internal standard) vs marker concentrations. A 1/x weighting of the 
calibration functions allowed for a reliable quantification of low as well as high 
concentrations. Based on the data obtained from the validation series, for (R,R)-D-84 ((R,R)-
1) calibration functions from 2.5 pM to 1 nM with a coefficient of determination (r2) of at 
least 0.9958 could be defined. For (S,S)-reboxetine ((S,S)-2), calibration functions ranging 
from 1 pM to 2.5 nM including eleven calibration levels were established (r2 ≥ 0.9978) and 
for (S)-citalopram ((S)-3), calibration functions with ten concentration levels between 2.5 pM 
and 2.5 nM were obtained (r2 ≥ 0.9950). The requirement that at least 75 % of all calibration 
standards should meet the acceptance criteria for accuracy was fulfilled for all three markers 
(see table 2 “Calibration”).  
Furthermore, the back-calculated concentration of at least 67 % of all QC samples and 50 % 
of the QC samples for each concentration level should deviate not more than 15 % from the 
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nominal concentration, which was fulfilled for all three markers (see table 2 “QCs”). This 
data supports the reliability of the established calibration functions. 
The acquired data from the validation runs demonstrate the capability of the developed LC-
MS/MS quantification method to deliver reliable results. This quantification method 
outperforms the published methods considering the sensitivities for (S,S)-reboxetine ((S,S)-2) 
and (S)-citalopram ((S)-3) by more than a factor of 1000 and has a much shorter run time of 
1.5 min, which makes it highly suitable for the quantification of bound markers in a large 
number of samples. Furthermore, this is the first published quantification method of (R,R)-D-
84 ((R,R)-1).  
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Figure 9: MRM chromatograms of (R,R)-D-84 ((R,R)-1, blue, m/z 420.2/167.1), (S,S)-
reboxetine ((S,S)-2, red, m/z 314.1/176.2), and (S)-citalopram ((S)-3, green, m/z 325.2/109.1) 
obtained with the developed LC-ESI-MS/MS quantification method. a) Matrix blank, b) 
1 pM, c) 2.5 pM, and d) 100 pM of each marker ((R,R)-1, (S,S)-2, (S)-3) with 90 pM rac-
[2H4]-D-84 (rac-[2H4]-1, blue dotted, m/z 424.2/176.1), rac-[2H5]-reboxetine (rac-[2H5]-2, red 
dotted, m/z 319.2/176.2), and rac-[2H6]-citalopram (rac-[2H6]-3, green dotted, m/z 
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331.2/109.0) as internal standards. All chromatograms were acquired, using a Luna PFP(2) 
column as the stationary phase and acetonitrile/ammonium formate buffer (0.75 mg/mL; 
85/15) at 800 µL/min as mobile phase. The temperature was set at 20 °C and the injection 
volume was 30 µL. Only the eluent from 0.4 min to 1.4 min was sent to the API 5000. 
 
Saturation assays 
 
As a proof of concept, the validated LC-ESI-MS/MS quantification method was used to carry 
out saturation experiments in MS Binding Assays. To determine the total binding, samples 
containing 36 free marker concentrations from 25 pM to 500 nM were prepared (n = 3). The 
same marker concentrations were used to measure the nonspecific binding in presence of 
10 µM rac-[2H3]-indatraline (rac-[2H3]-4). Preparation of the binding samples, marker 
quantification and data analysis is described in detail in the experimental section. Based on 
the data of the total binding (TB) and the nonspecific binding (NSB, see figure 10 a, c, e), the 
SB were calculated for each nominal marker concentration. Therefrom saturation isotherms 
were generated (see figure 10 b, d, f).  
Following this procedure, the affinities of the three markers towards their specific targets 
were calculated from the corresponding saturation isotherms. For (R,R)-D-84 ((R,R)-1) a Kd 
of 3.66 ± 1.35 nM together with a Bmax of 57.91 ± 8.43 pmol/mg protein (mean ± SEM, n = 4) 
towards hDAT binding (see table 3 and figure 10 a, b) was determined, which is in 
accordance with published Kd values. In a published competitive radioligand binding 
experiment using [3H]-WIN 35,428 as radioligand and rat striatum as target material, a Kd of 
0.46 nM was found (Ghorai et al., 2003) and for a competition experiment using an MS 
Binding Assay with (1R,3S)-indatraline as a marker and hDAT expressed in HEK293 cells 
(same cell line as in the present study) a Kd of 35.5 nM (Grimm et al., 2015b). The Kd of 
(S,S)-reboxetine ((S,S)-2) towards hNET was determined as 3.06 ± 0.46 nM with a Bmax of 
31.59 ± 8.85 pmol/mg protein (mean ± SEM, n = 3, see table 3 and figure 10 c, d). In the 
literature, a Kd value of 0.2 nM was published for (S,S)-reboxetine ((S,S)-2). This result was 
obtained from a competition experiment with [3H]-nisoxetine as a radioligand and hNET 
expressed in HEK293 cells as target material (Hajós et al., 2004; Tsuruda et al., 2010). Kd 
values published for rac-reboxetine (rac-2) range from 7.8 nM (determined in competition 
experiment with [3H]-nisoxetine towards hNET in MDCK cells) (Millan et al., 2001) to 
10.6 nM (determined in competition experiment with [125I]-β-CIT towards hNET in COS-7 
cells) (Andersen et al., 2011). With the above-mentioned MS Binding Assay employing 
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(1R,3S)-indatraline as marker a Ki of 3.6 nM for rac-reboxetine (rac-2) towards hNET 
(Grimm et al., 2015b) was found. The Kd values for rac-reboxetine (rac-2) are not directly 
comparable with the affinity for (S,S)-reboxetine ((S,S)-2), but in theory, the eutomer cannot 
show an affinity more than two times higher than the racemate. Thus, the affinities for (S,S)-
reboxetine ((S,S)-2) could be between 1.8 nM and 5.3 nM with which our result of 3.06 nM 
corresponds quite well. For (S)-citalopram ((S)-3) a Kd of 411 ± 26 pM with a Bmax of 10.11 ± 
1.71 pmol/mg protein (mean ± SEM, n = 3) towards hSERT was obtained (see table 3 and 
figure 10 e, f). This result is in good agreement with published binding affinities for (S)-
citalopram ((S)-3) towards SERT, determined in competition experiments with [3H]-rac-
citalopram and [3H]-(S)-citalopram towards rat brain cerebellum and brain stem, as well as 
hSERT expressed in HEK293 and CHO cells, ranging from 0.28 nM to 1.1 nM (Deupree et 
al., 2007; Owens et al., 2001; Zhong et al., 2009). A published saturation experiment of [3H]-
(S)-citalopram towards hSERT expressed in COS-1 cells resulted in a Kd of 1.0 nM (Plenge & 
Wiborg, 2005), which is in the same range as the result from this MS Binding Assays, too. 
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Figure 10: Saturation experiments performed with the established MS Binding Assays for 
(R,R)-D-84 ((R,R)-1) towards hDAT (blue symbols, a) and b)), (S,S)-reboxetine ((S,S)-2) 
towards hNET (red symbols, c), and d)), and (S)-citalopram ((S)-3) towards hSERT (green 
symbols, e) and f)). a), c), and e) Means ± SD (n = 3) of the total binding (circles) and the 
nonspecific binding in the presence of 10 µm rac-[2H3]-indatraline (rac-[2H3]-4, squares, 
linear regression of the nonspecific binding is shown as a line). b), d), and f) Means of 
specific binding (triangles) and resulting saturation isotherms derived from the results shown 
in a), c), and e). 
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Conclusion 
 
In summary, this study describes the successful development and validation of an LC-ESI-
MS/MS method for the quantification of (R,R)-D-84 ((R,R)-1), (S,S)-reboxetine ((S,S)-2) as 
well as (S)-citalopram ((S)-3) for their use as markers in MS Binding Assays addressing 
hDAT, hNET, and hSERT, respectively. This newly developed LC-ESI-MS/MS method 
enables the fast, robust, selective, and highly sensitive quantification of the three analytes 
within a chromatographic runtime of 1.5 min. A validation according to the CDER guideline 
for bioanalytical method validation demonstrates the selectivity, accuracy, precision, linearity, 
and sensitivity of the developed LC-MS/MS quantification method. The newly developed 
method allows for the simultaneous quantification of (R,R)-D-84 ((R,R)-1), (S,S)-reboxetine 
((S,S)-2), and (S)-citalopram ((S)-3) in lowest pM to low nM concentrations under the same 
method parameters. This means that the effort to develop and validate the quantification 
method is considerably lower than for the development and validation of multiple 
quantification methods for MS Binding Assays selectively targeting DAT, NET, and SERT. 
The LC-ESI-MS/MS quantification method was applied to carry out saturation experiments 
using (R,R)-D-84 ((R,R)-1) as a marker for hDAT, (S,S)-reboxetine ((S,S)-2) as a marker for 
hNET, and (S)-citalopram ((S)-3) as a marker for hSERT. The procedure of the MS Binding 
Assays follows the well-established setup of previously published MS Binding Assays using a 
filtration with glass fiber filters for the separation of the target-marker complexes from the 
nonbound marker. This procedure allowed for the determination of total and nonspecifically 
bound marker in the binding samples and the calculation of specific binding as the difference 
of total and nonspecific binding. For the calculated specific binding, saturation isotherms for 
all three applied markers could be generated to determine their affinities (Kd values) towards 
their specific targets and the densities of binding sites (Bmax values) in the corresponding 
target sources. The affinities of the markers towards their targets determined in this way were 
in good agreement with those published in literature, demonstrating that the established MS 
Binding Assays represent an efficient alternative to radioligand binding assays widely used 
for affinity characterisation at these targets so far. In this context, it is worth to mention that 
(R,R)-D-84 ((R,R)-1), (S,S)-reboxetine ((S,S)-2), and (S)-citalopram ((S)-3) can address their 
corresponding targets DAT, NET, and SERT, respectively, even in native target sources (e.g. 
brain homogenates), which may contain the desired target merely in the presence of many 
other targets. The use of (R,R)-D-84 ((R,R)-1), (S,S)-reboxetine ((S,S)-2), and (S)-citalopram 
((S)-3) as highly selective markers for DAT, NET, and SERT, respectively, may further 
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enable the implementation of Multiple MS Binding Assays addressing these three targets 
simultaneously in a single binding experiment. Therefore, the described LC-ESI-MS/MS 
quantification method for (R,R)-D-84 ((R,R)-1), (S,S)-reboxetine ((S,S)-2), and (S)-citalopram 
((S)-3) may have significant impact for mass spectrometry based affinity determination at 
DAT, NET, and SERT. 
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Tables 
 
 Luna PFP(2), 50 x 2 mm, 3 µm YMC PFP, 50 x 2 mm, 3 µm 
 (R,R)-D-
84 ((R,R)-
1) 
(S,S)-
reboxetine 
((S,S)-2) 
(S)-
citalopram 
((S)-3) 
(R,R)-D-
84 ((R,R)-
1) 
(S,S)-
reboxetine 
((S,S)-2) 
(S)-
citalopram 
((S)-3) 
k 1.15 1.56 2.47 1.90 3.33 5.44 
Peak Height 
/ cps 
1,510,000 397,000 1,390,000 1,010,000 197,000 681,000 
S/N 20,850 15,350 6,885 10,050 5,167 2,785 
Peak Width 
(50 %) / min 
0.0469 0.0327 0.0401 0.0604 0.0634 0.0891 
Peak 
Asymmetry 
2.32 2.33 1.61 4.01 2.97 1.79 
 
Table 1: Comparison of the chromatographic parameters obtained from chromatograms 
acquired with a Luna PFP(2) column and a Triart PFP column. Chromatography was 
performed with a mobile phase consisting of acetonitrile/ammonium formate buffer 
(1.0 mg/mL, 85/15) at a flow rate of 800 µL/min for both columns. The temperature was set 
to 20 °C and an injection volume of 30 µL of a 1 nM solution containing all 3 markers ((R,R)-
1, (S,S)-2, and (S)-3) was used. The recorded mass transitions at the API 5000 were m/z 
420.2/167.1 for (R,R)-D-84 ((R,R)-1), m/z 314.1/176.2 for (S,S)-reboxetine ((S,S)-2), and m/z 
325.2/109.2 for (S)-citalopram ((S)-3). Results in the table represent means (n = 6). 
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  (R,R)-D-84 
((R,R)-1) 
(S,S)-reboxetine 
((S,S)-2) 
(S)-citalopram 
((S)-3) 
Accuracy Accuracy in QCs 88.37 % - 
112.73 % 
96.08 % - 109.67 
% 
96.37 % - 110.33 
% 
Precision Intra-batch 
precision in QCs 
≤ 13.69 % ≤ 7.09 % ≤ 9.09 % 
Inter-batch 
precision in QCs 
≤ 10.07 % ≤ 6.20 % ≤ 6.50 % 
LLOQ S/N at LLOQ ≥ 29 ≥ 19 ≥ 18 
Within-run 
precision at 
LLOQ (cal. std.) 
≤ 9.75 % ≤ 9.01 % ≤ 6.24 % 
Between-run 
precision at 
LLOQ (cal. std.) 
7.06 % 8.89 % 7.67 % 
Within-run 
accuracy at LLOQ 
(cal. std.) 
95.87 % - 
109.20 % 
83.92 % - 99.55 
% 
88.80 % - 107.27 
% 
Between-run 
accuracy at LLOQ 
(cal. std.) 
101.60 % 93.65 % 97.04 
ULOQ Within-run 
precision at 
ULOQ (cal. std.) 
≤ 1.37 % ≤ 4.87 % ≤ 2.37 % 
Between-run 
precision at 
ULOQ (cal. std.) 
1.67 % 2.47 % 1.44 % 
Within-run 
accuracy at 
ULOQ (cal. std.) 
94.10 % - 98.40 
% 
96.80 % - 99.60 
% 
94-00 % - 96.80 
% 
Between-run 
accuracy at 
ULOQ (cal. std.) 
96.93 % 98.33 % 95.82 % 
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Calibration Range of 
calibration 
2.5 pM – 1 nM 1 pM – 2.5 nM 2.5 pM – 2.5 nM 
r2 of calibration 
function 
≥ 0.9958 ≥ 0.9978 ≥ 0.9950 
Cal. stds. meeting 
criteria for 
accuracy 
96.46 % 99.49 % 99.49 % 
QCs QCs meeting 
criteria for 
accuracy 
99.30 % 99.30 % 100 % 
QCs per 
concentration 
level meeting 
criteria for 
accuracy 
≥ 80.56 % ≥ 97.22 % 100 % 
 
Table 2: Summary of results from the validation. 
 (R,R)-D-84 ((R,R)-1) to 
hDAT (n = 4) 
(S,S)-reboxetine ((S,S)-2) 
to hNET (n = 3) 
(S)-citalopram ((S)-3) to 
hSERT (n = 3) 
Kd in nM (mean ± SEM) 3.66 ± 1.35 3.06 ± 0.46 0.411 ± 0.0026 
Bmax in pmol/mg protein 
(mean ± SEM) 
57.91 ± 8.43 31.59 ± 8.85 10.11 ± 1.71 
 
Table 3: Results from the saturation experiments performed with the established MS Binding 
Assays. 
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Structures of markers, internal standards and the inhibitor employed for determination of non-specific 
binding in MS Binding Assays. a Deuterated substances were used as racemates, but only one enantiomer is 
depicted in the figure. For the sake of simplicity, the racemic mixture of (R,R)-D-84 and (S,S)-D-83 (the 
enantiomer of (R,R)-D-84) is referred to as rac-D-84 and the racemic mixture of (R,R)-[2H4]-D-84 and 
(S,S)-[2H4]-D-83 is called rac-[2H4]-D-84 throughout this work.  
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Relative response factors (RRF) for rac-D-84 (rac-1) calculated as, ((peak area rac-D-84)/(concentration 
rac-D-84)  )/((peak area rac-reboxetine)/(concentration rac-reboxetine)), (mean ±SD, n = 3). Dilution 
series of rac-D-84 (rac-1, 500 pM – 25 nM) in pure water (circles) and 20 % DMA in water (triangles) were 
prepared, spiked with rac-reboxetine, subsequently diluted tenfold in acetonitrile and analyzed. Stationary 
phase: Triart PFP (50 x 2.0 mm, 3 µm), mobile phase: acetonitrile / ammonium formate buffer (1.0 mg/mL, 
85/15), 800 µL/min, detection at the API 3200: rac-D-84 (rac-1): m/z 420.3/167.0, rac-reboxetine (rac-2): 
m/z 314.2/176.1.  
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Workflow of the developed MS Binding Assays  
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Schematic workflow of the post-column infusion experiment.  
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MRM Chromatogram from a post-column infusion experiment for the determination of matrix effects 
resulting from binding samples, as described in the experimental section (“Investigation of the matrix effect 
by post-column infusion experiments”). 300 pM (R,R)-D-84 ((R,R)-1, blue signal), 2 nM (S,S)-reboxetine 
((S,S)-2, red signal), and 600 pM (S)-citalopram ((S)-3, green signal) were infused continuously, while 
blank matrix, containing 100 pM rac-[2H4]-D-84 (rac-[2H4]-1, blue dotted peak), rac-[2H5]-reboxetine (rac-
[2H5]-2, red dotted peak), and rac-[2H6]-citalopram (rac-[2H6]-3, green dotted peak at a retention time of 
4.5 min; peak at 1.5 min is caused by matrix components, generating a signal with the same MRM transition 
as rac-[2H6]-3), which was subjected to the chromatography.  
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Plot of marker peak intensities for a series of injections of solvent standards (full symbols) and matrix 
standards (100 pM of each marker, empty symbols, obtained from a simulated binding experiment, for 
details on the sample preparation and analysis see experimental section); (R,R)-D-84 ((R,R)-1): blue dots, 
(S,S)-reboxetine ((S,S)-2): red squares, (S)-citalopram ((S)-3): green triangles.  
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Recovery of markers ((R,R)-D-84 ((R,R)-1, blue), (S,S)-reboxtine ((S,S)-2, red), and (S)-citalopram ((S)-3, 
green, all at 100 pM) dissolved in acetonitrile after filtration through glass fiber filters. Reference sample 
was not filtrated, filtrated samples were filtrated through filters, pretreated with 200 µL water (“filter not 
pretreated with PEI”) or 200 µL 0.5 % PEI solution (“filter pretreated with PEI”) for 1 h and washed with 3 x 
150 µL ammonium formate buffer (0.75 mg/mL, pH 7.4) prior to filtration. All non-filtrated reference and 
filtrated samples were spiked with internal standards (rac-[2H4]-1, rac-[2H5]-2, rac-[2H6]-3) at a 
concentration of 100 pM in acetonitrile prior to analysis. Bars represent means of recovery (% relative to 
reference sample) ± SD (n = 6).  
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Nonspecific binding (mean ± SD, n = 3) derived from preliminary saturation experiments using different 
washing procedures. Binding samples were prepared according to the general procedure for the MS Binding 
Assays (see experimental section). After incubation, binding samples were filtrated over the glass fiber 
filters. Subsequently, the filters were washed with ammonium formate buffer (0.75 mg/mL, pH 7.4, filled 
symbols, (R,R)-1: blue, (S,S)-2: red, (S)-3: green) or 10 % DMA in ammonium formate buffer (0.75 
mg/mL, pH 7.4, only shown for (R,R)-1: empty blue symbols). Marker elution and analysis was carried out 
according to the procedure and with the LC-ESI-MS/MS quantification method, described in the experimental 
section.  
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MRM chromatograms of (R,R)-D-84 ((R,R)-1, blue, m/z 420.2/167.1), (S,S)-reboxetine ((S,S)-2, red, m/z 
314.1/176.2), and (S)-citalopram ((S)-3, green, m/z 325.2/109.1) obtained with the developed LC-ESI-
MS/MS quantification method. a) Matrix blank, b) 1 pM, c) 2.5 pM, and d) 100 pM of each marker ((R,R)-1, 
(S,S)-2, (S)-3) with 90 pM rac-[2H4]-D-84 (rac-[2H4]-1, blue dotted, m/z 424.2/176.1), rac-[2H5]-reboxetine 
(rac-[2H5]-2, red dotted, m/z 319.2/176.2), and rac-[2H6]-citalopram (rac-[2H6]-3, green dotted, m/z 
331.2/109.0) as internal standards. All chromatograms were acquired, using a Luna PFP(2) column as the 
stationary phase and acetonitrile/ammonium formate buffer (0.75 mg/mL; 85/15) at 800 µL/min as mobile 
phase. The temperature was set at 20 °C and the injection volume was 30 µL. Only the eluent from 0.4 min 
to 1.4 min was sent to the API 5000.  
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Saturation experiments performed with the established MS Binding Assays for (R,R)-D-84 ((R,R)-1) towards 
hDAT (blue symbols, a) and b)), (S,S)-reboxetine ((S,S)-2) towards hNET (red symbols, c), and d)), and 
(S)-citalopram ((S)-3) towards hSERT (green symbols, e) and f)). a), c), and e) Means ± SD (n = 3) of the 
total binding (circles) and the nonspecific binding in the presence of 10 µm rac-[2H3]-indatraline (rac-[2H3]-
4, squares, linear regression of the nonspecific binding is shown as a line). b), d), and f) Means of specific 
binding (triangles) and resulting saturation isotherms derived from the results shown in a), c), and 
   e).   
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1. Enantioseparation and ee-determination of (S,S)-reboxetine ((S,S)-2) 
 
1.1. Extraction of rac-reboxetine (rac-2) from Edronax tablettes 
 
80 Edronax 4 mg tablettes were disintegrated in 50 mL 0.1 N HCl and filtrated. The filter was washed twice with 
5 mL 0.1 N HCl. PH of the filtrate was adjusted to 9 with saturated NaHCO3-solution and extracted with 5 x 40 mL 
diethyl ether. The combined ether phases were dried over MgSO4, filtrated and the solvent was removed in vacuo. 
290.9 mg (90.9 %) rac-reboxetine (rac-2) was obtained as yellow oil. 
	
1.2. Semi-preparative enantioseparation of rac-reboxetine (rac-2) 
	
Rac-reboxetine was dissolved in propan-2-ol/diethylamine (DEA, 9/1, v/v) to a concentration of 100 mg/mL. 
Enantioseparation was carried out on an Agilent 1100 series HPLC (Agilent, Waldbronn, Germany, consisting of 
vacuum degasser, binary pump, autosampler, thermostated column compartment and UV-detector) with a Lux 
Cellulose-1 column (250 x 4.6 mm, 5 µm, Phenomenex, Aschaffenburg, Germany), protected by a security guard 
cartridge of the same stationary phase (4 x 3 mm, 5 µm, Phenomenex) and an in-line filter (0.5 µm, stainless steel, 
IDEX, Lake forrest, IL, USA). As mobile phase, a mixture of propan-2-ol containing 2 % DEA and 3 % formic 
acid with n-hexane (20/80) was used at a flow rate of 1.5 mL/min. The column oven temperature was set to 20 °C 
and a volume of 60 µL of the solution described above was injected. For detection, a wavelength of 270 nm was 
used. Fractions, containing the peaks of each reboxetine enantiomer were collected, collection of the first fraction 
was started as soon, as the signal of the peak was visible and collection of this fraction was finished when the 
signal reached a minimum before the signal of the second peak started to increase. After the first fraction, the 
collection of the second fraction was started immediately and finished when the signal of the second peak reached 
the baseline-level. After multiple chromatographic runs, collected fractions of the same peaks were combined, the 
eluent was removed in vacuo, the obtained yellow oil was again dissolved in propan-2-ol/diethylamine (DEA, 9/1, 
v/v) to a concentration of 100 mg/mL. This solution was chromatographed a second time with the same procedure 
as described above, but this time an additional fraction between both peaks was collected and discarded. The eluent 
of each fraction was removed in vacuo, the residue was dissolved in a mixture of 1,4-dioxane and water and freeze 
dried. After the enantioseparation, 2 fractions each containing one enantiomer of 2-[(2-
ethoxyphenoxy)phenylmethyl]morpholine-2-carbaldehyde as a yellow oil were obtained. 
	
1.3. Hydrolysis of (2R)-2-[(2R)-(2-ethoxyphenoxy)phenylmethyl]morpholine-2-
carbaldehyde and crystallization to (S,S)-reboxetine ((S,S)-2) mesylate 
	
The fraction obtained from the second peak, containing (2R)-2-[(R)-(2-ethoxyphenoxy)phenylmethoy]morpholine 
was dissolved in water (2.5 mL) and dioxane (2.0 mL) and stirred at 50 °C over night after the addition of 53.8 mg 
KOH (85 %, 3.5 equiv.). The aqueous phase was extracted with diethyl ether (3 x 8 mL). The combined ether 
phases were dried (MgSO4), filtered and the solvent was removed in vacuo to obtain 49.7 mg (S,S)-reboxetine 
((S,S)-2) as yellow oil, which was then dissolved in diethyl ether, cooled to -77 °C and 11.2 µL methansulfonic 
acid was added. The solvent was removed in vacuo, the residue was dissolved in H2O and freeze dried to obtain 
(S,S)-reboxetine ((S,S)-2) mesylate.	
	
1.4. Determination of the enantiomeric excess of (S,S)-reboxetine ((S,S)-2) 
	
Determination of the enantiomeric excess (ee} of (S,S)-reboxetine ((S,S)-2) was carried out on an Agilent 1100 
series HPLC (consisting of vacuum degasser, binary pump, autosampler, thermostated column compartment and 
UV-detector) with a Chiralpak IB-3 column (250 x 4.6 mm, 3 µm, Daicel – Chiral Technologies, Illkirch Cedex, 
France), protected by an in-line filter (0.2 µm, titan, IDEX). Mobile phase A was ammonium bicarbonate buffer 
(20 mM, pH 9.0) with methanol (HPLC grade, VWR Prolabo, Darmstadt, Germany) in a ratio of 2/1, which was 
mixed with acetonitrile (HPLC grade, VWR Prolabo) as mobile phase B in a ratio of 7.5/92.5. The flow rate was 
1.0 mL/min, the column oven was set to 5 °C and the detection wavelength was 270 nm. 5 µL of solution of 20 mM 
(S,S)-reboxetine ((S,S)-2) as the analyte in acetonitrile/H2O (90/10) was injected. Based on calibration functions 
for both enantiomers in a range of 10 µM to 25 mM, the concentrations of both enantiomers in the sample were 
calculated and thus the ee was determined. 
 
 
2. Synthesis of [2H3]-indatraline 
	
2.1. Synthesis of indatraline hydrochloride ((1R,3S)-4) 
	
	
	
	
	
a) 1. methanesulfonyl chloride (2 equiv.), NEt3 (4 equiv.), THF, -15 °C, 1 h; 2. NH2C2H3, 0 °C to rt, 20 h, 3. 
aqueous HCl (1 M). 
 
Depicted compounds are racemic although only one enantiomer is shown. 
 
2.1. General Methods 
 
THF and NEt3 were distilled from sodium. Methanesulfonyl chloride (Fluka) was used without further purification. 
All other chemical reagents were used from bulk without further purification. Common solvents for 
recrystallization, column chromatography were distilled before use. TLC plates were made from silica gel 60 F254 
on Glas plates (Merck). Compounds were first stained on silica then with 5% (NH4)6Mo7O24·4H2O, 0.2% 
Ce(SO4)2·4H2O and 5% conc. H2SO4. Merck silica gel (mesh 230–400) was used as stationary phase for flash 
chromatography (CC). Melting points: m.p. (uncorrected) were determined with an Electrothermal IA9100MK1 
Melting Point apparatus. IR spectroscopy: FT-IR Spectrometer Paragon 1000 (Perkin Elmer), solid sample was 
measured as KBr pellet. HR Mass spectrometry: JEOL GC Mate II; NMR spectroscopy: NMR spectra were 
recorded on Bruker Avance III (Bruker BioSpin, 500 MHz) and integrated with the program of MestReNova 
version 11.0.4-18998.  
	
2.2. [2H3]-indatraline hydrochloride (rac-[2H3]-4) [42,43]  
 
	
	
To a stirred solution of cis-(±)-3-(3,4-dichlorophenyl)indan-1-ol (0.500 g, 1.79 mmol) in THF (15 mL) was added 
NEt3 (0.997 mL, 7.16 mmol) at -15 °C and methanesulfonyl chloride (208 µL, 2.69 mmol). After 1 h the reaction 
mixture was warmed to 0 °C and gaseous [2H3]methylamine was introduced for 15 min with a syringe from a 
second vessel containing a large excess of a stirred mixture (1:1) of KOH and [2H3]methylamine hydrochloride. 
The reaction mixture was allowed to warm slowly to r.t. over 10 h.  The resulting orange solution was poured into 
saturated NaHCO3 solution (25 mL) followed by extraction with EtOAc (6 x 20 mL). The combined organic layers 
were dried (MgSO4), filtered and the solvent was removed in vacuo. The resulting crude product was purified by 
flash chromatography (heptane/EtOAc/i-PrOH = 85:5:10 + 1% N,N-dimethylethylamine). The resulting colorless 
oil was dissolved in dioxane (0.2 mL), treated with aqueous HCl (1 M, 1 mL) and freeze dried. The resulting 
product was recrystallized from EtOAc/EtOH (92:8, 8 mL) to yield colorless crystals (188 mg, 36 %): m.p. 156-
157 °C. 1H NMR (500 MHz, D2O): 2.28 (dt, J = 15.2/8.0 Hz, 1 H, CH2), 2.66 (ddd, J = 15.2/7.6/2.1 Hz, 1 H, CH2), 
4.55 (t, J = 7.9 Hz, 1 H, CH2CH), 4.82 (d, J = 7.8 Hz, 1 H, CHNCH3), 6.84 (d, J = 7.6 Hz, 1 H, CH(OH)CCCH), 
6.91 (dd, J = 8.3/2.1 Hz, 1 H, CCHCHCCl), 7.15 (d, J = 2.1 Hz, 1 H, CCHCCl),  7.32–7.18 (m, 3 H, 
CH(NCH3)CHCH),  CH(NCH3)CCCHCH, CCHCHCCl), 7.53 (d, J = 7.6 Hz,  1 H, CH(NCH3)CCH). 13C NMR 
(125 MHz, D2O): δ = 27.63 (quint., J = 23.5 Hz), 36.40, 45.98, 60.64, 123.77, 124.15, 125.94, 126.37, 127.87, 
128.52, 128.81, 128.93, 130.26, 134.41, 142.27, 145.33. IR (KBr): v~  = 3432 cm-1, 2941, 2738, 22649, 2598, 1596, 
1467, 766. HRMS (EI): m/z [M-HCl]+ cacld. for C16H122H3N35Cl2: 294.0770, found: 294.0778.  
	
3. Identification and tuning of MRM transitions 
 
	
	
SI-figure 1: Product ion scan of m/z 420.3 obtained in the Compound Optimization for rac-D-84 (rac-1). 
	
	
	
	
	
	
	
	
	
	
	
	
4. Development of the LC-ESI-MS/MS method 
	
		
	
SI-figure 2: Chromatograms of (R,R)-D-84 ((R,R)-1, blue), (S,S)-reboxetine ((S,S)-2, red) and (S)-citalopram ((S)-
3, green). Mobile phase: acetonitrile/ammonium formate buffer (1.0 mg/mL, 85/15), flow rate: 800 µL/min, 
column oven temperature: 20 °C, injection volume: 30 µL. a) Stationary phase: Luna PFP(2) column (50 x 2.0 mm, 
3 µm, Phenomenex), b) Stationary phase: Triart PFP (50 x 2.0 mm, 3 µm, YMC). 
 
5. Preliminary saturation experiments 
 
Preliminary saturation experiments to determine the influence of DMA in the washing buffer were carried out 
according to the final procedure for saturation experiments. For the preliminary experiments, no calibration was 
acquired, so the calculation for the Kd value was based on the area ratios (peak area marker / peak area internal 
standard). Experiments were carried out in duplicates, resulting in Kd values of 1.16 nM and 0.74 nM for the 
binding of (S)-citalopram ((S)-3) towards hSERT. 
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3.3. Third	Publication	
Simultaneous	Multiple	MS	Binding	Assays	for	the	Dopamine,	the	Norepinephrine,	and	
the	Serotonin	Transporter	
	
3.3.1. Summary	of	the	Results	
	
MS	Binding	Assays	have	been	successfully	established	as	an	alternative	for	radioligand	binding	
assays.	 In	 contrast	 to	 the	 latter,	 the	 use	 of	 mass	 spectrometry	 for	 the	 detection	 and	
quantification	of	unlabelled	reporter	ligands	in	MS	Binding	Assays	result	in	various	benefits.	
Besides	 the	 fact,	 that	 no	 radioactively	 labelled	 compounds	 are	 needed,	meaning	 that	MS	
Binding	 Assays	 can	 be	 performed	 without	 considerations	 about	 radiation	 protection	
regulations	and	problematic	waste	disposal,	MS	Binding	Assays	offer	the	possibility	to	monitor	
multiple	reporter	 ligands	simultaneously.	Scintillation	counting,	used	 in	radioligand	binding	
assays,	is	hardly	suited	to	distinguish	between	different	radioactive	labelled	analytes,	whereas	
LC-MS	enables	the	quantification	of	 large	numbers	of	analytes	 in	a	single	chromatographic	
run.	To	make	use	of	this	advantage,	for	each	of	the	targets	to	be	employed	in	the	Simultaneous	
Multiple	MS	 Binding	 Assays	 a	 selective	 marker	 has	 to	 be	 applied.	 Since	 this	 was	 already	
considered	in	the	method	development	of	an	LC-ESI-MS/MS	method	for	the	quantification	of	
D-84,	 reboxetine,	 and	 citalopram,	 this	method	 can	be	used	 for	 Simultaneous	Multiple	MS	
Binding	 Assays.	 The	 aim	 of	 this	 work	 was	 to	 establish	 Simultaneous	Multiple	MS	 Binding	
Assays	 for	 the	 hDAT,	 hNET,	 and	 hSERT,	 which	 enable	 the	 performance	 of	 simultaneous	
saturation	as	well	as	simultaneous	competition	experiments.	
	
Simultaneous	 saturation	 experiments	were	performed	with	 a	mixture	of	 hDAT,	 hNET,	 and	
hSERT,	which	was	incubated	together	with	the	three	markers	(R,R)-D-84,	(S,S)-reboxetine,	and	
(S)-citalopram	 according	 to	 the	 previously	 published	 conditions.	 As	 a	 result,	 saturation	
isotherms	 for	 each	marker	 at	 its	 target	 could	 be	 generated	 in	 only	 one	 experiment.	 The	
affinities	of	the	markers	found	in	these	experiments	towards	their	targets	(4.01	±	0.21	nM	for	
(R,R)-D-84	 towards	hDAT,	 2.20	±	 0.29	nM	 for	 (S,S)-reboxetine	 towards	hNET,	 and	0.440	±	
0.004	nM	for	(S)-citalopram	towards	hSERT)	were	in	excellent	agreement	with	results	from	
individual	 saturation	 experiments,	 in	which	 only	 one	 target	 and	 its	 selective	marker	were	
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applied.	This	demonstrates,	that	each	marker	selectively	binds	towards	its	target,	even	in	the	
presence	of	the	other	targets	and	markers.		
	
In	simultaneous	competition	experiments,	all	three	targets	were	incubated	together	with	the	
three	markers	and	a	test	compound.	As	test	compounds,	a	set	of	seven	monoamine	reuptake	
inhibitors	 with	 different	 selectivity	 profiles	 were	 chosen.	 The	 test	 compound	 3-a-bis-(4-
fluorophenyl)methoxytropane	is	a	selective	dopamine	reuptake	inhibitor,	rac-bupropione	a	
selective	dopamine	and	norepinephrine	reuptake	 inhibitor,	desipramine	and	rac-nisoxetine	
are	 selective	norepinephrine	 reuptake	 inhibitors,	 (S)-fluoxetine	and	sertraline	are	 selective	
serotonin	reuptake	inhibitors,	while	rac-indatraline	(applied	as	rac-[2H3]-indatraline)	is	a	non-
selective	 triple	 reuptake	 inhibitor.	 In	 the	 simultaneous	 competition	 experiments,	 in	which	
these	test	compounds	were	applied,	 three	competition	curves	–	one	for	each	of	 the	three	
target-marker	systems	–	were	obtained.	The	determined	affinities	of	these	test	compounds	
resulting	from	these	experiments	were	in	good	agreement	with	published	data	generated	by	
an	alternative	MS	Binding	Assay	and	radioligand	binding	experiments.		
	
The	results	of	the	simultaneous	saturation	as	well	as	competition	experiments	demonstrate,	
that	 Simultaneous	 Multiple	 MS	 Binding	 Assays	 can	 be	 used	 to	 determine	 the	 affinity	 of	
multiple	selective	markers	at	their	targets	or	the	affinity	of	a	test	compound	at	several	targets	
reliably	in	a	single	experiment.	As	a	result,	in	comparison	to	radioligand	binding	assays	and	
classical	MS	Binding	Assays,	Simultaneous	Multiple	MS	Binding	Assays	offer	a	much-improved	
efficiency	 due	 to	 the	possibility	 to	 characterize	 the	 affinity	 of	 a	 test	 compound	 at	 various	
targets	with	only	one	set	of	samples.		
	
	
3.3.2. Declaration	of	Contributions	
	
All	binding	experiments	were	performed	and	evaluated	by	Angela	De	Simone	and	myself.	 I	
wrote	the	manuscript	and	prepared	the	graphics	and	tables,	assisted	by	Georg	Höfner	and	
Angela	De	Simone.	Klaus	T.	Wanner	corrected	the	manuscript.	
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Abstract: In this work, we present label-free, mass-spectrometry 
based binding assays (MS Binding Assays), targeting the human 
dopamine, norepinephrine, and serotonin transporters (hDAT, hNET, 
and hSERT) in simultaneous binding experiments. Using a validated 
LC-ESI-MS/MS method for quantification of the selective dopamine 
transporter inhibitor (R,R)-4-(2-benzhydryloxyethyl)-1-(4-
fluorobenzyl)piperidin-3-ol ((R,R)-D-84), the selective norepinephrine 
transporter inhibitor (S,S)-reboxetine, and the selective serotonin 
reuptake inhibitor (S)-citalopram, binding affinities at the three 
monoamine transporters could be characterized simultaneously in a 
single binding experiment. The performed simultaneous saturation 
and competition experiments yielded results that were in good 
accordance with those determined in MS Binding Assays addressing 
the monoamine transporters individually. The results obtained from 
this study underscore the potential of MS Binding Assays for 
simultaneous affinity determination at different targets which is hardly 
to accomplish with conventional radioligand binding assays.  
Introduction 
An important step in the development of new drugs is the 
identification of compounds interacting with a target of interest.[1,2] 
Various techniques directed towards determination of the 
functional activity of a test compound or its affinity at the desired 
target have been established serving this purpose.[3] As binding 
of a test compound towards a specific binding site at the target is 
the essential prerequisite for functional activity, characterization 
of binding affinity is a more direct approach in comparison to 
functional assays.[4] A broad spectrum of detection principles has 
been successfully exploited for affinity determination of potential 
ligands and deduction of corresponding structure-affinity 
relationships at the beginning of a drug development process.[5–
11] Not all of these techniques, however, are equally well suited for 
each target. This is especially true for membrane-bound proteins, 
comprising G protein-coupled receptors (GPCRs), ion channels, 
and transport proteins for example, that belong to the most 
important drug targets addressed in current therapeutic 
approaches.[12,13] Many highly sophisticated detection principles 
are hardly applicable to these targets, as membrane-bound 
proteins are typically difficult to express in large scale and also 
difficult to purify without loss of function. For affinity determination 
of potential ligands at membrane proteins, radioligand binding 
assays have proven to be an efficient tool.[4,14] Although 
developed already in the 1970s, they are still the gold standard to 
characterize affinity of ligands to membrane–bound targets, such 
as GPCRs, ion channels or transport proteins.[6,15] To perform 
radioligand binding assays, a suitable target preparation (e.g. a 
membrane preparation containing the desired membrane protein) 
has just to be incubated with the radioligand (i.e. the radio-labeled 
reporter ligand). In the conventional setup, incubation is stopped 
by separation of the unbound radioligand from the bound 
radioligand (i.e. from the radioligand-target complexes), which is 
typically achieved by filtration or centrifugation.[4] After this, the 
radioactivity of the bound radioligand can be quantified with high 
sensitivity by radiometric methods. This experimental setup 
allows determination of the binding affinity of the radioligand 
towards the target in so-called saturation experiments and 
characterization of binding affinities of test compounds, which are 
competing with the radioligand for its specific binding site at the 
target, in so-called competition experiments and furthermore, 
kinetic experiments.[4] As an alternative to radioligand binding 
assays, MS Binding Assays have been developed that do, in 
contrast to radioligand binding assays, not require a radio-labeled 
reporter ligand. MS Binding Assays use instead of a radioligand a 
nonlabeled reporter ligand, which is often referred to as MS 
Marker or simply marker. MS Binding Assays follow for the most 
part the general setup of radioligand binding assays, using either 
a filtration or centrifugation step for separation of the marker-
target complexes from the unbound marker. In contrast to the 
workflow common for radioligand binding assays, MS Binding 
Assays require an additional step, the liberation of the bound 
marker from the target prior to analysis by LC-MS (see figure 1 
where the complete procedure of MS Binding Assays is explained 
in a scheme). This is typically achieved by denaturation of the 
target protein and subsequent elution of the formerly bound 
marker by an organic solvent. According to this strategy MS 
Binding Assays for several neurotransmitter receptors and 
transporters could be established in the last years.[16–20] 
The use of mass spectrometry (MS) for the detection of the 
reporter ligand offers some important benefits in comparison to 
detection by radioactivity. Since a radioactive label is not 
necessary for the reporter ligands used in MS Binding Assays, 
binding experiments with native, i.e. nonlabeled compounds can 
Manuscript Click here to download Manuscript Simultaneous Multiple MS
Binding Assays _241117.docx
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be performed. This means that issues inherently coupled with the 
use of radioactivity, such as obligatory safety precautions, strict 
regulations issued by authorities, or disposal of radioactive waste 
– to name just a few – become irrelevant when nonlabeled 
reporter ligands quantified by means of MS are used. An 
additional fundamental benefit of MS Binding Assays results from 
MS as the detection principle in comparison to measurement of 
radioactivity, the latter of which is typically accomplished by liquid 
scintillation counting (LSC). LSC provides high sensitivity, but no 
selectivity with respect to discrimination between different 
radioligands, labeled with the same radioisotope (that is typically 
tritium). To enable quantification of different radioligands present 
in one sample, different radioisotopes would have to be employed 
for labeling or alternatively, the different radioligands would have 
to be separated by an additional analytical technique (e.g. by 
chromatography) prior to quantification. As both approaches 
cause considerable additional expenses, it is not attractive to 
perform radioligand binding experiments targeting different 
targets simultaneously in a single binding experiment. In MS 
Binding Assays, LC-MS/MS is used for quantification of the 
reporter ligand that provides besides high sensitivity also 
excellent selectivity, due to its capability to differentiate all 
analytes that differ in their m/z ratios of precursor or fragment ions 
or in their chromatographic retention behavior. Therefore, LC-
MS/MS allows quantification of an enormous number of different 
analytes simultaneously in the same sample in a single run. This 
means MS Binding Assays offer excellent conditions to perform 
multiple binding experiments in which binding affinities at different 
targets are characterized simultaneously in one and the same 
binding sample when different reporter ligands with sufficient 
selectivity for the individual targets are employed. This strategy 
termed “Simultaneous Multiple MS Binding Assays” has been 
recently introduced in a study by Schuller et al. where it was 
successfully applied to perform saturation as well as competition 
experiments simultaneously at D1 and D2 dopamine receptors.[21] 
Simultaneous Multiple MS Binding Assays are of particular value 
when it is necessary to characterize binding affinities of test 
compounds at various targets as it is the case, when for example 
several related targets contribute to the intended therapeutic 
effect or subtype selectivity has to be determined.  
Such a scenario is given in the development of drug candidates 
addressing monoamine transporters, namely the dopamine (DAT), 
the norepinephrine (NET), and the serotonin transporter (SERT), 
which have an important function in the control of human mood 
and behavior and belong to the most relevant drug targets for 
many mental disorders. The relevance of the monoamine 
transporters for mental disorders finds expression in the catechol 
hypothesis.[22–24] This widely-accepted hypothesis implies, that an 
imbalance in the monoaminergic neurotransmitters dopamine 
(DA), norepinephrine (NE), and serotonin (5-HT) correlates with 
affective disorders. The importance of affective disorders is 
demonstrated in a study issued by the world health organization 
(WHO), which has identified mental disorders, especially 
depression, as a major burden of disease worldwide. Unipolar 
depressive disorders are the cause of the third highest healthcare 
expenditures of disease globally, primarily in middle- and high-
income countries. Till 2030, unipolar depressive disorders may 
even surpass the abundance of the most prevalent diseases, e.g. 
lower respiratory infections and diarrhea.[25] Since only 60 – 70% 
of the patients treated against depression respond to the therapy, 
the search for new antidepressants is still a relevant topic in 
contemporary drug discovery.[26] The situation is even aggravated 
by the fact that, due to the complex impact of the different 
monoamines on the patient’s mood and behavior, the profile of 
binding affinities towards all three monoamine transporters is 
decisive for the intended therapeutic effects, but also for the side 
effects.  
As Simultaneous Multiple MS Binding Assays can be a highly 
efficient tool to characterize binding affinities of test compounds 
at multiple targets simultaneously in a single binding experiment, 
the application of this strategy seems to be straightforward in this 
case. Such Simultaneous Multiple MS Binding Assays at DAT, 
NET, and SERT would clearly surpass the efficiency of 
conventional “individually performed” radioligand binding assays, 
which are commonly used for this purpose, by considerably 
reducing the number of binding samples required for affinity 
determination and thus - in total - also reduce expenditure.  
Recently, an LC-ESI-MS/MS method for the quantification of 
(R,R)-4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol 
((R,R)-D-84, (R,R)-1), (S,S)-reboxetine ((S,S)-2), (S)-citalopram 
((S)-3) was developed and applied to establish MS Binding 
Assays individually addressing the human dopamine transporter 
(hDAT), the human norepinephrine transporter (hNET), and the 
human serotonin transporter (hSERT, see figure 1 and 2), 
respectively.[27] Sufficient selectivity of individual markers for the 
desired targets is a crucial requirement for the approach of 
Simultaneous Multiple MS Binding Assays, as it must be 
guaranteed that each of the different markers labels only one 
defined target in presence of other targets. As the above 
mentioned markers are claimed to be highly selective for their 
corresponding targets [18,28–30] and can, furthermore, be quantified 
with the sensitivity required in MS Binding Assays in a single LC-
MS/MS run, the decisive prerequisites for Simultaneous Multiple 
MS Binding Assays addressing these targets appear to be fulfilled. 
It was thus the aim of the present study to establish Simultaneous 
Multiple MS Binding Assays for the three monoamine transporters 
based on the aforementioned LC-ESI-MS/MS quantification 
method for (R,R)-D-84 ((R,R)-1), (S,S)-reboxetine ((S,S)-2), and 
(S)-citalopram ((S)-3) previously published to prove their reliability 
and to demonstrate their high efficiency. Therefore, saturation 
and competition assays should be carried out with all three 
markers and the three targets (hDAT, hNET, and hSERT) in one 
binding experiment. To proof the reliability of Simultaneous 
Multiple MS Binding Assays, the results (i.e. the affinities) 
determined thereby should be compared with those obtained in 
individual MS Binding Assays and radioligand binding 
experiments. 
 
Figure 1. Workflow of the developed MS Binding Assays 
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Figure 2. Structures of markers and the inhibitor employed for determination 
of nonspecific binding in MS Binding Assays, as published previously.[27]  
a Deuterated indatraline was used as racemate, though only one enantiomer is 
depicted in the figure. 
Results and Discussion 
Calibration 
 
In any case samples from binding experiments were analyzed 
together with a set of calibration standards and QC samples 
prepared at the day of the assay. A full validation of the LC-ESI 
MS/MS quantification method according to the CDER guideline 
for bioanalytical method validation[31] was performed and 
published previously.[27] Each subsequent calibration was 
evaluated pursuant to the CDER guideline to confirm the 
validation. For Simultaneous MS Binding Assays, the 
concentration of target material in the incubation samples had to 
be increased, but this change had no effect on linearity, accuracy, 
and precision of the LC-ESI-MS/MS quantification method. The 
results of all sets of calibration standards and QC samples 
complied with the limits set in the CDER guideline (see supporting 
information for results of the validation). 
 
Simultaneous saturation assays 
 
Binding affinities for (R,R)-D-84 ((R,R)-1) towards hDAT, (S,S)-
reboxetine ((S,S)-2) towards hNET, and (S)-citalopram ((S)-3) 
towards hSERT have been characterized in individual saturation 
experiments published recently.[27] Simultaneous Multiple MS 
Binding Assays offer the possibility to determine the binding 
affinities of these three markers at their targets in a single 
experiment. We started to test the feasibility of this approach in 
the case of the three monoamine transporters with simultaneous 
saturation experiments. In these simultaneous saturation 
experiments, all three markers were incubated together with all 
three targets. Conditions of the simultaneous binding experiments 
were identical as for the individual experiments described 
previously.[27] In short, the three markers in 32 concentrations 
were incubated together with the three targets for 2 h at 20 °C 
before the target-marker complexes were separated from the 
nonbound markers by a filtration step. For simultaneous 
saturation experiments, the amount of each individual target was 
the same as in individual saturation experiments leading to higher 
total amount of membrane material in the binding samples in 
comparison with the individual binding experiments. To determine 
the nonspecific binding (NSB), the same set of samples was 
incubated together with rac-[2H3]-indatraline (rac-[2H3]-4) in 
excess to block specific binding sites as it was done recently 
(Neiens et al.[27]). After the elution of the bound markers and their 
quantification using LC-ESI-MS/MS, the specific binding (SB) was 
calculated by subtraction of the nonspecific binding from the total 
binding (TB, SB = TB – NSB). The simultaneous saturation 
experiments resulted in Kd values of 4.01 nM for the binding of 
(R,R)-D-84 ((R,R)-1) towards hDAT, 2.20 nM for (S,S)-reboxetine 
((S,S)-2) towards hNET and 440 pM for (S)-citalopram ((S)-3) 
towards hSERT (see table 1 and figure 3). With the binding 
affinities for all three markers towards their individual targets 
agreeing excellently with those obtained from individual saturation 
experiments, it could be unambiguously demonstrated that 
simultaneous saturation experiments performed according the 
approach of Simultaneous Multiple MS Binding Assays lead to 
reliable results. Thus, each marker is able to label its target 
selectively, even in presence of the other markers and targets in 
the performed simultaneous saturation experiments. Since the 
membrane material employed for the simultaneous binding 
experiments was obtained by pooling of the individual membrane 
preparations prior to the protein determination, the Bmax values 
are given as bound marker in relation to the total amount of 
protein in the binding samples. According to the proportion the 
membrane preparation (hDAT, hNET, and hSERT) have been 
employed in the combined (“pooled”) target preparation, the 
monoamine transporters hDAT, hNET, and hSERT were 
estimated to be present roughly in a ratio of about 1:1:2. To 
compare the Bmax values determined in the Simultaneous MS 
Binding Assays to the ones obtained in individual MS Binding 
Assays, it is necessary to calculate the Bmax values for each 
target transporter preparation individually instead of the Bmax 
values for the combined target preparation. Taking into account 
the proportion of the individual target membrane preparation in 
the binding sample, the Bmax for binding of (R,R)-D-84 ((R,R)-1) 
to hDAT in Simultaneous MS Binding Assays can be estimated 
approximately to 110 pmol/mg protein, being twice as high, as 
determined in individual MS Binding Assays. Bmax values 
obtained in Simultaneous MS Binding Assays for the binding of 
(S,S)-reboxetine ((S,S)-2) to hNET would be approximately 33 
pmol/mg protein and for the binding of (S)-citalopram ((S)-3) to 
hSERT a Bmax value approximately 11 pmol/mg protein, both of 
which are in excellent agreement with results obtained from 
individual MS Binding Assays. 
Table 1. Results from the saturation experiments performed simultaneously and 
those from individual MS Binding Assays for comparison purposes. Bmax values 
in this table are related to the total protein content in the binding samples. As 
discussed above for comparison of the Bmax values from this study with those in 
individual binding assays requires their calculation based on the individual 
target material employed in the Simultaneous Multiple MS Binding Assay. 
Results are given as mean r SEM, n = 3, except for [a] n = 4 [27] 
 Simultaneous Multiple MS 
Binding Assays 
Individual MS Binding 
Assays  
Kd in nM 
Bmax in 
pmol/mg 
protein 
Kd in nM 
Bmax in 
pmol/mg 
protein 
(R,R)-D-84      
((R,R)-1) to 
hDAT 
4.01 r 0.21 27.6 r 7.7 3.66 r 1.35a 57.9 r 8.4[a] 
(S,S)-
reboxetine 
((S,S)-2) to 
hNET 
2.20 r 0.29 8.22 r 1.60 3.06 r 0.46 31.6 r 8.9 
(S)-
citalopram 
((S)-3) to 
hSERT 
0.440  r 
0.0038 5.26 r 1.40 
0.411 r 
0.0026 10.1 r 1.7 
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Figure 3. Simultaneous saturation experiments for (R,R)-D-84 ((R,R)-1) towards hDAT (blue symbols), (S,S)-reboxetine ((S,S)-2) towards hNET (red symbols) 
and (S)-citalopram ((S)-3) towards hSERT (green symbols). a), b), and c) Means r SD (n = 3) of the total binding (circles) and the nonspecific binding in the 
presence of 10 µM rac-[2H3]-indatraline (rac-[2H3]-4) (squares, linear regression of the nonspecific binding is shown as a straight line). d) Means of specific binding 
(triangular symbols) and resulting saturation isotherms derived from the results shown in a), b), and c). Only data points up to a free marker concentration of 
75 nM are shown. Data points of higher free marker concentrations do not change the plateau of the saturation isotherms. 
 
Competition experiments 
 
In competition experiments, the inhibitory constant of a test 
compound towards a target in presence of a marker can be 
determined. Simultaneous MS Binding Assays enable the 
determination of the affinity of one test compound at multiple 
target proteins in one experiment. To carry out simultaneous 
competition experiments, the procedure of the established 
simultaneous saturation experiments was adapted. For 
competition experiments, the markers are applied at a fixed 
concentration in all binding samples, whilst the competitor is 
added in multiple concentration levels. Commonly, the marker 
concentration is chosen near the Kd value of the marker.[32] In 
recently published MS Binding Assays for the three monoamine 
transporters, the selectivity of (R,R)-D-84 ((R,R)-1) was 
characterized as 1:9:84 (hDAT:hNET:hSERT).[18] Due to this low 
selectivity of (R,R)-D-84 ((R,R)-1) for hDAT, its concentration was 
chosen to be at one fourth of the Kd values, while concentrations 
of (S,S)-reboxetine ((S,S)-2) and (S)-citalopram ((S)-3) were 
chosen to be ten times the Kd values of these markers, thus 1 nM 
(R,R)-D-84 ((R,R)-1), 20 nM (S,S)-reboxetine ((S,S)-2), and 4 nM 
(S)-citalopram ((S)-3) were applied in the incubation samples. 
The use of these marker concentrations, the lower concentration 
for (R,R)-D-84 ((R,R)-1) and higher concentrations for (S,S)-
reboxetine ((S,S)-2) and (S)-citalopram ((S)-3) were expected to 
ensure that hNET and hSERT are almost exclusively labeled by 
their respective markers, but not by (R,R)-D-84 ((R,R)-1).  
Seven monoamine reuptake inhibitors with different selectivity 
profiles were chosen as test compounds for the competition 
experiments. The test compounds (see figure 1 and 4) were 
added to the binding samples in 15 concentration levels (20 
concentration levels for sertraline (10), due to its large difference 
in affinity towards hNET and hSERT) in a range around published 
binding affinities, that was necessary to obtain competition curves 
for the marker displacement at all three targets (for concentrations 
of each compound, see “Competition assays” in the experimental 
section). All other conditions of the binding assay were maintained 
according to the procedure described above for the simultaneous 
saturation assays. As for the previously published saturation 
experiments, nonspecific binding was determined in samples 
where the specific binding sites were blocked by rac-[2H3]-
indatraline (rac-[2H3]-4), which was added in a large excess, for 
eight marker concentrations between 12.5 nM and 200 nM. 
Based on the concentrations of nonspecific binding for these 
marker concentrations, a linear regression was obtained, which 
was then used to calculate the nonspecific binding for marker 
concentrations used in the binding samples of the competition 
experiments. 
After determination of the specific binding of three markers in the 
binding samples (for detail see “Data evaluation” in the 
experimental section), three competition curves – one for each 
target – were generated for a single simultaneous binding 
experiment for every test compound (see figure 5 for example). 
This reflects the major advantage of Simultaneous MS Binding 
Assays in comparison to radioligand binding assays and the 
previously published MS Binding Assays addressing DAT, NET, 
and SERT.[18] They allow to characterize binding affinities of test 
compounds at multiple targets in one experiment which results in 
a higher efficiency due to lower numbers of samples to be 
prepared and analyzed. The results for the investigated 
compounds are summarized in table 2 and discussed in detail in 
the following paragraph.  
3-D-Bis-(4-fluorophenyl)methoxytropane (5), claimed as a 
selective dopamine reuptake inhibitor, was characterized in 
competitive Simultaneous MS Binding Assays with pKi values of 
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7.43 at hDAT, 6.84 at hNET, and 5.73 at hSERT (see figure 5 a 
and table 2). These results can be best compared with published 
data, obtained from individual binding experiments with the 
previously established MS Binding Assay, which uses (1R,3S)-
indatraline as a marker for all three targets and the same target 
material under assay conditions which differ only in the incubation 
temperature from the Simultaneous MS Binding Assays 
performed in the present study. In comparison to these (1R,3S)-
indatraline MS Binding Assays, the results for the competition at 
hDAT (pKi of 7.43 in Simultaneous MS Binding Assays vs. 7.52 in 
(1R,3S)-indatraline MS Binding Assays) and hSERT (pKi of 5.73 
in Simultaneous MS Binding Assays vs. 5.71 in (1R,3S)-
indatraline MS Binding Assays) are in excellent agreement (see 
table 2). In the Simultaneous MS Binding Assays, the determined 
affinity towards hNET with a pKi of 6.84 is slightly lower than the 
affinity (pKi of 7.22) resulting from the (1R,3S)-indatraline MS 
Binding Assays.[18] In other references in literature, 3-D-Bis-(4-
fluorophenyl)methoxytropane (5) is described with pKi values of 
7.93 at DAT, 5.07 at NET and 5.61 at SERT, determined by [3H]-
(–)-2-E-carbomethoxy-3-E-(4-fluorophenyl)tropane ([3H]-WIN 
35,428), [3H]-desmethylimipramine and [3H]-citalopram binding 
towards rat caudate putamen.[33,34] For the binding at DAT and 
SERT, the pKi values determined in Simultaneous MS Binding 
Assays and radioligand binding experiments are in good 
agreement. The binding affinity of 3-D-bis-(4-
fluorophenyl)methoxytropane (5) towards NET in Simultaneous 
MS Binding Assays was  considerably higher than in the 
radioligand binding assays. This is likely to be due to the different 
incubation conditions and the different target materials used in 
both binding assays.  
For rac-bupropione (rac-6), Simultaneous MS Binding Assays 
resulted in pKi values of 5.83 at hDAT, 5.20 at hNET, and 5.15 at 
hSERT (see table 2). These results are in good accordance with 
pKi values of 5.59 at hDAT, 5.08 at hNET and 4.83 at hSERT, 
determined with (1R,3S)-indatraline MS Binding Assays.[18] In 
radioligand binding experiments, slightly lower binding affinities 
with pKi values of 5.58 at hDAT, 4.68 at hNET, and 4.46 at hSERT 
were determined showing a higher selectivity for hDAT, but the 
same rank order of potencies.[35] 
Desipramine (7), a selective noradrenaline reuptake inhibitor, was 
characterized with pKi values of 5.09 at hDAT, 8.92 at hNET, and 
7.69 at hSERT in Simultaneous MS Binding Assays. Compared 
to the results from the (1R,3S)-indatraline MS Binding Assays 
(8.35 at hNET, and 6.80 in (1R,3S)-indatraline MS Binding Assays 
at hSERT), the pKi values at hDAT and hNET are in good 
accordance whereas the pKi value at hSERT is showing a lower 
affinity towards this target when determined in (1R,3S)-indatraline 
MS Binding Assays (see table 2).[18] Furthermore, the affinities 
determined in Simultaneous MS Binding Assays are in excellent 
agreement with pKi values of 5.50 at hDAT, 9.08 at hNET and 
7.75 at hSERT in radioligand binding assays using [3H]-WIN 
35,428, [3H]-nisoxetine, and [3H]-imipramine binding towards 
hDAT, hNET, and hSERT expressed in HEK293 cells reported in 
literature.[36]  
(S)-fluoxetine ((S)-8) is the eutomer of the selective serotonin 
reuptake inhibitor fluoxetine. It was characterized in Simultaneous 
MS Binding Assays with pKi values of 5.53 at hDAT, 6.10 at hNET, 
and 9.48 at hSERT (see figure 5 b and table 2). In (1R,3S)-
indatraline MS Binding Assays pKi values of 4.60 at hDAT, 5.99 
at hNET, and 8.50 at hSERT were determined.[18] Though the pKi 
values derived from Simultaneous MS Binding Assays are 
somewhat higher than those from (1R,3S)-indatraline MS Binding 
Assays, they are in good accord with the latter with regard to the 
subtype selectivity at the three transporters. Only a few other 
studies characterized the binding affinities of (S)-fluoxetine. One 
of these publications uses hNET and hSERT expressed in COS-
7 cells to determine the binding affinities of (S)-fluoxetine which 
amounted to a pKi value of 5.88 towards hNET and 8.52 towards 
hSERT in competition with [125I]-(–)-2E-carbomethoxy-3E-(4-
iodophenyl)tropane ([125I]-E-CIT).[37] These affinities deviate only 
slightly from the ones determined by Simultaneous MS Binding 
Assays.  
Since it had been used as a blocking reagent for the determination 
of the nonspecific binding in all Simultaneous MS Binding Assays, 
the affinities of rac-[2H3]-indatraline (rac-[2H3]-4) were also 
characterized in competition experiments. As the deuteration of 
indatraline is unlikely to lead to a considerable change of binding 
affinities, the results of the Simultaneous MS Binding Assays were 
compared to binding affinities obtained for nondeuterated, 
indatraline. In this context, it should be mentioned that only 
enantiopure indatraline had been used in the (1R,3S)-indatraline 
MS Binding Assays, this being the first time, that binding affinities 
of rac-[2H3]-indatraline (rac-[2H3]-4) towards monoamine 
transporters are characterized. So there are no reference values 
from MS Binding Assays (for deuterated as well as racemic 
indatraline) and from radioligand binding assays in general (for 
deuterated indatraline) for comparison. In Simultaneous MS 
Binding Assays, pKi values of 8.34 at hDAT, 9.16 at hNET and 
9.91 at hSERT were determined for rac-[2H3]-indatraline (rac-
[2H3]-4, see table 2). These results match well with pKi values of 
8.40 at hDAT, 8.70 at hNET and 9.22 at hSERT, found for the 
binding of racemic indatraline at rat brain homogenates as target 
material in radio ligand binding assays with [3H]-WIN 35,428, [3H]-
nisoxetine, and [3H]-citalopram as radioligands.[38] In other 
publications, a pKi value of 8.52 for the binding at DAT in rat 
striatum, determined in competition with [3H]-WIN 35,428, as well 
as a pKi value of 9.89 at SERT in [3H]-paroxetine binding at rat 
frontal cortical membranes and a pKi value of 9.64 again at SERT 
in [3H]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-
benzonitrile ([3H]-DASB) binding at rat brain cortex material were 
determined, which are in good correspondence with the results 
obtained in this study in Simultaneous MS Binding Assays.[39–41] 
In Simultaneous MS Binding Assays, the selective norepinephrine 
reuptake inhibitor rac-nisoxetine (rac-9) has been characterized 
with pKi values of 5.49 at hDAT, 8.46 at hNET, and 7.37 at hSERT 
(see figure 5 c and table 2). These results are in good agreement 
with pKi values of 5.67 at hDAT, 7.89 at hNET, and 6.55 at hSERT, 
determined in (1R,3S)-indatraline MS Binding Assays and pKi 
values of 5.77 at hDAT, 7.49 at hNET, and 7.14 at hSERT, which 
were obtained in radioligand binding experiments.[18,35] 
Simultaneous MS Binding Assays show a slightly higher affinity of 
rac-nisoxetine (rac-9) towards hSERT than the (1R,3S)-
indatraline MS Binding Assays, but are in good accordance to the 
results from radioligand binding assays.  
A similar situation concerning the concordance of the 
characterized binding affinities could be observed for the selective 
SERT inhibitor sertraline (10) as a test compound in competition 
experiments. Simultaneous MS Binding Assays revealed pKi 
values of 7.19 at hDAT, 6.66 at hNET, and 10.44 at hSERT, 
whereas (1R,3S)-indatraline MS Binding Assays had yielded the 
pKi values of 6.61 at hDAT, 6.23 at hNET, and 8.72 at hSERT 
(see table 2).[18] Similarly, the binding affinities from radioligand 
binding experiments, using [3H]-WIN 35,428, [3H]-nisoxetine, and 
[3H]-imipramine as radioligands in competition experiments 
towards hDAT, hNET, and hSERT expressed in HEK293 cells, 
yielding pKi values of 7.60 towards hDAT and 6.38 at hNET are in 
good agreement with the results from the Simultaneous MS 
Binding Assay. The binding affinity towards hSERT has been 
characterized with a pKi values of 9.54 in radioligand binding 
assays and is hence slightly lower than in Simultaneous MS 
Binding Assays.[36] Despite this slight disparity in binding affinity 
at hSERT, Simultaneous MS Binding Assays show the same 
selectivity of sertraline (10) for hSERT like all of the mentioned 
studies. 
In summary, the pKi values determined in Simultaneous MS 
Binding Assays for hDAT, hNET, and hSERT are for the most part 
in good correspondence with the results from the individual 
(1R,3S)-indatraline MS Binding Assays (see figure 6), indicating 
that Simultaneous MS Binding Assays are as reliable as individual 
MS Binding Assays for the characterization of binding affinities. A 
correlation of the pKi values determined in Simultaneous (y-axes) 
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and with those from the (1R,3S)-indatraline MS Binding Assays 
(x-axes) all showing a linear relationship is illustrated in figure 6. 
This correlation was generated for the competition of the test 
compounds for each of the targets. The three graphs obtained are 
characterized by the following equations and coefficients of 
determination (R2): y = 0.8414x + 1.164, R2 = 0.8219 for the 
competition at hDAT, y = 1.106x - 0.4861, R2 = 0.9421 for the 
competition at hNET and y = 1.331x - 1.474, R2 = 0.9787 for the 
competition at hSERT. As apparent from these diagrams, 
Simultaneous MS Binding Assays tend to provide higher pKi 
values than (1R,3S)-indatraline MS Binding Assays, especially for 
hSERT. A possible explanation for this finding could be that the 
binding sites labeled by (R,R)-D-84 ((R,R)-1) at hDAT, by (S,S)-
reboxetine ((S,S)-2) at hNET and by (S)-citalopram ((S)-3) at 
hSERT might be slightly different to those addressed by (1R,3S)-
indatraline at the corresponding targets.  
 
 
 
 
 
Figure 4. Structures of test compounds applied as competitors in simultaneous competition experiments 
 
Table 2. Affinity (pKi) and selectivity (Ki ratios hDAT:hNET:hSERT) values of inhibitors towards hDAT, hNET, and hSERT determined in competitive Simultaneous 
Multiple MS Binding Assays using (R,R)-D-84 ((R,R)-1), (S,S)-reboxetine ((S,S)-2), and (S)-citalopram ((S)-3) as markers with published data from (1R,3S)-
indatraline MS Binding Assays for comparison. [18] [a] Simultaneous Multiple MS Binding Assays: Affinity values (pKi; mean r SEM, n = 4 – 5) determined in 
Simultaneous Multiple MS Binding Assays using (R,R)-D-84 ((R,R)-1), (S,S)-reboxetine ((S,S)-2), and (S)-citalopram ((S)-3) as markers. [b] (1R,3S)-indatraline MS 
Binding Assays: Affinity values (pKi; mean r SEM, n = 3 – 7) determined in MS Binding Assays using (1R,3S)-indatraline ((1R,3S)-4) as marker. [c] Ki ratios showing 
selectivity of the test compound.   
Compound pKi 
Ki-ratio determined in 
Simultaneous MS 
Binding Assays 
(hDAT:hNET:hSERT)[c] No Name 
Simultaneous Multiple MS Binding 
Assays[a] (1R,3S)-indatraline MS Binding Assays
[b] 
hDAT hNET hSERT hDAT hNET hSERT 
5 3-D-bis-(4-fluorophenyl)methoxytropane 7.43 r 0.10 6.84 r 0.03 5.73 r 0.04 7.52 r 0.04 7.22 r 0.02 5.71 r 0.05 1:4:47 
rac-6 rac-bupropione 5.83 r 0.06 5.20 r 0.05 5.15 r 0.05 5.59 r 0.12 5.08 r 0.09 4.83 r 0.10 1:4:5 
7 desipramine 5.09 r 0.15 8.92 r 0.13 7.69 r 0.15 5.16 r 0.05 8.35 r 0.03 6.80 r 0.11 7347:1:18 
(S)-8 (S)-fluoxetine 5.53 r 0.09 6.10 r 0.09 9.48 r 0.11 4.60 r 0.08 5.99 r 0.06 8.50 r 0.01 8651:2343:1 
rac-[2H3]-
4 rac-[
2H3]-indatraline 8.34 r 0.15 9.16 r 0.09 9.91 r 0.10    41:5:1 
rac-9 rac-nisoxetine 5.49 r 0.15 8.46 r 0.02 7.37 r 0.05 5.67 r 0.03 7.89 r 0.06 6.55 r 0.06 1099:1:12 
10 sertraline 7.19 r 0.23 6.66 r 0.04 10.44 r 0.09 6.61 r 0.05 6.23 r 0.05 8.72 r 0.08 2455:5756:1 
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Figure 5. Results for three compounds investigated from simultaneous 
competition experiments. Diagrams show the specific binding given as means 
(n = 3) and the resulting competition curve of (R,R)-D-84 ((R,R)-1) towards 
hDAT (blue), (S,S)-reboxetine ((S,S)-2) towards hNET (red), and (S)-citalopram 
((S)-3) towards hSERT (green) with a) 3-D-bis-(4-fluorophenyl)methoxytropane 
(rac-6), b) (S)-fluoxetine ((S)-8), and c) rac-nisoxetine (rac-9) as competitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Correlations of pKi values for six monoamine transporter inhibitors determined in Simultaneous Multiple MS Binding Assays using (R,R)-D-84 ((R,R)-1), 
(S,S)-reboxetine ((S,S)-2), and (S)-citalopram ((S)-3) as markers (y-axes) and those determined in MS Binding Assays using (1R,3S)-indatraline ((1R,3S)-4) as 
marker (x-axes) [18]. Shown are correlations of pKi values at a) hDAT (y = 0.8414x + 1.164, R2 = 0.8219), b) hNET (y = 1.106x - 0.4861, R2 = 0.9421), and c) hSERT 
(y = 1.331x - 1.474, R2 = 0.9787). Data points represent mean values as given in table 2. 
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Conclusions 
In this work, we demonstrated that MS Binding Assays have the 
potential for the simultaneous characterization of binding affinities 
towards multiple targets, in this case, for the monoamine 
transporters DAT, NET, and SERT. With the previously 
established and validated LC-ESI-MS/MS quantification method, 
the bound concentrations of the three selective markers (R,R)-D-
84 ((R,R)-1) addressing DAT, (S,S)-reboxetine ((S,S)-2) 
addressing NET, and (S)-citalopram ((S)-3) addressing SERT 
could be determined in a single LC-ESI-MS/MS run. Based on this 
quantification method Simultaneous Multiple MS Binding Assays 
were established in which all three markers were incubated 
together with all three targets in a single binding experiment. The 
simultaneous saturation experiments performed this way yielded 
the corresponding three saturation isotherms at once. The Kd 
values for each marker calculated therefrom were in good 
agreement with those obtained for the corresponding binding 
experiments addressing the targets individually. Additionally, we 
could show that this approach provides also the possibility for 
simultaneous affinity profiling of test compounds in competition 
experiments. The affinities exemplarily determined for a set of 
seven known monoamine reuptake inhibitors (consisting of 
selective as well as nonselective ones) were as well in a good 
accordance with published data.  
Clearly, the established Simultaneous Multiple MS Binding 
Assays, addressing the monoamine transporters DAT, NET, and 
SERT, distinctly surpass the efficiency of radioligand binding 
assays predominantly used for this purpose up to now, though 
there is still some potential to improve the established setup 
especially by employing a more favored DAT inhibitor - especially 
with higher selectivity and less of the recently described analytical 
drawbacks.[27] Hence, the present study may be an important 
contribution for a more efficient affinity profiling at monoamine 
transporters that is still a highly important task in the development 
of drug candidates for mental disorders such as depression.  
Experimental Section 
Chemicals: LC-MS grade acetonitrile and water were obtained from VWR 
Prolabo (Darmstadt, Germany), water for incubation buffers and washing 
buffers was prepared by distillation of demineralized water (reverse 
osmosis) and filtration through a 0.45 µm filter. Ammonium formate was 
bought in mass spectrometry grade from Fluka (Teufelskirchen, Germany). 
(S)-citalopram ((S)-3) oxalate was bought from TCI (Eschborn, Germany), 
racemic [2H6]-citalopram (rac-[2H6]-3) oxalate from Alsachim (Illkirch, 
France), racemic [2H5]-reboxetine (rac-[2H5]-2) mesylate was obtained 
from TRC (North York, ON, Canada), 3-D-bis-(4-
fluorophenyl)methoxytropane hydrochloride from Tocris (Wiesbaden-
Nordenstadt, Germany), hydrochlorides of desipramine and (S)-fluoxetine 
from Sigma-Aldrich (Taufkirchen, Germany), rac-bupropione from Alfa 
Aesar (Karlsruhe, Germany), rac-nisoxetine from Biotrend (Cologne, 
Germany), and sertraline hydrochloride from abcr GmbH (Karlsruhe, 
Germany), each in the highest commercially available quality. (R,R)-4-(2-
Benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol ((R,R)-D-84, (R,R)-1) 
was synthesized and purified in-house [29,42] and racemic reboxetine (rac-
2) was extracted from Edronax tablets (4 mg, Pfizer Europe, Kent, UK) 
which was further used to perform a semipreparative CSP-HPLC to obtain 
(S,S)-reboxetine ((S,S)-2).[27] Enantiopurities of ≥ 99.8% ee for (R,R)-D-84 
((R,R)-1) and 99.3% ee for (S,S)-reboxetine ((S,S)-2) were determined by 
CSP-HPLC.[27,42] Racemic [2H4]-4-(2-benzhydryloxyethyl)-1-(4-
fluorobenzyl)piperidin-3-ol (rac-[2H4]-D-84, rac-[2H4]-1, for the sake of 
simplicity, the racemic mixture of (R,R)-[2H4]-D-84 and (S,S)-[2H4]-D-83 
((S)-[2H4]-83 is the enantiomer of (R,R)-[2H4]-D-84 according to the 
denotation in literature[43,44]) is referred to as rac-[2H4]-D-84 throughout this 
work. synthesis of rac-[2H4]-D-84 is to be published soon) and racemic 
[2H3]-indatraline (rac-[2H3]-4) were synthesized in-house.[27] 
Polyethylenimine (PEI) solution (50% in H2O) was obtained from Fluka, 
sodium chloride from Bernd Kraft (Duisburg, Germany), potassium 
chloride and dimethylacetamide (DMA) from Sigma-Aldrich (Taufkirchen, 
Germany), HEPES and roti-quant (5 x concentrated) for determination of 
total protein in membrane preparations from Roth (Karlsruhe, Germany). 
All percentages and ratios are specified as (v/v) if not indicated otherwise. 
Instrumentation: MS Binding Assays were performed with an API 5000 
triple quadrupole mass spectrometer, equipped with a TurboV ESI ion 
source (AB Sciex, Darmstadt, Germany). The mass spectrometer was 
coupled to an Agilent 1200 series HPLC system (Agilent, Waldbronn, 
Germany), consisting of a vacuum degasser, a binary pump and a column 
oven in combination with a HTS-Pal autosampler (50 µL syringe, 50 µL 
sample loop, CTC Analytics, Zwingen, Switzerland). As a stationary phase, 
a Luna PFP(2) column (50 mm x 2.0 mm, 3 µm, Phenomenex, 
Aschaffenburg, Germany) was used. 
Solutions: Separately prepared stock solutions of the markers and 
internal standards with a concentration of 1 mM in H2O/DMA (80/20) as 
well as stock solutions for the competitors with a concentration of 10 mM 
in H2O were stored at -20 °C until the day of the experiment. For binding 
and calibration samples, equal volumes of marker stock solutions were 
mixed and diluted with H2O/DMA (80/20) to working solutions containing 
all three markers with the 100-fold concentration of the intended final 
concentration in binding samples or calibration samples. In these working 
solutions, all three markers had equal concentrations for the use in 
simultaneous saturation experiments. For competition experiments a 100-
fold concentrated working solution with 100 nM (R,R)-D-84 ((R,R)-1), 2 µM 
(S,S)-reboxetine ((S,S)-2), 400 nM (S)-citalopram ((S)-3) in H2O/DMA 
(80/20) was prepared to obtain final concentrations of 1 nM (R,R)-D-84 
((R,R)-1), 20 nM (S,S)-reboxetine ((S,S)-2), and 4 nM (S)-citalopram ((S)-
3) when diluted in the binding samples. Competitor stock solutions were 
diluted to a 100-fold concentrated working solution with respect to the 
intended final concentration in competition experiments. Equal volumes of 
internal standard stock solutions were mixed and diluted in acetonitrile to 
obtain a solution of all three internal standards at a concentration of 
100 pM in acetonitrile/water/DMA (99/0.8/0.2). For the calibration, 100-fold 
concentrated working solutions of all three markers in H2O/DMA (80/20) 
were diluted in acetonitrile to 10-fold concentrated solutions and finally 
diluted with the internal standard solution to obtain solutions containing 
1 pM to 2.5 nM of all three markers and 90 pM of all three internal 
standards. All solutions were prepared in 1.5 mL polypropylene micro 
tubes (Sarstedt, Nürmbrecht, Germany). As pipet tips, non-coated tips 
without filter (quality tips without filters, 20 µL neutral, 200 µL yellow, 
300 µL neutral, 1000 µL blue and 1250 µL neutral, Sarstedt) were used. 
LC-ESI-MS/MS quantification method: Quantification of (R,R)-D-84, 
(S,S)-reboxetine and (S)-citalopram ((R,R)-1, (S,S)-2, (S)-3) was 
performed with the LC-ESI-MS/MS method previously described.[27] In 
short, a Luna PFP(2) column was used in combination with 
acetonitrile/ammonium formate buffer (0.75 mg/mL; 85/15) at a flow rate 
of 800 µL/min as mobile phase. The column oven temperature was set to 
20 °C, the injection volume was 30 µL and the eluate of the first 0.4 min of 
each chromatographic run was directed to waste. Using pneumatically 
assisted ESI in positive polarity, mass transitions for each marker (m/z 
420.2/167.1 and m/z 420.2/109.1 for (R,R)-D-84 ((R,R)-1), m/z 
314.1/176.2 and m/z 314.1/91.1 for (S,S)-reboxetine ((S,S)-2), m/z 
325.2/109.2 and m/z 325.2/262.2 for (S)-citalopram ((S)-3)) and internal 
standard (m/z 424.2/167.1 for rac-[2H4]-D-84 (rac-[2H4]-1), m/z 319.2/176.2 
for rac-[2H5]-reboxetine (rac-[2H5]-2) and m/z 331.2/109.0 for rac-[2H6]-
citalopram (rac-[2H6]-3)) were acquired in multiple reaction monitoring 
(MRM) mode. 
General procedure for MS Binding Assays: MS Binding Assays were 
performed according to the procedure previously described[27] with 
membrane preparations of HEK293 cells, stably expressing hDAT, hNET 
or hSERT, respectively.[45] For 20 mL of the target preparation containing 
hDAT, hNET, and hSERT to be used in Simultaneous MS Binding Assays, 
hDAT, hNET, and hSERT membrane preparation (stored at -80 °C and 
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thawed at the day of the experiment) were pooled (1 part hDAT, 1 part 
hNET and 2 parts hSERT) and diluted in 20 mL cold assay buffer (50 mM 
HEPES, 120 mM NaCl, 5 mM KCl, pH 7.4). The suspension was 
centrifuged (20 min, 20000 rpm, 4 °C, Sorvall Evolution, SS-34 rotor, 
Thermo Fisher Scientific, Dreieich, Germany), the supernatant was 
discarded and the remaining pellet resuspended in 20 mL cold assay 
buffer. Binding samples for determination of total binding were prepared 
as triplicates in a polypropylene 96-deep-well plate (1.2 mL, polypropylene, 
Sarstedt, Nürmbrecht, Germany) by addition of the 100-fold concentrated 
marker working solution ((R,R)-1, (S,S)-2, (S)-3, see “Solutions”) and if 
needed the 100-fold concentrated competitor working solution (see 
“Solutions”) to assay buffer (reaching a volume of 200 µL per well). 
Incubation was started by the addition of 50 µL target preparation to each 
well and carried out for 2 h at 20 °C in a shaking water bath. The incubation 
was terminated by filtration. For the pipetting, a 12-channel pipette (25 µL 
- 300 µL, Eppendorf, Hamburg, Germany) was used and the filtration as 
well as washing was carried out row after row. 200 µL of each binding 
sample were transferred from the 96-deep-well plate to a 96-well glass 
fiber filter plate (AcroPrep Advance, glass fiber, 1.0 µm, 350 µL, Pall, 
Dreieich, Germany) which had been pretreated for 2 h with 150 µL 0.5% 
(m/v) PEI solution per well at 4 °C. The binding samples were rapidly 
filtrated through the filter with a multi well plate vacuum manifold (Pall). 
Directly after the filtration of one row of binding samples, the same row on 
the filter plate was washed three times with 150 µL ice cold wash buffer 1 
(0.75 mg/mL ammonium formate, pH 7.4 + 10% DMA) and once with 
150 µL ice cold wash buffer 2 (0.75 mg/mL ammonium formate, pH 7.4) 
before the next row was filtrated and washed. After filtration of all binding 
samples, the filter plate was dried for 2 h at 60 °C. For elution of the binding 
samples, 70 µL acetonitrile containing all three internal standards (rac-
[2H4]-1, rac-[2H5]-2, rac-[2H6]-3), each at concentration of 90 pM, were 
transferred into each well of the filter plate (containing the remaining 
marker-target complexes). After a residence time of 20 s the elution 
solution was aspirated into a 96-deep-well plate under vacuum. This step 
was repeated two more times resulting in 210 µL eluate per binding sample. 
The 96-deep-well plate was sealed with aluminum foil and centrifuged 
(10 min, 2000 rpm, 4 °C; Biofuge Stratos, Rotor: #3048, Heraeus, 
Germany) prior to analysis by LC-MS/MS. Nonspecific binding was 
determined under the same conditions as total binding, but in presence of 
10 µM rac-[2H3]-indatraline (rac-[2H3]-4). In all binding samples, the marker 
depletion was not higher than 10%. Matrix samples, used for the 
calibration (see “Calibration”) were prepared equally but without the 
addition of marker or competitor to the binding samples. Every day an MS 
Binding Assay was performed, a set of samples, containing blanks, 
calibration standards (in a range of 1 pM – 2.5 nM for all three markers) 
and QC samples (2.5 pM, 10 pM, 100 pM, and 1 nM of all three markers 
in hexaplicates) was prepared and analyzed together with the binding 
samples, as described previously.[27] All binding samples were quantified 
based on this calibration. 
Simultaneous saturation assays: Simultaneous saturation assays were 
performed according to the “General procedure for MS Binding Assays” 
with all three markers and a target preparation containing all three 
monoamine transporters. Binding samples with all three markers in 32 
concentration levels ranging from 25 pM to 500 nM were prepared in 
triplicates. For the determination of nonspecific binding, samples for all 32 
marker concentration levels were prepared. 
Competition assays: The competition assays were performed according 
to the “General procedure for MS Binding Assays” with all three markers 
and a target preparation containing all three monoamine transporters. 
Binding samples were prepared with 1 nM (R,R)-D-84 ((R,R)-1), 20 nM 
(S,S)-reboxetine ((S,S)-2), 4 nM (S)-citalopram ((S)-3) and the competitor 
in 15 concentration levels (20 concentration levels for sertraline) ranging 
from 10 pM to 1 mM for 3-D-bis-(4-fluorophenyl)methoxytropane, rac-
bupropione, desipramine and rac-nisoxetine, respectively from 1 pM to 
100 µM for (S)-fluoxetine as well as rac-[2H3]-indatraline (rac-[2H3]-4) and 
from 300 fM to 1 mM for sertraline. Each set of samples for a competitor 
consisted of the binding samples with varying concentrations of the 
competitor and one triplicate of samples without the addition of the 
competitor (100% level of the competition curve, see “Data evaluation”). 
To determine the nonspecific binding (which was set to be the 0% level of 
the competition curve, see “Data evaluation”), binding samples containing 
the three markers in eight concentration levels ranging from 12.5 nM to 
200 nM, 10 µM rac-[2H3]-indatraline (rac-[2H3]-4), and the target 
preparation, were prepared and processed according to the procedure 
described under “General procedure for MS Binding Assays”. 
Data evaluation: Calibration functions for each marker were determined 
in the Analyst 1.6 software based on the calibration standards by plotting 
the obtained peak area ratios (y-axes, marker peak area / internal standard 
peak area) against the marker concentration (x-axes) followed by a linear 
regression with a 1/x weighting. Further data evaluation was carried out 
with Prism 6 software (GraphPad Software, San Diego, CA, USA). With 
the calibration functions, peak area ratios for each binding sample were 
transformed to bound marker concentrations. Samples with bound marker 
concentrations not covered by the linear range of the LC-ESI-MS/MS 
quantification method (linear ranges from validation: 2.5 pM – 1 nM for 
(R,R)-D-84 ((R,R)-1), 1 pM – 2.5 pM for (S,S)-reboxetine ((S,S)-2), and 
2.5 pM – 2.5 nM for (S)-citalopram ((S)-3)) were not used for further 
calculations. For the determination of the nonspecific binding, a straight 
line was calculated for the data points of the nonspecific binding by a linear 
regression (forced through the origin). Concentrations of nonspecifically 
bound marker concentrations for each free marker concentration was 
calculated based on the resulting linear function. Subtraction of the 
calculated nonspecific binding (NSB) from the total binding (TB, mean 
concentration calculated from triplicate) resulted in specifically bound 
marker concentrations (SB = TB – NSB) for the binding samples at each 
nominal marker concentration level. In saturation assays, equilibrium 
dissociation constants (Kd) and the maximum amount of binding sites 
(Bmax) were derived from the data of the specific binding by a nonlinear 
regression analysis (“one site – specific binding”, Prism 6). For the 
evaluation of competition experiments, the specifically bound marker 
concentrations were transformed in % bound marker concentration where 
0% bound marker represents the level of the nonspecific binding and 100% 
the level of specifically bound marker in binding samples without the 
addition of a competitor. The inhibitory constants (Ki) were then derived by 
processing this data with a “one site – Fit Ki” nonlinear regression. Kd 
values used for the calculation were as determined in simultaneous 
saturation experiments (4.01 nM for (R,R)-D-84 ((R,R)-1), 2.20 nM for 
(S,S)-reboxetine ((S,S)-2), and 0.440 nM for (S)-citalopram ((S)-3)). 
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4. Summary	of	the	Thesis	
	
The	monoamine	transporters	DAT,	NET,	and	SERT	are	important	targets	for	the	treatment	of	
affective	 disorders	 like	 major	 depressive	 disorders.	 Therapy	 of	 MDD	 is	 mostly	 based	 on	
nonselective	or	selective	monoamine	reuptake	inhibitors,	which	interact	with	one	or	multiple	
monoamine	transporters.	Due	to	the	different	functions	of	the	monoamines,	the	individual	
profile	 of	 binding	 activities	 at	 each	monoamine	 transporter	 can	 help	 to	 explain	 intended	
effects	–	but	also	side	effects	–	of	antidepressants.	Since	MS	Binding	Assays,	an	alternative	to	
conventional	radioligand	binding	assays,	have	the	potential	to	characterize	binding	affinities	
at	multiple	targets	simultaneously,	they	are	a	promising	technique	to	determine	selectivities	
and	activities	of	antidepressants	at	the	monoamine	transporters	with	high	efficiency.	
	
The	aim	of	this	work	was	to	develop	Simultaneous	Multiple	MS	Binding	Assays,	which	allow	
the	characterization	of	binding	affinities	at	hDAT,	hNET,	and	hSERT	 in	a	single	experiment,	
thus	resulting	in	a	much-improved	efficiency	in	comparison	to	radioligand	binding	assays	and	
the	recently	published	(1R,3S)-indatraline	MS	Binding	Assays.		
	
As	a	requirement	for	Simultaneous	Multiple	MS	Binding	Assays,	a	selective	marker	for	each	of	
the	three	targets	had	to	be	found.	These	markers	should	have	a	high	affinity,	ideally	in	the	low	
nanomolar	 range,	 just	 for	 one	 of	 the	 three	 monoamine	 transporters.	 (R,R)-4-(2-
benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol	((R,R)-D-84)	is	one	of	the	most	selective	
DAT	inhibitors	and	was	therefore	chosen	as	a	marker	for	this	target.	For	hNET	(S,S)-reboxetine	
was	chosen	and	(S)-citalopram	was	used	as	marker	for	hSERT.		
	
Since	the	enantiomerically	pure	compounds	should	be	applied	as	markers	and	(R,R)-D-84	is	
not	commercially	available,	a	semipreparative	method	for	the	chiral	separation	of	rac-D-84,	
which	was	synthesized	in	house	according	to	the	original	publication,	was	developed	[70].	This	
semipreparative	HPLC	method	was	based	on	a	cellulose-based	chiral	stationary	phase	(CSP)	
and	 enabled	 the	 separation	 of	 up	 to	 8	 mg	 rac-D-84	 per	 chromatographic	 run.	 For	 the	
successive	determination	of	the	enantiomeric	purity	of	(R,R)-D-84,	again	a	CSP-HPLC	method	
with	 slightly	 modified	 conditions	 was	 used	 and	 validated.	 With	 the	 analytical	 CSP-HPLC	
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method	it	was	possible	to	determine	an	ee	of	up	to	99.8	%.	The	(R,R)-D-84	sample	obtained	
from	the	semipreparative	method	was	found	to	possess	an	ee	>	99.8	%,	thus	its	quality	was	
adequate	for	its	use	in	MS	Binding	Assays.	(S,S)-reboxetine	was	extracted	as	a	racemate	from	
commercially	available	tablets	and	semipreparatively	separated	by	CSP-HPLC.	With	a	newly	
developed	 analytical	 CSP-HPLC	 method	 the	 ee	 of	 the	 obtained	 (S,S)-reboxetine	 was	
determined	as	99.3	%.	
	
For	 the	quantification	of	 (R,R)-D-84,	 (S,S)-reboxetine,	 and	 (S)-citalopram,	an	ESI-LC-MS/MS	
quantification	method	had	to	be	developed,	allowing	the	analysis	of	the	three	markers	in	a	
single	chromatographic	run.	A	HPLC	method	could	be	established	that	allowed	the	efficient	
separation	 of	 the	 markers	 from	 the	 matrix,	 hence	 minimizing	 matrix	 effects.	 During	 the	
method	development,	different	stationary	phase	materials	were	investigated	concerning	their	
suitability	for	the	chromatographic	analysis	of	the	three	markers.	Additionally,	the	influence	
of	 the	 mobile	 phase	 parameters,	 such	 as	 pH	 and	 concentration	 of	 the	 buffer,	 on	 the	
chromatography	 were	 assessed.	 The	 final	 chromatographic	 method	 was	 based	 on	 a	 LC-
column	with	a	pentafluorophenyl	(PFP)	phase,	which	was	used	in	combination	with	a	mobile	
phase	 consisting	 of	 acetonitrile	 and	 ammonium	 formate	 buffer.	 Under	 the	 chosen	
chromatographic	 conditions,	 all	 three	markers	were	 separated	 from	 each	 other	 and	 from	
interfering	matrix	components	within	a	run	time	of	only	1.5	min.	For	the	detection,	an	API	
5000	triple	quadrupole	mass	spectrometer,	equipped	with	a	TurboV	electrospray	ionization	
(ESI)	 source	was	used.	As	 internal	 standards,	 rac-[2H4]-D-84,	 rac-[2H5]-reboxetine,	 and	 rac-
[2H6]-citalopram	 were	 employed	 to	 compensate	 for	 matrix	 effects	 and	 variations	 in	 the	
ionization	efficiency.	
	
The	setup	for	the	binding	experiments	was	kept	similar	to	that	of	the	previously	published	MS	
Binding	 Assays.	 During	 the	 LC-MS	 method	 development	 it	 was	 observed,	 that	 (R,R)-D-84	
undergoes	extensive	adsorption	to	the	used	containers,	resulting	in	non-reproducible	results.	
This	 issue	was	 solved	 by	 the	 addition	 of	DMA	 to	 the	 solutions	 containing	 this	 compound,	
preventing	 the	adsorption	of	 this	marker	 in	 the	working	solutions.	To	separate	 the	 target-
marker	complexes	from	the	unbound	marker	after	the	incubation,	a	filtration	through	glass	
fiber	 filters	was	used.	 Similarly	 to	 the	adsorption	of	 (R,R)-D-84	 towards	 the	containers,	 an	
extensive	binding	of	(R,R)-D-84	towards	the	filter	material	was	noticed.	The	filter	binding	of	
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(R,R)-D-84	could	be	dramatically	reduced	by	the	addition	of	DMA	to	the	washing	buffer.	After	
the	filtration	and	washing	of	the	filters	containing	the	target-marker	complexes,	the	bound	
markers	 were	 liberated	 by	 exposing	 the	 protein	 samples	 to	 elevated	 temperatures	 and	
subsequently	eluting	them	with	an	organic	solvent.	The	resulting	samples	were	then	analysed	
with	the	developed	LC-ESI-MS/MS	quantification	method.		
	
To	 ensure	 the	 reliability	 and	 robustness,	 the	 LC-ESI-MS/MS	 quantification	 method	 was	
validated	using	matrix	samples,	obtained	by	performing	the	previously	described	procedure	
for	the	binding	experiments.	The	validation	was	carried	out	according	to	the	CDER	guideline	
for	bioanalytical	method	validation,	regarding	the	selectivity,	validity	of	the	calibration	curve,	
range,	precision	and	accuracy.	Based	on	the	data	from	the	validation,	analytical	quantification	
ranges	from	2.5	pM	to	1	nM	for	(R,R)-D-84,	1	pM	to	2.5	nM	for	(S,S)-reboxetine,	and	2.5	pM	
to	2.5	nM	for	(S)-citalopram	could	be	defined.	The	developed	LC-ESI-MS/MS	quantification	
method	 is	 the	 first	 quantification	 method	 for	 D-84.	 In	 addition,	 it	 is	 by	 a	 factor	 of	
approximately	1000-fold	more	sensitive	than	other	published	LC-MS	quantification	methods	
reported	for	reboxetine	and	citalopram.		
	
With	the	established	MS	Binding	Assays,	the	binding	affinities	and	selectivities	of	(R,R)-D-84,	
(S,S)-reboxetine,	 and	 (S)-citalopram	 towards	 their	 targets	 were	 determined	 in	 individual	
saturation	experiments.	Simultaneously	performed	saturation	experiments,	in	which	all	three	
markers	 together	 with	 all	 three	 targets	 were	 employed,	 resulted	 in	 comparable	 binding	
affinities	 for	 the	 three	markers	 towards	 their	 targets,	 thus	demonstrating	 the	 feasibility	of	
Simultaneous	Multiple	MS	Binding	Assays.	Following	the	procedure	of	Simultaneous	Multiple	
MS	 Binding	 Assays,	 the	 binding	 affinities	 and	 selectivities	 of	 a	 set	 of	 known	 monoamine	
transporter	 inhibitors	were	characterized	in	competition	experiments.	The	results	from	the	
simultaneous	 competition	 experiments	 were	 in	 good	 accord	 with	 published	 data,	 which	
demonstrates	the	potency	and	reliability	of	Simultaneous	Multiple	MS	Binding	Assays	as	an	
alternative	to	radioligand	binding	studies.	 	
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5. List	of	Abbreviations	
	
5-HT	 	 serotonin	
Bmax	 	 maximum	amount	of	binding	sites	
[C]	 	 competitor	concentration	
CDER	 	 center	for	drug	evaluation	and	research	
CNS	 	 central	nervous	system	
COMT	 	 catechol-O-methyltransferase	
CSP	 	 chiral	stationary	phase	
DA	 	 dopamine	
DAT	 	 dopamine	transporter	
dDAT	 	 Drosophila	melanogaster	dopamine	transporter	
dDATcryst	 crystal	structure	of	Drosophila	melanogaster	dopamine	transporter	
DEA	 	 diethylamine	
DMA	 	 dimethylacetamide	
(S,S)-D-83	 (S,S)-4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol	
(R,R)-D-84	 (R,R)-4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol	
ee	 	 enantiomeric	excess	
EL	 	 extracellular	loop	
ESI	 	 electrospray	ionization	
GABA	 	 g-amonibutyric	acid	
hDAT	 	 human	dopamine	transporter	
HEPES	 	 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic	acid	
hNET	 	 human	norepinephrine	transporter	
HPLC	 	 high	performance	liquid	chromatography	
hSERT	 	 human	serotonin	transporter	
IC50	 	 half	maximal	inhibitory	concentration	
Kd	 	 equilibrium	dissociation	constant	
Ki	 	 inhibitory	constant	
LC	 	 liquid	chromatography	
LC-MS	 	 liquid	chromatography-mass	spectrometry	
LeuT	 	 leucine	transporter	
LeuTAa	 	 Aquifex	aeolicus	leucine	transporter	
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LeuTcryst	 crystal	structure	of	Aquifex	aeolicus	leucine	transporter	
[L]	 	 reporter	ligand	concentration	
[LT]	 	 concentration	of	reporter	ligand-target	complexes	
MAO	 	 monoamine	oxygenase	
MDD	 	 major	depressive	disorder	
mGAT1	 murine	g-amonibutyric	acid	transporter	subtype	1	
MRM	 	 multiple	reaction	monitoring	
MS	 	 mass	spectrometry	
MS/MS	 tandem	mass	spectrometry	
m/z	 	 mass/charge-ratio	
NDRI	 	 norepinephrine-dopamine	reuptake	inhibitor	
NE	 	 norepinephrine	
NET	 	 norepinephrine	transporter	
NMR	 	 nuclear	magnetic	resonance	
NP	 	 normal	phase	
NRI	 	 selective	norepinephrine	reuptake	inhibitor	
NSB	 	 nonspecific	binding	
NSS	 	 neurotransmitter-sodium-symporter	
NTT	 	 neurotransmitter	transporter	
PFP	 	 pentafluorophenyl	
qNMR	 	 quantitative	nuclear	magnetic	resonance	
SB	 	 specific	binding	
SERT	 	 serotonin	transporter	
SLC6	 	 solute	carrier	6	
SNRI	 	 serotonin-norepinephrine	reuptake	inhibitor	
SSRI	 	 selective	serotonin	reuptake	inhibitor	
TB	 	 total	binding	
TCA	 	 tricyclic	antidepressant	
TFA	 	 trifluoroacetic	acid	
TM	 	 transmembrane	helix		
[T]	 	 target	concentration	
X-ray	 	 röntgen	radiation	
b-CIT	 	 (–)-2b-carbomethoxy-3b-(4-iodophenyl)tropane	
b-CFT	 	 (–)-2b-carbomethoxy-3b-(4-fluorophenyl)tropane	
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